Kinase inhibitor as well as preparation method and application thereof

By developing new DGK inhibitor compounds and compositions, the shortcomings in the treatment of cancer and viral infections in the prior art have been solved, effective inhibition of DGK and the improvement of immunotherapy have been achieved, and treatment plans for various drug delivery methods have been provided.

CN118974049APending Publication Date: 2024-11-15INVENTISBIO CO LTD +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380028014.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-09-15
Filing Date
2023-03-31
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing DGK inhibitors have not been effective in the treatment of a variety of diseases, especially cancer and viral infections, and there is a lack of effective targeted treatments.

Method used

A series of novel compounds and pharmaceutical compositions have been developed as inhibitors of DGKa and DGKz for the treatment of cancer and viral infections, administered by oral, parenteral administration or inhalation.

Benefits of technology

These compounds and compositions can effectively inhibit DGK, enhance T cell signaling pathways, improve the effectiveness of immunotherapy, and have therapeutic potential for a variety of cancer and viral infections, providing new targeted therapeutic options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005044661640000031
    Figure BDA0005044661640000031
  • Figure BDA0005044661640000041
    Figure BDA0005044661640000041
  • Figure BDA0005044661640000063
    Figure BDA0005044661640000063
Patent Text Reader

Abstract

Provided herein are novel compounds, such as compounds having the structure of formulae III-1 to III-12, or pharmaceutically acceptable salts thereof. Also provided herein are methods of making the compounds and methods of using the compounds, for example, for inhibiting DGK in cells and / or for treating various diseases such as cancer or viral infections.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to international application No. PCT / CN2022 / 084377 filed on March 31, 2022 and international application No. PCT / CN2022 / 118935 filed on September 15, 2022, the entire contents of each of which are incorporated herein by reference. Technical Field

[0003] In various embodiments, the present disclosure is generally directed to novel compounds, compositions comprising the compounds, methods of making the compounds, and methods of using the compounds, for example, for inhibiting DGK and / or for treating various diseases or conditions (eg, cancer or infection). Background Art

[0004] Diacylglycerol kinases (DGKs) have been shown to function as intracellular checkpoints. Inhibition of DGKs is expected to enhance T cell signaling pathways and T cell activation. For example, see Riese MJ et al., Journal of Biological Chemistry, (2011) 7:5254-5265; Zha Y et al., Nature Immunology, (2006) 12:1343; Olenchock BA et al., (2006) 11:1174-81). DGKa (DGK alpha) and DGKz (DGK zeta) are considered targets for cancer immunotherapy. Compounds that act as inhibitors of one or both of DGKa and DGKz are still needed.

[0005] Brief Description

[0006] This disclosure is based in part on the discovery by applicants of compounds that are active as inhibitors of one or both of DGKa and DGKz. In various embodiments, the disclosure provides novel compounds, pharmaceutical compositions thereof, methods for their preparation, and methods for their use. Generally, the compounds herein are DGK inhibitors, such as DGKa and / or DGKz inhibitors. The compounds and compositions herein can be used to treat various diseases or conditions, such as cancer or viral infections.

[0007] In some embodiments, the present disclosure provides a compound of Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12 as defined herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of formula III-2 can also be characterized as having a structure according to a subformula of formula III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-1, III-2-D-2, III-2-D-3, III-2-D-4, III-2-E-1, III-2-E-2, III-2-E-3, III-2-E-1a, III-2-E-2a, III-2-E-3a, III-2-E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F-3a or III-2-F-3b. In some embodiments, the compound of formula III-3 can also be characterized as having a structure according to the sub-general formula of formula III-3-A. In some embodiments, the compound of formula III-4 can also be characterized as having a structure according to the sub-general formula of formula III-4-A, III-4-B, III-4-C, III-4-D, III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1, III-4-D-2, III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f. In some embodiments, the compound of formula III-8 can also be characterized as having a structure according to the sub-general formula of formula III-8-A or III-8-B. In some embodiments, the present disclosure also provides a compound selected from the compounds shown in Table A herein, or a pharmaceutically acceptable salt. In some embodiments, the present disclosure also provides a compound selected from Compounds 1-347 herein, or a pharmaceutically acceptable salt thereof.

[0008] Certain embodiments of the present disclosure relate to pharmaceutical compositions comprising one or more compounds of the present disclosure (e.g., compounds of Formula III-1, III-2 (e.g., III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-1, III-2-D-2, III-2-D-3, III-2-D-4, III-2-E-1, III-2-E-2, III-2-E-3, III-2-E-1a, III-2-E-2a, III-2-E-3a, III-2-E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F-3a or III-2-F-3b), III-3 (e.g., III-3-A), III-4 (e.g., III-4-A, III-4-B, III-4-C, III-4-D, III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1, III-4-D-2, III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f), III-5, III-6, III-7, III-8 (e.g., III-8-A or III-8-B), III-9, III-10, III-11 or III-12, any compound selected from the group consisting of compounds shown in Table A herein, or a pharmaceutically acceptable salt thereof) and optionally a pharmaceutically acceptable excipient. The pharmaceutical compositions described herein can be formulated for various routes of administration, such as oral administration, parenteral administration, or inhalation.

[0009] Certain embodiments relate to methods for treating diseases or conditions associated with the activity of DGKa, DGKz, or both DGKa and DGKz. In some embodiments, the methods comprise administering to a subject in need thereof a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of Formula III-1, III-2 (e.g., III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-1, III-2-D-2, III-2 -D-3, III-2-D-4, III-2-E-1, III-2-E-2, III-2-E-3, III-2-E-1a, III-2-E-2a, III-2-E-3a, III- 2-E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F-3 a or III-2-F-3b), III-3 (e.g., III-3-A), III-4 (e.g., III-4-A, III-4-B, III-4-C, III-4-D, III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1, III-4-D-2, III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f), III-5, III-6, III-7, III-8 (e.g., III-8-A or III-8-B), III-9, III-10, III-11 or III-12, any compound selected from the group consisting of compounds shown in Table A herein, or a pharmaceutically acceptable salt thereof) or a therapeutically effective amount of a pharmaceutical composition as described herein. Diseases or conditions associated with the activity of DGKa, DGKz, or both DGKa and DGKz that are suitable for treatment using the methods include those described herein.

[0010] In some embodiments, a method for treating cancer is provided. In some embodiments, the method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of Formula III-1, III-2 (e.g., III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-1, III-2-D-2, III-2-D -3, III-2-D-4, III-2-E-1, III-2-E-2, III-2-E-3, III-2-E-1a, III-2-E-2a, III-2-E-3a, III-2- E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F-3a or III-2-F-3b), III-3 (e.g., III-3-A), III-4 (e.g., III-4-A, III-4-B, III-4-C, III-4-D, III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1, III-4-D-2, III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f), III-5, III-6, III-7, III-8 (e.g., III-8-A or III-8-B), III-9, III-10, III-11 or III-12, any compound selected from the group consisting of compounds shown in Table A herein, or a pharmaceutically acceptable salt thereof) or a therapeutically effective amount of a pharmaceutical composition described herein. In various embodiments, the cancer can be colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, kidney cancer, head and neck cancer, lymphoma, leukemia, and / or melanoma.

[0011] In some embodiments, a method for treating a viral infection is provided. In some embodiments, the method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of Formula III-1, III-2 (e.g., III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-1, III-2-D-2, III-2-D -3, III-2-D-4, III-2-E-1, III-2-E-2, III-2-E-3, III-2-E-1a, III-2-E-2a, III-2-E-3a, III-2- E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F-3a or III-2-F-3b), III-3 (e.g., III-3-A), III-4 (e.g., III-4-A, III-4-B, III-4-C, III-4-D, III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1, III-4-D-2, III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f), III-5, III-6, III-7, III-8 (e.g., III-8-A or III-8-B), III-9, III-10, III-11 or III-12, any compound selected from the group consisting of compounds shown in Table A herein, or a pharmaceutically acceptable salt thereof) or a therapeutically effective amount of a pharmaceutical composition described herein.

[0012] The administration in the methods described herein is not limited to any particular route of administration. For example, in some embodiments, administration can be oral, nasal, transdermal, pulmonary, inhalation, buccal, sublingual, intraperitoneal, subcutaneous, intramuscular, intravenous, rectal, intrapleural, intrathecal, and parenteral.

[0013] The compounds of the present disclosure can be used as monotherapy or in combination therapy. In some embodiments, the combination therapy includes treating the subject with a targeted therapeutic agent, a chemotherapeutic drug, a therapeutic antibody, radiotherapy, a cell therapy, and / or an immunotherapy. In some embodiments, the combination therapy includes treating the subject with an immuno-oncology drug described herein. In some embodiments, the combination therapy includes treating the subject with one or more additional antiviral drugs.

[0014] In some embodiments, the present disclosure provides the following exemplary listed embodiments 1-49:

[0015] Embodiment 1. A compound of formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, or a pharmaceutically acceptable salt thereof:

[0016]

[0017]

[0018] in:

[0019] R 1 is hydrogen, halogen (such as F, Cl or Br), CN, OH, NH2, COOH, CONH2, R A , OR A NH(R A )、N(R A 2. COOR A 、CONH(R A )、CON(R A )2、SR A 、SOR A 、SO2R A or P(O)(R A )2, where R A Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl;

[0020] R 2 is hydrogen, halogen (such as F, Cl or Br), CN, OH, NH2, R B , OR B NH(R B ) or N(R B )2, where R B Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, or an optionally substituted 4-7 membered heterocyclic group;

[0021] R3 is hydrogen, optionally substituted C 1-4 Alkyl, or an optionally substituted 3-7 membered ring, such as an optionally substituted C 3-6 Cycloalkyl, or an optionally substituted 4-7 membered heterocyclic group (such as a saturated 4-7 membered heterocyclic group);

[0022] J is O, CO, SO2, NR 15 or optionally substituted methylene;

[0023] W does not exist or is (W 1 ) p , where p is 1, 2, or 3, and where W 1 Each occurrence is independently C(O), NR 15 , SO2, O or an optionally substituted methylene, provided that W 1 The maximum number of instances is C(O), NR 15 , SO2 or O;

[0024] Among them, R 15 Each occurrence is independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, an optionally substituted 3-6 membered ring, or a nitrogen protecting group;

[0025] X is N or CR 5 , where R 5 For hydrogen, halogen, OH, NH2, NH(R C )、N(R C )2, CN, CONH2, COOH, CONH(R C )、CON(R C )2、OR C , or COOR C , where R C Each occurrence is independently optionally substituted C 1-4 alkyl;

[0026] U is N or CR 6 , where R 6 is hydrogen, halogen (e.g., F, Cl, or Br), CN, OH, NH2, R D , OR D NH(R D )、N(R D )2、COOH、CONH2、COOR D 、CONH(R D )、CON(R D )2、SR D 、SOR D、SO2R D , or P(O)(R D )2, where R D Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl;

[0027] Y is N or CR 7 , where R 7 is hydrogen, F, Cl, CN, optionally substituted C 1-4 Alkyl, or optionally substituted C 1-4 heteroalkyl;

[0028] Z is C(O), C(=N-OH), C(=NO-(C 1-4 alkyl)), C(=N-NH2), C(=N-NH-(C 1-4 alkyl)), C(=NN(C 1-4 Alkyl)(C 1-4 alkyl)), SO, SO2, S(O)(=NH) or S(O)(=N-(C 1-4 alkyl);

[0029] Ring C is a 5-membered or 6-membered ring, preferably a 5-membered or 6-membered heteroaryl ring having 2-3 ring heteroatoms, such as a 5-membered heteroaryl group having 2-3 ring nitrogen atoms, such as an imidazole ring or a triazole ring, wherein in Formula III-8, Ring C shares two ring atoms with the adjacent ring;

[0030] L 1 is an optionally substituted 4-12 membered ring, preferably a 4-12 membered heterocyclic ring having one or more rings and 1-4 ring heteroatoms each independently selected from O, N or S, or -N(R E )-, where R E is optionally substituted C 1-4 Alkyl or an optionally substituted 3-7 membered ring;

[0031] L 2 is absent, O, NH, -N(R E2 )-, C(O), SO2, optionally substituted C 1-4 Alkylene, optionally substituted C 2-4 Alkenylene, optionally substituted C 1-4 Alkynylidene, optionally substituted C 1-4 heteroalkylene, or an optionally substituted 3-7 membered ring, wherein R E2is optionally substituted C 1-4 Alkyl or an optionally substituted 3-7 membered ring;

[0032] R 30 is hydrogen, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, or an optionally substituted 8- to 12-membered ring having two or more rings;

[0033] R 9 Each occurrence is independently halogen, CN, OH, R N , OR N 、NHR N 、N(R N 2. COOR N 、COR N 、CONH(R N ), or CON(R N )2, where R N Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, or an optionally substituted 3-7 membered ring, such as an optionally substituted C 3-6 cycloalkyl, optionally substituted phenyl, optionally substituted 4-7 membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl; and

[0034] n1 is 0, 1, 2 or 3, preferably, n1 is 0 or 1, and R 9 Each occurrence is independently CH3, CH2CH3, CH2CH2CH3, fluorinated C 1-3 Alkyl (e.g., CF2H), cyclopropyl, cyclobutyl, CH2OH, CH2OCH3, CH2OCH2CH3, CH2NH2, CH2N3, or CH2NHC(O)OCH3.

[0035] Embodiment 2. The compound of Embodiment 1, or a pharmaceutically acceptable salt thereof, wherein Y is N.

[0036] Embodiment 3. The compound of Embodiment 1, or a pharmaceutically acceptable salt thereof, wherein Y is CH.

[0037] Embodiment 4. The compound of any one of Embodiments 1-3, or a pharmaceutically acceptable salt thereof, wherein U is N.

[0038] Embodiment 5. The compound according to any one of Embodiments 1-3, or a pharmaceutically acceptable salt thereof, wherein U is CR 6 .

[0039] Embodiment 6. The compound of embodiment 5, or a pharmaceutically acceptable salt thereof, wherein R 6 For hydrogen.

[0040] Embodiment 7. The compound of embodiment 5, or a pharmaceutically acceptable salt thereof, wherein R 6 C 1-4 Alkoxy or

[0041] Embodiment 8. The compound according to any one of Embodiments 1-7, or a pharmaceutically acceptable salt thereof, wherein, if applicable, R 1 For CN.

[0042] Embodiment 9. The compound of any one of Embodiments 1-7, or a pharmaceutically acceptable salt thereof, wherein, if applicable, (i) R 1 is halogen, such as F or Cl; (ii) R 1 for (iii)R 1 is an optionally substituted 5- or 6-membered heteroaryl group having 1-4 ring heteroatoms independently selected from O, S and N, such as an optionally substituted pyrimidinyl group or an optionally substituted thiazolyl group, for example, R 1 for or (iv) R 1 SR A1 , where R A1 are independently optionally substituted C 1-4 Alkyl groups, such as R 1 For SCH3.

[0043] Embodiment 10. The compound of embodiment 1, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to formula III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1 or III-4-D-2

[0044]

[0045] Embodiment 11. The compound according to any one of Embodiments 1-9, or a pharmaceutically acceptable salt thereof, wherein R 2 For hydrogen.

[0046] Embodiment 12. The compound according to any one of Embodiments 1-11, or a pharmaceutically acceptable salt thereof, wherein (i) R 3 is optionally substituted C 1-4 Alkyl, such as CH3, CD3, etc.; (ii) R 3 is hydrogen; (iii) R 3 is optionally substituted C 1-4Alkyl, such as CH(CH3)2, CH2CH3, CH2CHF2, etc.; or (iv) R 3 is optionally substituted C 3-6 Cycloalkyl, such as cyclopropyl, cyclobutyl, etc.

[0047] Embodiment 13. The compound of any one of Embodiments 1-12, or a pharmaceutically acceptable salt thereof, wherein Z is C(O).

[0048] Embodiment 14. A compound according to any one of Embodiments 1-13, or a pharmaceutically acceptable salt thereof, wherein, if applicable, R 9 Each occurrence is independently optionally substituted C 1-4 Alkyl or optionally substituted C 3-6 Cycloalkyl, preferably CH3, CH2CH3, CH2CH2CH3, fluorine-substituted C 1-3 Alkyl (e.g., CF2H), cyclopropyl, cyclobutyl, CH2OH, CH2OCH3, CH2OCH2CH3, CH2NH2, CH2N3, or CH2NHC(O)OCH3.

[0049] Embodiment 15. The compound of any one of Embodiments 1-14, or a pharmaceutically acceptable salt thereof, wherein, if applicable, X is N.

[0050] Embodiment 16. A compound according to any one of Embodiments 1-14, or a pharmaceutically acceptable salt thereof, wherein, if applicable, X is CR 5 , where R 5 For CN.

[0051] Embodiment 17. A compound according to any one of Embodiments 1-14, or a pharmaceutically acceptable salt thereof, wherein, if applicable, X is CR 5 , where R 5 CONH2, COOH, CONH(R C1 ), CON(R C1 )2, or COOR C1 , where R C1 Each occurrence is independently C 1-4 Alkyl groups, such as methyl.

[0052] Embodiment 18. A compound according to any one of Embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein, if applicable, L 1 for (One of the two connection points of piperidine, N or C, can be connected to L 2 ),

[0053] in:

[0054] n is 0, 1, 2, 3, or 4, and

[0055] (1)R 9A Each occurrence is independently halogen, CN, OH, R N , OR N 、NHR N 、N(R N 2. COOR N 、COR N 、CONH(R N ) or CON(R N )2, where R N Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, or an optionally substituted 3-7 membered ring, such as an optionally substituted C 3-6 cycloalkyl, optionally substituted phenyl, optionally substituted 4-7 membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl; or

[0056] (2)R 9A Two instances of can be connected to form a double bond or a 3-5 membered ring and R 9A Any remaining instances of are defined as in (1).

[0057] Embodiment 19. The compound of embodiment 18, or a pharmaceutically acceptable salt thereof, wherein R 9A Each occurrence is independently CH3, CH2CH3, CH2CH2CH3, fluorinated C 1-3 Alkyl (e.g., CF2H), cyclopropyl, cyclobutyl, CH2OH, CH2OCH3, CH2OCH2CH3, CH2NH2, CH2N3, or CH2NHC(O)OCH3.

[0058] Embodiment 20. A compound according to any one of embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein, if applicable, L 1 Select from the following (bottom connection point N or C connection L 2 ):

[0059]

[0060] Embodiment 21. A compound according to any one of Embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein, if applicable, L 1 Select from the following (bottom connection point N or C connected to L 2 ):

[0061]

[0062] Embodiment 22. A compound according to any one of Embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein, if applicable, L 1 is an optionally substituted 7-12 membered heterocyclylene group having two or more rings and 1-4 ring heteroatoms each independently selected from O, N or S. When substituted, the substituents may be attached to any one or more of the two or more rings.

[0063] Embodiment 23. A compound according to any one of Embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein, if applicable, L 1 Select from the following bicyclic heterocyclic groups (the bottom connection point is N or C connected to L 2 ):

[0064]

[0065] Wherein, in each bicyclic heterocyclylene group, each of the two rings can be optionally substituted by 1-3 R 10 Substituted, where R 10 Each occurrence is independently halogen, OH, NH2, oxo (if applicable), R J , OR J 、CN、NH(R J ) or N(R J )2, where R J Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 alkynyl, or an optionally substituted 3-4 membered ring.

[0066] Embodiment 24. A compound according to any one of Embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein, if applicable, L 1 Select from the following bicyclic heterocyclic groups (the bottom connection point is N or C connected to L 2 ):

[0067]

[0068] Embodiment 25. A compound according to any one of Embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein, if applicable, L 1 -N(C 1-4 alkyl)-, such as -N(CH3)-.

[0069] Embodiment 26. The compound according to any one of embodiments 1-25, or a pharmaceutically acceptable salt thereof, wherein L 2 Does not exist.

[0070] Embodiment 27. The compound according to any one of Embodiments 1-25, or a pharmaceutically acceptable salt thereof, wherein L 2 is an optionally substituted C selected from the following 1-4 Alkylene:

[0071]

[0072] in:

[0073] R 13 selected from hydrogen, halogen (e.g., F, Cl or Br), CN, OH, NH2, COOH, CONH2, SO2NH2, COR K 、COOR K 、CONH(R K )、CON(R K 2. SO2R K 、SO2NH(R K )、SO2N(R K )2、R K , OR K NH(R K )、N(R K )2、SR K 、SOR K 、SO2R K or P(O)(R K )2, where R K Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 1-4 Heteroalkyl, optionally substituted C 3-6 cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl, wherein, when substituted, the optionally substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl, phenyl, 5- or 6-membered heteroaryl, or 4-7-membered heterocyclyl substituted with 1-3 substituents independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted with 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F 1-4 heteroalkyl, and 3-4 membered rings optionally substituted with F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.).

[0074] Embodiment 28. The compound of embodiment 27, or a pharmaceutically acceptable salt thereof, wherein R 13 It's hydrogen.

[0075] Embodiment 29. The compound of embodiment 27, or a pharmaceutically acceptable salt thereof, wherein R 13 is CN, OH, COOH, CONH2, methoxy, ethoxy, cyclopropyl, cyclobutyl, optionally substituted phenyl, or optionally substituted 5- or 6-membered heteroaryl having 1-3 ring heteroatoms independently selected from N, O, and S, wherein, when substituted, the optionally substituted phenyl or 5- or 6-membered heteroaryl is independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted with 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F C 1-4 Heteroalkyl, and optionally substituted with 1-3 substituents of a 3-4 membered ring substituted with F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.).

[0076] Embodiment 30. The compound according to any one of embodiments 1-25, or a pharmaceutically acceptable salt thereof, wherein L 2 is O or C(O).

[0077] Embodiment 31. The compound of any one of Embodiments 1-25, or a pharmaceutically acceptable salt thereof, wherein:

[0078] L 2 is an optionally substituted 5- or 6-membered heteroarylene group, for example Embodiment 32. A compound according to any one of embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein, if applicable, L 1 -N(R E )-,L 2 is an optionally substituted phenylene group, for example, R 30 It's hydrogen.

[0079] Embodiment 33. A compound according to any one of embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein, if applicable, L 1 , L 2 and R 30 Together they are:

[0080]

[0081] Embodiment 34. The compound of any one of Embodiments 1-31, or a pharmaceutically acceptable salt thereof, wherein R 30is an optionally substituted phenyl group, for example, consisting of 1 to 3 (eg, 1 or 2) R 22 Substituted phenyl, wherein R 22 Each occurrence is independently halogen (e.g., F, Cl, or Br), CN, OH, NH2, R M , OR M 、COOH、CONH2、COOR M 、CONH(R M )、CON(R M )2、NHCO(R M )、N(R M )CO(R M ), SO2R M 、SO2NH2、S(O)(NH)R M 、S(O)(NR M )R M 、SO2N(R M 2. NHSO2R M 、N(R M )SO2R M 、P(O)(R M )2、P(O)(OR M )2、NH(R M )、N(R M )2、SR M or SF5, where R M Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl.

[0082] Embodiment 35. The compound of embodiment 34, or a pharmaceutically acceptable salt thereof, wherein R 30 It is composed of 1-3 (e.g., 1 or 2) R 22 Substituted phenyl, wherein R 22 Each occurrence is independently halogen (eg, F, Cl, or Br), CN, OH, R M1 , OR M1 、SO2R M1 、P(O)(R M1 )2、SR M1 or SF5, where R M1 Each occurrence is independently optionally substituted C 1-4alkyl or an optionally substituted 3-4 membered ring (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), wherein when substituted, the optionally substituted C 1-4 The alkyl group or the 3-4 membered ring is substituted by 1-3 substituents independently selected from the group consisting of halogen (preferably F or Cl), OH, CN, C optionally substituted by 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F 1-4 Heteroalkyl, 3-4 membered ring optionally substituted with F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.).

[0083] Embodiment 36. The compound of embodiment 34, or a pharmaceutically acceptable salt thereof, wherein R 30 It is composed of 1-3 (e.g. 1 or 2) R 22 Substituted phenyl, wherein R 22 Each occurrence is independently F, Cl, CN, R M2 , OR M2 SR M2 or SF5, where R M2 Each occurrence is independently C optionally substituted with 1-3 F 1-4 Alkyl groups, such as CF3.

[0084] Embodiment 37. The compound of any one of Embodiments 1-31, or a pharmaceutically acceptable salt thereof, wherein R 30 is an optionally substituted 5- or 6-membered heteroaryl group, such as pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Substitute, where R 22 Each occurrence is independently halogen (e.g., F, Cl, or Br), CN, OH, NH2, R M , OR M 、COOH、CONH2、COOR M 、CONH(R M )、CON(R M )2、NHCO(R M )、N(R M )CO(R M ), SO2R M 、SO2NH2、S(O)(NH)R M 、S(O)(NR M )R M 、SO2N(R M 2. NHSO2R M 、N(R M )SO2R M、P(O)(R M )2、P(O)(OR M )2、NH(R M )、N(R M )2、SR M or SF5, where R M Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl.

[0085] Embodiment 38. The compound of embodiment 37, or a pharmaceutically acceptable salt thereof, wherein R 30 is a 5-membered heteroaryl group (e.g., ) or pyridyl (e.g., ) or pyrimidinyl (e.g., ), which is replaced by 1-3 (e.g., 1 or 2) R 22 Substitution, where valence permits, where R 22 Each occurrence is independently halogen (eg, F, Cl, or Br), CN, OH, R M1 , OR M1 、SO2R M1 、P(O)(R M1 )2、SR M1 or SF5, where R M1 Each occurrence is independently optionally substituted C 1-4 alkyl or an optionally substituted 3-4 membered ring (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), wherein when substituted, the optionally substituted C 1-4 The alkyl group or the 3-4 membered ring is substituted by 1-3 substituents independently selected from the group consisting of halogen (preferably F or Cl), OH, CN, C optionally substituted by 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F 1-4 Heteroalkyl, 3-4 membered ring optionally substituted with F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.).

[0086] Embodiment 39. The compound of embodiment 37, or a pharmaceutically acceptable salt thereof, wherein R 30 is a 5-membered heteroaryl group (e.g., ) or pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Substitution, where valence permits, where R 22 Each occurrence is independently F, Cl, CN, R M2 , OR M2 SR M2 or SF5, where R M2 Each occurrence is independently C optionally substituted with 1-3 F 1-4 Alkyl groups, such as CF3.

[0087] Embodiment 40. The compound of any one of Embodiments 1-31, or a pharmaceutically acceptable salt thereof, wherein R 30 Having the structure according to S-1-A, S-1-B, S-1-C or S-1-D:

[0088]

[0089]

[0090] where R 8 is C optionally substituted with 1-3 F 1-4 Alkyl (such as CH3, CF3, etc.), C optionally substituted by 1-3 F 1-4 Alkoxy (such as OCH3, OCF3, etc.), SCF3, SF5, cyclopropyl, cyclobutyl, or

[0091] Embodiment 41. A compound according to any one of embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein L 1 , L 2 , and R 30 Together (ie L 1 -L 2 -R 30 ) is selected from:

[0092]

[0093] or L 1 -L 2 -R 30 Selected from:

[0094]

[0095] Embodiment 42. The compound of any one of Embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein L 1 , L 2 , and R 30 Selected from:

[0096]

[0097] or L 1 -L 2 -R 30 Selected from:

[0098]

[0099] Embodiment 43. A compound according to any one of embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein L 1 , L 2 , and R 30 Selected from:

[0100]

[0101] or L 1 -L 2 -R 30 Selected from:

[0102]

[0103]

[0104] or L 1 , L 2 , and R 30 Selected from:

[0105]

[0106] or L 1 , L 2 , and R 30 Selected from:

[0107]

[0108] Embodiment 44. The compound of any one of Embodiments 1-31, or a pharmaceutically acceptable salt thereof, wherein R 30 Select from the following:

[0109]

[0110] or R 30 Selected from:

[0111]

[0112] or R 30 Selected from:

[0113]

[0114] or R 30 Selected from:

[0115]

[0116] Embodiment 45. A compound selected from Compound Nos. 1-347 or any compound disclosed in Table A, or a pharmaceutically acceptable salt thereof.

[0117] Embodiment 46. A pharmaceutical composition comprising the compound according to any one of Embodiments 1-45 or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

[0118] Embodiment 47. A method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound according to any one of embodiments 1-45, wherein the disease is cancer or a viral infection.

[0119] Embodiment 48. The method of embodiment 47, wherein the cancer is selected from colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, kidney cancer, head and neck cancer, lymphoma, leukemia and melanoma.

[0120] Embodiment 49. A method of inhibiting the activity of at least one diacylglycerol kinase selected from diacylglycerol kinase alpha (DGKa) and diacylglycerol kinase zeta (DGKz), comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound according to any one of Embodiments 1-45.

[0121] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0122] Figure 1 The antitumor activity of compound 67 (cpd67) as a single agent and in combination with an anti-mouse PD-1 antibody (mPD-1) was shown in the MC38 syngeneic tumor model. DETAILED DESCRIPTION

[0123] Detailed description

[0124] Broadly speaking, the present disclosure provides compounds and compositions that are useful for inhibiting DGK (diacylglycerol kinase), such as DGKa and / or DGKz, and / or treating or preventing various diseases or conditions described herein, such as cancer or infectious diseases, such as viral infections.

[0125] Compound

[0126] Some embodiments of the present disclosure relate to novel compounds. The compounds herein can generally be DGK inhibitors and can be used to treat various diseases or conditions, such as those described herein, such as cancer or viral infection.

[0127] Formulas III-1 to III-12

[0128] In some embodiments, the present disclosure provides a compound of Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, or a pharmaceutically acceptable salt thereof:

[0129]

[0130]

[0131] in:

[0132] R 1 is hydrogen, halogen (such as F, Cl or Br), CN, OH, NH2, COOH, CONH2, R A , OR A NH(R A )、N(R A 2. COOR A 、CONH(R A )、CON(R A )2、SR A 、SOR A 、SO2R A or P(O)(R A )2, where R A Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl;

[0133] R 2 is hydrogen, halogen (such as F, Cl or Br), CN, OH, NH2, R B , OR B NH(R B ) or N(R B )2, where R B Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, or an optionally substituted 4-7 membered heterocyclic group;

[0134] R 3 is hydrogen, optionally substituted C 1-4 Alkyl, or an optionally substituted 3-7 membered ring, such as an optionally substituted C 3-6 Cycloalkyl, or an optionally substituted 4-7 membered heterocyclic group (such as a saturated 4-7 membered heterocyclic group);

[0135] J is O, CO, SO2, NR 15 or optionally substituted methylene;

[0136] W does not exist or is -(W 1 ) p -, where p is 1, 2 or 3, where W 1 Each occurrence is independently C(O), NR 15 , SO2, O or an optionally substituted methylene, provided that W 1 The maximum number of instances is C(O), NR 15 , SO2 or O; it should be noted that when W is absent, the ring containing J is a 5-membered ring; when p is 1, the ring containing J and W is a 6-membered ring; when p is 2 or 3, the ring containing J and W is a 7-membered ring or an 8-membered ring, respectively;

[0137] Among them, R 15 Each occurrence is independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, an optionally substituted 3-6 membered ring, or a nitrogen protecting group;

[0138] X is N or CR 5 , where R 5 For hydrogen, halogen, OH, NH2, NHR C 、N(R C )2, CN, CONH2, COOH, CONH(R C )、CON(R C )2、OR C , NO2 or COOR C , where R C Each occurrence is independently optionally substituted C 1-4 alkyl;

[0139] U is N or CR 6 , where R 6 is hydrogen, halogen (e.g., F, Cl, or Br), CN, OH, NH2, R D, OR D NH(R D )、N(R D )2、COOH、CONH2、COOR D 、CONH(R D )、CON(R D )2、SR D 、SOR D 、SO2R D or P(O)(R D )2, where R D Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl;

[0140] Y is N or CR 7 , where R 7 is hydrogen, F, Cl, CN, optionally substituted C 1-4 Alkyl or optionally substituted C 1-4 heteroalkyl;

[0141] Z is C(O), C(=N-OH), C(=NO-(C 1-4 alkyl)), C(=N-NH2), C(=N-NH-(C 1-4 alkyl)), C(=NN(C 1-4 Alkyl)(C 1-4 alkyl)), SO, SO2, S(O)(=NH) or S(O)(=N-(C 1-4 alkyl);

[0142] Ring C is a 5-membered or 6-membered ring, preferably a 5-membered or 6-membered heteroaryl group having 2-3 ring heteroatoms, such as a 5-membered heteroaryl group having 2-3 ring nitrogen atoms, such as an imidazole ring or a triazole ring, wherein in Formula III-8, Ring C shares two ring atoms with the adjacent ring;

[0143] L 1 is an optionally substituted 4-12 membered ring, preferably a 4-12 membered heterocyclic ring having one or more rings and 1-4 ring heteroatoms each independently selected from O, N or S, or -N(R E )-, where R E is optionally substituted C 1-4 Alkyl or an optionally substituted 3-7 membered ring;

[0144] L 2Not present or O, NH, -N(R E2 )-, C(O), SO2, optionally substituted C 1-4 Alkylene, optionally substituted C 2-4 Alkenylene, optionally substituted C 1-4 Alkynylidene, optionally substituted C 1-4 heteroalkylene or an optionally substituted 3-7 membered ring, wherein R E2 is optionally substituted C 1-4 Alkyl or optionally substituted 3-7 membered ring;

[0145] R 30 is hydrogen, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, or an optionally substituted 8- to 12-membered ring having two or more rings;

[0146] R 9 Each occurrence is independently halogen, CN, OH, R N , OR N 、NHR N 、N(R N 2. COOR N 、COR N 、CONH(R N ) or CON(R N )2, where R N Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl or an optionally substituted 3-7 membered ring, such as an optionally substituted C 3-6 cycloalkyl, optionally substituted phenyl, optionally substituted 4-7 membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl; and

[0147] n1 is 0, 1, 2, or 3.

[0148] As used herein, unless specified or otherwise clearly contradicted by the context, an "xy-membered ring" is understood to include any ring structure having the specified number of ring members. For example, such a ring may be carbocyclic, heterocyclic, aryl, or heteroaryl, and may be monocyclic, bicyclic, or have more than two rings, each of which may be saturated, partially unsaturated, or aromatic, and may optionally contain one or more ring heteroatoms. Furthermore, where applicable, such an "xy-membered ring" is understood to be attached to the remainder of the molecule via one or more ring atoms.

[0149] It should be understood that the term "substituted" or "unsubstituted" used in conjunction with a variable described herein should be understood to refer to whether the variable is substituted, without regard to the desired bonding of the variable to the rest of the molecule. For example, an unsubstituted phenylene group is understood to be one in which the remaining ring atoms of the phenylene group are unsubstituted, except for the two ring atoms that connect the phenylene group to the rest of the molecule, while a substituted phenylene group is one in which at least one ring atom is substituted with a substituent described herein, except for the two ring atoms that connect the phenylene group to the rest of the molecule.

[0150] In some embodiments, the compound of formula III-1 to III-12 can have stereoisomers. In such embodiments, the compound of formula III-1 to III-12 can be present as a single enantiomer, diastereomer, atropisomer and / or geometric isomer, as applicable, or a mixture of stereoisomers, including a racemic mixture and a mixture enriched with one or more stereoisomers. In some embodiments, when applicable, the compound of formula III-1 to III-12 can exist as a mixture of a pair of enantiomers in any ratio, including a racemic mixture with a ratio of 1: 1. In some embodiments, when applicable, the compound of formula III-1 to III-12 can exist as a single enantiomer substantially free of (e.g., by weight, by HPLC or SFC area, or both, less than 20%, less than 10%, less than 5%, less than 1% or with undetectable amount) separation of other enantiomers or enrichment.

[0151] In some embodiments, the present disclosure provides a compound having a structure according to Formula III-1, or a pharmaceutically acceptable salt thereof, with the variables defined and preferred herein. In some embodiments, the present disclosure provides a compound having a structure according to Formula III-2, or a pharmaceutically acceptable salt thereof, with the variables defined and preferred herein. In some embodiments, the present disclosure provides a compound having a structure according to Formula III-3, or a pharmaceutically acceptable salt thereof, with the variables defined and preferred herein. In some embodiments, the present disclosure provides a compound having a structure according to Formula III-4, or a pharmaceutically acceptable salt thereof, with the variables defined and preferred herein. In some embodiments, the present disclosure provides a compound having a structure according to Formula III-5, or a pharmaceutically acceptable salt thereof, with the variables defined and preferred herein. In some embodiments, the present disclosure provides a compound having a structure according to Formula III-6, or a pharmaceutically acceptable salt thereof, with the variables defined and preferred herein. In some embodiments, the present disclosure provides a compound having a structure according to Formula III-7, or a pharmaceutically acceptable salt thereof, with the variables defined and preferred herein. In some embodiments, the present disclosure provides a compound having a structure according to Formula III-8, or a pharmaceutically acceptable salt thereof, with the variables defined and preferred herein. In some embodiments, the compound of Formula III-8 can be represented as having a structure according to Formula III-8-A or Formula III-8-B:

[0152]

[0153] The variable R 1 、R 2 , U, X, Y, L1, L 2 and R 30 As defined herein, for example, those described below in conjunction with Formula III-2 in the enumerated embodiments A2-A36. In some embodiments, the present disclosure provides a compound having a structure according to Formula III-9, or a pharmaceutically acceptable salt thereof, with the variables defined and preferred herein. In some embodiments, the present disclosure provides a compound having a structure according to Formula III-10, or a pharmaceutically acceptable salt thereof, with the variables defined and preferred herein. In some embodiments, the present disclosure provides a compound having a structure according to Formula III-11, or a pharmaceutically acceptable salt thereof, with the variables defined and preferred herein. In some embodiments, the present disclosure provides a compound having a structure according to Formula III-12, or a pharmaceutically acceptable salt thereof, with the variables defined and preferred herein.

[0154] It should also be understood that the definitions and preferred definitions of any variable in Formulas III-1 to III-12 described herein also apply to the corresponding variables in any subformula thereof, unless specifically defined or contradicted in such subformula. For example, the definitions and preferred definitions of the variables in Formula III-2 described herein also apply to the corresponding variables in the subformulas herein, such as Formulas III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-1, III-2-D-2, III-2-D-3, III-2-D-4, III-2-E-1, III-2-E-2, III-2-E-3, III-2-E-4, III-2-E-5, III-2-E-6, III-2-E-7, III-2-E-8, III-2-E-9, III-2-A-10, III-2-B-11, III-2-C-12, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-13, III-2-D-2, III-2-D-3, III-2-D-4, III-2-E-14, III-2-E-15, III-2-E-2 I-2-E-2, III-2-E-3, III-2-E-1a, III-2-E-2a, III-2-E-3a, III-2-E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F-3a, or III-2-F-3b, unless expressly defined or contradicted in this subformula. Similarly, the definitions and preferred definitions described herein for the variables in formula III-4 also apply to the corresponding substituents in the subformulae herein, such as III-4-A, III-4-B, III-4-C, III-4-D, III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1, III-4-D-2, III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f, unless explicitly defined or contradicted in such subformulae.

[0155] Typically, in Formula III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, Y is N.

[0156] In some embodiments, in Formula III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, Y is CR 7 , where R 7 is hydrogen, F, Cl, CN, optionally substituted C 1-4 Alkyl, or optionally substituted C 1-4 For example, in some embodiments, Y is CH.

[0157] Typically, U in formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12 is CR 6 , where R 6 is hydrogen, halogen (e.g., F, Cl, or Br), CN, OH, NH2, R D , OR D NH(R D )、N(R D )2、COOH、CONH2、COOR D 、CONH(R D )、CON(R D )2、SR D 、SOR D 、SO2R D or P(O)(R D )2, where R D Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl. In some preferred embodiments, R 6 is hydrogen, i.e., U is CH. In some embodiments, R 6 It can also be a halogen, such as F or Cl. In some embodiments, R 6 It can also be OR D , where R D As defined herein. In some embodiments, R 6 It can be OR D1 , where R D1 is optionally substituted C 1-4 Alkyl, optionally substituted C 3-6 cycloalkyl, or optionally substituted 4-7 membered heterocyclyl having 1 or 2 ring heteroatoms independently selected from O, N and S; wherein, when substituted, the optionally substituted C 1-4 Alkyl, C 3-6 The cycloalkyl or 4-7 membered heterocyclyl may be substituted by one or more (e.g., 1-3) substituents, for example, each substituent may be independently selected from halogen (e.g., F), OH, CN, C 1-4 Alkyl or C 1-4 For example, in some embodiments, R 6 Can be C 1-4 In some embodiments, R6 Can be In some specific embodiments, R 6 Can be In some specific embodiments, R 6 Can be

[0158] In some embodiments, U is N in Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11, or III-12.

[0159] For formula III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, various groups are suitable as R 1 For example, in some embodiments, R 1 Can be OH, COOH, CONH2, NH2, R A , OR A 、COOR A NH(R A )、N(R A )2、CONH(R A )、CON(R A )2、SR A 、SOR A 、SO2R A or P(O)(R A )2, where R A As defined herein. In some embodiments, R A Each occurrence may be optionally substituted C 1-4 alkyl.

[0160] In some preferred embodiments, in Formula III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, R 1 For CN.

[0161] In some preferred embodiments, R1 in formula III-2, III-3, III-4, III-5, III-6, III-7, R in III-8, III-9, III-10, III-11 or III-12 is 1 is a halogen, preferably F or Cl.

[0162] In some embodiments, in Formula III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, R 1 It is C 2-3 Alkynyl, such as

[0163] In some embodiments, in Formula III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, R 1 is an optionally substituted 5- or 6-membered heteroaryl group having 1-4 heteroatoms independently selected from O, S, and N. For example, in some embodiments, R 1 It may be an optionally substituted pyrimidinyl or an optionally substituted thiazolyl, for example, R 1 yes

[0164] In some embodiments, in Formula III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, R 1 It's SR A , where R A As defined herein. For example, in some embodiments, R 1 Can be SR A1 , where R A1 are independently optionally substituted C 1-4 Alkyl groups, such as R 1 are independently SCH3. Other suitable R 1 As described in this article.

[0165] In some embodiments, in Formula III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, R 1 It can be characterized as follows: (i) R 1 is a halogen, such as F or Cl; (ii) R 1 yes (iii)R 1 is an optionally substituted 5- or 6-membered heteroaryl group having 1-4 ring heteroatoms independently selected from O, S and N, such as an optionally substituted pyrimidinyl group or an optionally substituted thiazolyl group, for example, R 1 for or (iv) R 1 SR A1 , where R A1are independently optionally substituted C 1-4 Alkyl groups, such as R 1 For SCH3.

[0166] Typically, in formula III-1, III-2, III-3, III-4, III-6, III-7, or III-8, R 2 In some embodiments, R 2 It can be halogen (e.g., F, Cl or Br), CN, OH, NH2, R B , OR B NH(R B ) or N(R B )2, where R B As defined herein. In some embodiments, R B It may be an optionally substituted C 1-4 alkyl or an optionally substituted 3-4 membered cycloalkyl.

[0167] Typically, R in Formula III-1, III-3, III-4, III-6, or III-7 3 is an optionally substituted C 1-4 Alkyl, such as CH3, CD3, etc. In some preferred embodiments, R 3 In some preferred embodiments, R 3 In some preferred embodiments, R 3 In some preferred embodiments, R 3 is CH(CH3)2. In some preferred embodiments, R 3 is CH2CHF2. In some embodiments, R 3 It may also be an optionally substituted C 3-6 In some preferred embodiments, R 3 In some preferred embodiments, R 3 In some preferred embodiments, R 3 For hydrogen.

[0168] Typically, Z in formula III-1, III-3, III-4, III-5, III-6, III-7, III-9, III-11 or III-12 is C(O).

[0169] In some embodiments, Z in Formula III-1, III-3, III-4, III-5, III-6, III-7, III-9, III-11 or III-12 can also be S(O)2.

[0170] In some typical embodiments, X in Formula III-1, III-2, III-5, III-6, III-7, III-8 or III-9 is N.

[0171] In some embodiments, X in Formula III-1, III-2, III-5, III-8, or III-9 is CR 5 , where R 5 As defined herein. In some embodiments, X is CR 5 , where R 5 In some embodiments, X is CR 5 , where R 5 CONH2, COOH, CONH(R C1 )、CON(R C1 )2 or COOR C1 , where R C1 Each occurrence is independently C 1-4 Alkyl groups, such as methyl.

[0172] In some embodiments, n1 is 0. In some embodiments, n1 is 1. In some embodiments, R 9 is independently CH3, CH2CH3, CH2CH2CH3, fluorinated C 1-3 Alkyl (e.g., CF2H), cyclopropyl or cyclobutyl, CH2OH, CH2OCH3, CH2OCH2CH3, CH2NH2, CH2N3 or CH2NHC(O)OCH3.

[0173] In some embodiments, in Formula III-6 or III-7, J is NR 15 , where R 15 As defined herein. For example, in some embodiments, J is N(C 1-4 alkyl), such as NCH3.

[0174] In some embodiments, in formula III-6 or III-7, J is an optionally substituted methylene. For example, in some embodiments, J is CH2. In some embodiments, J is CF2, CHCH3, C(CH3)2, CHOH, etc.

[0175] In some embodiments, in Formula III-6 or III-7, J is O. In some embodiments, in Formula III-6 or III-7, J is NH or NCH3.

[0176] In some embodiments, in Formula III-6 or III-7, W is absent. Thus, the ring containing J is a 5-membered ring.

[0177] In some embodiments, in Formula III-6 or III-7, p is 1 and W is W 1 , where W 1 As defined herein. For example, in some embodiments, W 1 is C(O), SO2, CH2, CF2, CHCH3, C(CH3)2, CHOH, etc. In such an embodiment, the ring containing J and W is a 6-membered ring.

[0178] In some embodiments, in formula III-6 or III-7, p is 2 and W is -W 1 -W 1 -, where each W 1 As defined herein. For example, in some embodiments, each W 1 are independently C(O), SO2, CH2, CF2, CHCH3, C(CH3)2, CHOH, etc. In some embodiments, the two W 1 In some embodiments, one W 1 For O, another W 1 is CH2. In some embodiments, one W 1 It is C(O), another W 1 is O, NH, NCH3 or CH2. In such embodiments, the ring containing J and W is a 7-membered ring.

[0179] Typically, in Formula III-1, III-2, III-5, III-8, or III-9, L 1 Herein is an optionally substituted 4-12 membered heterocyclylene. In some embodiments, L in Formula III-1, III-2, III-5, III-8 or III-9 1 is an optionally substituted 4-12 membered heterocyclylene group having one or more rings and 1-4 ring heteroatoms each independently being O, N, or S. In some embodiments, L in Formula III-1, III-2, III-5, III-8, or III-9 1 Can be -N(R E )-, where R E is optionally substituted C 1-4 alkyl or an optionally substituted 3-7 membered ring. For example, in some embodiments, L 1 Yes-N(C 1-4 alkyl)-, for example –N(CH3)-.

[0180] In some embodiments, L in Formula III-1, III-2, III-5, III-8, or III-9 1It is an optionally substituted 4-7 membered monocyclic heterocyclylene group having 1 or 2 ring heteroatoms, each of which is independently O, N or S. In some embodiments, the 4-7 membered monocyclic heterocyclylene group is a saturated heterocyclylene group having 1 or 2 ring heteroatoms (such as 1 or 2 ring nitrogen atoms), such as a piperazine or piperidine ring. The heterocyclylene group is typically attached to the rest of the molecule through two ring nitrogen atoms or one ring nitrogen atom and one ring carbon atom.

[0181] In some embodiments, in Formula III-1, III-2, III-5, III-8, or III-9, L 1 Can be (One of the two connection points of piperidine, N or C, can be connected to L 2 ),

[0182] in:

[0183] n is 0, 1, 2, 3, or 4, and

[0184] (1)R 9A Each occurrence is independently halogen, CN, OH, R N , OR N 、NHR N 、N(R N 2. COOR N 、COR N 、CONH(R N ) or CON(R N )2, where R N Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted 3-7 membered ring, such as optionally substituted C 3-6 cycloalkyl, optionally substituted 4-7 membered heterocyclyl, optionally substituted phenyl, or optionally substituted 5- or 6-membered heteroaryl; or

[0185] (2)R 9A Two instances of can be connected to form a double bond or a 3-5 membered ring and R 9A The remaining instances of are defined as (1).

[0186] In some embodiments, R 9A Each occurrence is independently R N In some embodiments, R 9A Each occurrence is independently optionally substituted C 1-4 Alkyl, and when substituted, the substituents may be independently selected from F, OH, C with 1 or 2 heteroatoms optionally substituted with F 1-4In some embodiments, R 9A Each occurrence is independently CH3, CH2CH3, CH2CH2CH3, fluorinated C 1-3 Preferably, R 9A Each occurrence is independently CH3, CH2CH3 or CH2CH2CH3, more preferably, R 9A is CH2CH3 at each occurrence. Typically, in Formula III-1, III-2, III-5, III-8, III-9, III-10, III-11 or III-12, n is 0, 1 or 2. For example, L 1 Can be selected from: Either of the two connection points can be connected to L 2 .

[0187] In some preferred embodiments, in Formula III-1, III-2, III-5, III-8 or III-9, L 1 Can be selected from the following (bottom connection point N or C connected to L 2 ):

[0188]

[0189] In some preferred embodiments, in Formula III-1, III-2, III-5, III-8 or III-9, L 1 Can be selected from the following (bottom connection point N or C connected to L 2 ):

[0190]

[0191] In some embodiments, L in Formula III-1, III-2, III-5, III-8, or III-9 1 It can also be an optionally substituted 7-12 membered heterocyclylene group having two or more rings and 1-4 ring heteroatoms each independently being O, N or S. When substituted, the substituents may be attached to any one or more of the two or more rings. For example, in some embodiments, L 1may be an optionally substituted 8-12 membered fused, spiro or bridged bicyclic heterocyclylene having 1-4 ring heteroatoms each independently being O, N or S, wherein each ring of the bicyclic heterocyclylene may be saturated, partially unsaturated, or aromatic, and each ring of the bicyclic heterocyclylene may have 0, 1, 2 or 3 ring heteroatoms, provided that the bicyclic heterocyclylene as a whole is not fully aromatic and the total number of heteroatoms in the bicyclic heterocyclylene does not exceed 4. In some embodiments, L 1 It can be an optionally substituted 8-11 membered fused bicyclic heterocyclylene having 1-3 ring heteroatoms each independently being O, N or S, wherein (1) one of the two fused rings is phenyl or a 5- or 6-membered heteroaryl, and (2) the other of the two fused rings is a 5-7 membered heterocyclic ring having one or two ring heteroatoms each independently being O, N or S, preferably the 5-7 membered heterocyclic ring has at least one ring nitrogen atom. In some embodiments, L 1 It can be an optionally substituted 8-11 (e.g., 8, 9, or 10)-membered spirobicyclic heterocyclylene group having 1-4 ring heteroatoms each independently being O, N, or S, wherein (1) one of the two spiro rings is a 5-7-membered heterocycle having one or two ring heteroatoms each independently being O, N, or S, preferably, the 5-7-membered heterocycle has one ring nitrogen atom, and (2) the other of the two spiro rings is a 4-6-membered heterocycle having 1-3 ring heteroatoms each independently being O, N, or S, for example, one of the two spiro rings is a pyrrole ring, a piperidine ring, or an azacycle, and the other of the two spiro rings is azetidine, pyrrole, pyrrolidone, piperidone, oxazoline, isoxazoline, thiazoline, isothiazolinone, etc.

[0192] For example, in some preferred embodiments, L in Formula III-1, III-2, III-5, III-8, or III-9 1 Can be selected from the following (bottom connection point N or C connected to L 2 ):

[0193]

[0194] Wherein, in each bicyclic heterocyclylene group, each of the two rings can be optionally substituted by 1-3 R 10 Substituted, where R 10 Each occurrence is independently halogen, OH, NH2, oxo (if applicable), R J , OR J 、CN、NH(R J ) or N(R J )2, where R J Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C2-4 alkynyl or an optionally substituted 3-4 membered ring.

[0195] In some preferred embodiments, L in Formula III-1, III-2, III-5, III-8 or III-9 1 Can be selected from the following (bottom connection point N or C connected to L 2 ):

[0196]

[0197] In some embodiments, L in Formula III-1, III-2, III-5, III-8, or III-9 1 It can also be -N(C 1-4 alkyl)-, such as -N(CH3)-.

[0198] In some embodiments, in Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, L 2 It may not exist.

[0199] In some embodiments, L in Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12 2 It may be an optionally substituted C 1-4 Alkylene, for example, with one or more R as defined herein 13 In some embodiments, R 13 Each occurrence is independently selected from halogen (e.g., F, Cl, or Br), CN, OH, NH2, COOH, CONH2, SO2NH2, COR K 、COOR K 、CONH(R K )、CON(R K 2. SO2R K 、SO2NH(R K )、SO2N(R K )2、R K , OR K NH(R K )、N(R K )2、SR K 、SOR K 、SO2R K or P(O)(R K )2, where R KEach occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 1-4 Heteroalkyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms each independently selected from O, N or S, or optionally substituted 4-7 membered heterocyclyl.

[0200] In some embodiments, L in Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12 2 Can be unsubstituted C 1-4 Alkylene, such as CH2, CH(CH3), CH(C2H5), CH(C3H7), etc.

[0201] In some embodiments, L in Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12 2 Can be unsubstituted C 1-4 Alkylene, selected from: CH2, or

[0202]

[0203] In some embodiments, L in Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12 2 It may be an optionally substituted C 1-4 Alkylene, selected from:

[0204]

[0205] in:

[0206] R 13 Selected from hydrogen, halogen (such as F, Cl or Br), CN, OH, NH2, COOH, CONH2, SO2NH2, COR K 、COOR K 、CONH(R K )、CON(R K 2. SO2R K 、SO2NH(R K )、SO2N(RK )2、R K , OR K NH(R K )、N(R K )2、SR K 、SOR K 、SO2R K or P(O)(R K )2, where R K Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 1-4 Heteroalkyl, optionally substituted C 3-6 cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl, wherein, when substituted, the optionally substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl, phenyl, 5- or 6-membered heteroaryl or 4-7-membered heterocyclyl is substituted by 1-3 substituents independently selected from halogen (preferably F or Cl), OH, CN, C 1-4 Alkyl, optionally substituted with 1-3 F 1-4 and heteroalkyl and 3-4 membered rings optionally substituted with F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.). For example, in some embodiments, R 13 In some embodiments, R 13 It is C 1-4 Alkyl, such as methyl, ethyl, isopropyl, etc. In some embodiments, R 13 In some embodiments, R 13 In some embodiments, R 13 is R as defined in this paper K In some embodiments, R 13 Is OH or OR K , where R K In this paper, it is defined that, for example, C 1-4 In some embodiments, R 13is CN, OH, COOH, CONH2, methoxy, ethoxy, cyclopropyl, cyclobutyl, optionally substituted phenyl, or optionally substituted 5- or 6-membered heteroaryl having 1-3 ring heteroatoms independently selected from N, O and S, wherein, when substituted, the optionally substituted phenyl or 5- or 6-membered heteroaryl is substituted with 1-3 substituents independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted with 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F C 1-4 In some embodiments, R 13 is a 3-4 membered ring, such as cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc., which may be optionally substituted, for example, by F and / or methyl. For example, in some embodiments, R 13 In some embodiments, R 13 is optionally substituted phenyl or optionally substituted 5- or 6-membered heteroaryl having 1-3 ring heteroatoms independently selected from N, O and S, such as optionally substituted phenyl or thiazolyl, which is optionally substituted with 1-3 substituents independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted with 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F 1-4 and heteroalkyl and 3-4 membered rings optionally substituted with F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.). For example, in some embodiments, R 13 yes In some embodiments, R 13 OH, methoxy, cyclopropyl, phenyl,

[0207] In some embodiments, in Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, L 2 Can be C(O). In some embodiments, in Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, L 2 It can be O, preferably in formula III-4, L 2 Not O.

[0208] In some embodiments, in Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, L 2 It may be an optionally substituted phenylene group, for example

[0209] In some embodiments, in Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, L 2 It may be an optionally substituted 5- or 6-membered heteroarylene group, for example,

[0210] In some embodiments, in Formula III-1, III-2, III-5, III-8, or III-9, L 1 Can be -N(R E )-,L 2 is an optionally substituted phenylene group, for example, And R 30 is hydrogen. For example, in some embodiments, L 1 , L 2 and R 30 Together they are:

[0211]

[0212] In some embodiments, in Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, R 30 is an optionally substituted phenyl group, for example, substituted with 1 to 3 (eg, 1 or 2) R 22 Substituted phenyl, wherein R 22 Each occurrence is independently halogen (e.g., F, Cl, or Br), CN, OH, NH2, R M , OR M 、COOH、CONH2、COOR M 、CONH(R M )、CON(R M )2、NHCO(R M )、N(R M )CO(R M ), SO2R M 、SO2NH2、S(O)(NH)R M 、S(O)(NR M )RM 、SO2N(R M 2. NHSO2R M 、N(R M )SO2R M 、P(O)(R M )2、P(O)(OR M )2、NH(R M )、N(R M )2、SR M or SF5, where R M Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl. In some embodiments, R 22 An example of is a halogen, such as F, Cl or Br, and R 22 The remaining examples of (if any) are as defined herein. In some embodiments, R 22 Two or three examples of are halogen, each independently F, Cl or Br, and R 22 The remaining examples of (if any) are as defined herein. In some embodiments, R 22 An example is CN, R 22 The remaining examples of (if any) are as defined herein. In some embodiments, R 22 An example of R is M , OR M SR M , SF5 or SO2R M , where R M As defined herein, for example, C optionally substituted with F 1-3 alkyl (eg, CF3, CF2CH3, CHF2, etc.) or cyclopropyl, and R 22 The remaining examples of (if any) are as defined herein. For example, in some embodiments, R 30 is a phenyl group consisting of 1 to 3 (e.g., 1 or 2) R 22 Substitute, where R 22 Each occurrence is independently halogen (eg, F, Cl, or Br), CN, OH, R M1 , OR M1 、SO2R M1 、P(O)(R M1 )2、SR M1 or SF5, where R M1Each occurrence is independently optionally substituted C 1-4 alkyl or an optionally substituted 3-4 membered ring (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), wherein when substituted, the optionally substituted C 1-4 The alkyl group or the 3-4 membered ring is substituted by 1-3 substituents independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted by 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F 1-4 Heteroalkyl, 3-4 membered ring optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.). More preferably, R 30 It is composed of 1-3 (e.g., 1 or 2) R 22 Substituted phenyl, wherein R 22 Each occurrence is independently F, Cl, CN, R M2 , OR M2 SR M2 or SF5, where R M2 Each occurrence is independently C optionally substituted with 1-3 F 1-4 In some embodiments, R 22 Each occurrence may independently be halogen, CN, C optionally substituted with 1-3 F 1-4 Alkyl (such as CH3, CF3, etc.), optionally substituted by 1-3 F 1-4 Alkoxy (such as OCH3, OCF3, etc.), SCF3, SF5, cyclopropyl, cyclobutyl or In some preferred embodiments, R 22 Each occurrence is independently F, Cl, Br, CF3, OCF3, SCF3, SF5, OMe, CN, methyl, CHF2, CF2CH3, cyclopropyl, CH3SO2 and OCH2-(cyclopropyl).

[0213] In some embodiments, in Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, R 30 is an optionally substituted 5-membered or 6-membered heteroaryl, such as pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Substitute, where R 22 Each occurrence is independently halogen (e.g., F, Cl, or Br), CN, OH, NH2, R M , OR M、COOH、CONH2、COOR M 、CONH(R M )、CON(R M )2、NHCO(R M )、N(R M )CO(R M ), SO2R M 、SO2NH2、S(O)(NH)R M 、S(O)(NR M )R M 、SO2N(R M 2. NHSO2R M 、N(R M )SO2R M 、P(O)(R M )2、P(O)(OR M )2、NH(R M )、N(R M )2、SR M or SF5, where R M Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl. In some embodiments, R 22 An example of is a halogen, such as F, Cl or Br, and R 22 The remaining examples of (if any) are as defined herein. In some embodiments, R 22 Two or three examples of are halogen, each independently F, Cl or Br, and R 22 The remaining examples of (if any) are as defined herein. In some embodiments, R 22 An example is CN, R 22 The remaining examples of (if any) are as defined herein. In some embodiments, R 22 An example of R is M , OR M SR M , SF5 or SO2R M , where R M As defined herein, for example, C optionally substituted by F 1-3 alkyl (eg, CF3, CF2CH3, CHF2, etc.) or cyclopropyl, and R 22The remaining examples of (if any) are as defined herein. For example, in some embodiments, R 30 is a 5-membered heteroaryl group (e.g., ) or pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Substitution, where valence permits, where R 22 Each occurrence is independently halogen (eg, F, Cl, or Br), CN, OH, R M1 , OR M1 、SO2R M1 、P(O)(R M1 )2、SR M1 or SF5, where R M1 Each occurrence is independently optionally substituted C 1-4 alkyl or an optionally substituted 3-4 membered ring (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), wherein when substituted, the optionally substituted C 1-4 The alkyl group or the 3-4 membered ring is substituted by 1-3 substituents independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted by 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F 1-4 Heteroalkyl, 3-4 membered ring optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.). More preferably, R 30 is a 5-membered heteroaryl group (e.g., ) or pyridyl (e.g., ) or pyrimidinyl (e.g., ), which is replaced by 1-3 (e.g., 1 or 2) R 22 Substitution, where valence permits, where R 22 Each occurrence is independently F, Cl, CN, R M2 , OR M2 SR M2 or SF5, where R M2 Each occurrence is independently C optionally substituted with 1-3 F 1-4 In some embodiments, R 22 Each occurrence is independently halogen, CN, C optionally substituted with 1-3 F 1-4 Alkyl (such as CH3, CF3, etc.), C optionally substituted by 1-3 F 1-4 Alkoxy (such as OCH3, OCF3, etc.), SCF3, SF5, cyclopropyl, cyclobutyl or In some preferred embodiments, R 22Each occurrence is independently F, Cl, Br, CF3, OCF3, SCF3, SF5, OMe, CN, methyl, CHF2, CF2CH3, cyclopropyl, CH3SO2 and OCH2-(cyclopropyl).

[0214] In some embodiments, in Formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12, R 30 It may have the structure of the following formula S-1, S-2, S-3 or S-4:

[0215]

[0216] in:

[0217] Ring B connects to L 2 ,

[0218] wherein Ring B is a 5-7 membered ring containing 0, 1 or 2 ring heteroatoms and optionally substituted by 1-3 R G Substituted, where R G Each occurrence is independently halogen, OH, oxo, NH2, NH(C 1-4 alkyl), N(C 1-4 Alkyl)(C 1-4 alkyl), optionally substituted C 1-4 Alkyl or optionally substituted C 1-4 alkoxy;

[0219] wherein the phenyl, pyridyl or pyrimidyl group in formula S-1, S-2, S-3 or S-4 is optionally replaced by q R 8 ; where:

[0220] q is an integer in the range of 0-3, preferably 1 or 2,

[0221] R 8 Each occurrence is independently halogen (e.g., F, Cl, or Br), CN, OH, NH2, R H , OR H NH(R H )、N(R H )2、SR H , SF5, or an optionally substituted 5-8 membered carbon ring having two or more rings, wherein R H Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6Cycloalkyl, or optionally substituted 4-7 membered heterocyclic group;

[0222] wherein, when substituted, the optionally substituted C 1-4 Alkyl, C 1-4 Alkoxy, 5-8 membered carbon ring, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 The cycloalkyl or 4-7 membered heterocyclyl may be substituted by one or more (eg, 1-3) substituents, for example, each substituent may be independently selected from halogen (eg, F), OH, CN, C 1-4 Alkyl or C 1-4 It should be understood that in the display of the S-1, S-2, S-3 or S-4 structural formula, R 8 (if present) the phenyl, pyridyl or pyrimidyl moiety in the attached structure, i.e. not on ring B, if ring B is substituted, is understood to be substituted by 1 to 3 R as defined herein. G replace.

[0223] In some embodiments, in S-1, S-2, S-3 or S-4, Ring B contains no ring heteroatoms. In some embodiments, in S-1, S-2, S-3 or S-4, Ring B contains one ring heteroatom, such as O, N or S. In some embodiments, in S-1, S-2, S-3 or S-4, Ring B contains no ring heteroatoms and is unsubstituted. In some embodiments, in S-1, S-2, S-3 or S-4, Ring B contains no ring heteroatoms and is optionally substituted with one or more substituents described herein, for example, in some embodiments, Ring B is optionally substituted with 1-3 R G1 Substituted, where R G1 Each occurrence is independently F, OH, C optionally substituted with 1-3 F 1-4 Alkyl, or C optionally substituted by 1-3 F 1-4 Alkoxy.

[0224] The phenyl, pyridyl or pyrimidyl moiety of S-1, S-2, S-3 or S-4 is usually replaced by one R 8 Substitution, i.e., q is 1, wherein R 8 As defined herein. In some embodiments, the phenyl, pyridyl, or pyrimidinyl moiety of S-1, S-2, S-3, or S-4 may be composed of two R 8 Substituted, where R 8 As defined herein. In some embodiments, R 8 Each occurrence is independently R H1 , OR H1 SR H1 , SF5 or an optionally substituted 5-8 membered carbon ring having two or more rings, wherein RH1 is C optionally substituted with 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F C 1-4 Alkoxy or C optionally substituted by 1-3 substituents 3-6 Cycloalkyl, the substituents being independently selected from F, OH, methyl and methoxy, wherein when substituted, the optionally substituted 5-8 membered carbocyclic ring is substituted by 1-3 substituents, each substituent being independently selected from halogen (e.g., F), OH, CN, C 1-4 Alkyl and C 1-4 In some embodiments, R 8 It can be an optionally substituted 5-8 membered carbocyclic ring having two or more rings, such as a bicyclic carbocyclic ring. For example, in some embodiments, R 8 It can be a 5-8 membered bicyclic carbocycle, such as a bridged bicyclic carbocycle, such as It is optionally substituted, wherein, when substituted, the bicyclic carbocycle may be substituted by one or more (e.g., 1-3) substituents, for example, each substituent may be independently selected from halogen (e.g., F), OH, CN, C 1-4 Alkyl or C 1-4 In some embodiments, R 8 Can be In some embodiments, R 8 Each occurrence may independently be C optionally substituted with 1-3 F 1-4 Alkyl (such as CH3, CF3, etc.), C optionally substituted by 1-3 F 1-4 Alkoxy (such as OCH3, OCF3, etc.), SCF3, SF5, cyclopropyl, cyclobutyl or

[0225] For example, in some embodiments, R 30 May have a structure according to S-1-A, S-1-B, S-1-C or S-1-D:

[0226]

[0227] where R 8 is C optionally substituted with 1-3 F 1-4 Alkyl (such as CH3, CF3, etc.), optionally substituted by 1-3 F 1-4 Alkoxy (such as OCH3, OCF3, etc.), SCF3, SF5, cyclopropyl, cyclobutyl, or

[0228] In some preferred embodiments, R in Formulas III-1 to III-12 30 You can choose from the following options:

[0229]

[0230] In some preferred embodiments, R in Formulas III-1 to III-12 30 You can choose from the following options:

[0231]

[0232] In some preferred embodiments, R in Formulas III-1 to III-12 30 You can choose from the following options:

[0233]

[0234] In some preferred embodiments, R in Formulas III-1 to III-12 30 You can choose from the following options:

[0235]

[0236] In some preferred embodiments, R in Formulas III-1 to III-12 30 You can choose from the following options:

[0237]

[0238] In some preferred embodiments, R in Formulas III-1 to III-12 30 You can choose from the following options:

[0239]

[0240] In some preferred embodiments, R in Formulas III-1 to III-12 30 You can choose from the following options:

[0241]

[0242] In some preferred embodiments, R in Formulas III-1 to III-12 30 You can choose from the following options:

[0243]

[0244] In some preferred embodiments, R in Formulas III-1 to III-12 30 Not selected from the following options:

[0245]

[0246] In some preferred embodiments, R in Formulas III-1 to III-12 30You can choose from the following options:

[0247]

[0248] In some embodiments, in Formulas III-1 to III-12, -L 2- R 30 It can be:

[0249]

[0250] In some embodiments, in Formulas III-1 to III-12, -L 2 -R 30 no

[0251]

[0252] In some embodiments, in Formulas III-1 to III-12, -L 2- R 30 You can choose from the following:

[0253]

[0254] In some embodiments, in Formulas III-1 to III-12, -L 2- R 30 Can be selected from:

[0255]

[0256] In some embodiments, in Formulas III-1 to III-12, -L 2- R 30 Can be selected from:

[0257]

[0258] In some embodiments, in Formulas III-1 to III-12, -L 2- R 30 Can be selected from:

[0259]

[0260] In some embodiments, in Formulas III-1 to III-12, -L 2- R 30 It can be:

[0261]

[0262] In some embodiments, in formulas III-1 to III-12, -L 2- R 30 no

[0263]

[0264] In some embodiments, in Formula III-1, III-2, III-5, III-8, or III-9, L 1 、L 2 and R 30 (i.e. L 1- L 2- R 30 ) can be selected from:

[0265]

[0266] In some embodiments, in Formula III-1, III-2, III-5, III-8, or III-9, L 1 、L 2 and R 30 Together you can choose from:

[0267]

[0268] In some embodiments, in Formula III-1, III-2, III-5, III-8, or III-9, L 1 、L 2 and R 30 Together you can choose from:

[0269]

[0270] In some embodiments, in Formula III-1, III-2, III-5, III-8, or III-9, L 1 -L 2 -R 30 Selected from the following:

[0271]

[0272]

[0273] In some embodiments, in Formula III-1, III-2, III-5, III-8, or III-9, L 1 、L 2 and R 30 Together you can choose from:

[0274]

[0275] In some embodiments, in Formula III-1, III-2, III-5, III-8, or III-9, L 1 、L2 and R 30 Together you can choose from:

[0276]

[0277] In some embodiments, in Formula III-1, III-2, III-5, III-8, or III-9, L 1 , L 2 and R 30 Together you can choose from:

[0278]

[0279] In some embodiments, the present disclosure provides the following listed exemplary embodiments A1-A38:

[0280] Implementation Plans A1-A38

[0281] Embodiment A1. A compound of formula III-2, or a pharmaceutically acceptable salt thereof,

[0282]

[0283] Among them, variables X, Y, U, R1, R 2 , L 1 , L 2 and R 30 As defined herein.

[0284] Embodiment A2. The compound of Embodiment A1, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-2-A:

[0285]

[0286] Embodiment A3. The compound of Embodiment A1, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-2-B:

[0287]

[0288] Embodiment A4. A compound according to any one of Embodiments A1-A3, or a pharmaceutically acceptable salt thereof, wherein (i) R 1 is CN; (ii) R 1 is a halogen, such as F or Cl; (iii) R 1 yes (iv)R 1 is an optionally substituted 5- or 6-membered heteroaryl group having 1-4 ring heteroatoms independently selected from O, S and N, such as an optionally substituted pyrimidinyl group or an optionally substituted thiazolyl group, for example, R 1for or (v)R 1 SR A1 , where R A1 are independently optionally substituted C 1-4 Alkyl groups, such as R 1 For SCH3.

[0289] Embodiment A5. A compound according to any one of Embodiments A1-A4, or a pharmaceutically acceptable salt thereof, wherein L 1 Select from the following options (bottom connection point N or C connected to L 2 ):

[0290]

[0291] Embodiment A6. A compound according to any one of Embodiments A1-A4, or a pharmaceutically acceptable salt thereof, wherein L 1 Select from the following options (bottom connection point N or C connected to L 2 ):

[0292]

[0293] Embodiment A7. The compound of any one of Embodiments A1-A4, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-2-C:

[0294]

[0295] Where n is 0, 1, 2 or 3, R 9A As defined herein.

[0296] Embodiment A8. The compound of Embodiment A7, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-2-C-1, III-2-C-2, III-2-C-3 or III-2-C-4:

[0297]

[0298]

[0299] Among them, the two R in formula III-2-C-3 9A are independently selected.

[0300] Embodiment A9. A compound as described in embodiment A7 or A8, wherein R 9A Each occurrence is independently CH3, CH2CH3, CH2CH2CH3, fluorinated C 1-3Alkyl (e.g., CF2H), cyclopropyl, cyclobutyl, CH2OH, CH2OCH3, CH2OCH2CH3, CH2NH2, CH2N3, or CH2NHC(O)OCH3.

[0301] Embodiment A10. The compound of any one of Embodiments A1-A4, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-2-D:

[0302]

[0303] Where n is 0, 1, 2 or 3, R 9A As defined herein.

[0304] Embodiment A11. The compound of Embodiment A10, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-2-D-1, III-2-D-2, III-2-D-3 or III-2-D-4:

[0305]

[0306]

[0307] The two R in formula III-2-D-3 9A are independently selected.

[0308] Embodiment A12. A compound according to embodiment A10 or A11, or a pharmaceutically acceptable salt thereof, wherein R 9A Each occurrence is independently CH3, CH2CH3, CH2CH2CH3, fluorine-substituted C 1-3 Alkyl (e.g., CF2H), cyclopropyl, cyclobutyl, CH2OH, CH2OCH3, CH2OCH2CH3, CH2NH2, CH2N3, or CH2NHC(O)OCH3.

[0309] Embodiment A13. The compound of any one of Embodiments A1-A12, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-2-E-1, III-2-E-2, or III-2-E-3:

[0310]

[0311] Among them, R 13 As defined herein.

[0312] Embodiment A14. The compound of any one of Embodiments A1-A12, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-2-E-1a, III-2-E-2a, III-2-E-3a, III-2-E-1b, III-2-E-2b, or III-2-E-3b:

[0313]

[0314]

[0315] Among them, R 13 As defined herein.

[0316] Embodiment A15. The compound of Embodiment A13, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F-3a or III-2-F-3b:

[0317]

[0318] in:

[0319] R 9A Each occurrence is independently CH3, CH2CH3, CH2CH2CH3, fluorinated C 1-3 Alkyl (e.g., CF2H), cyclopropyl, cyclobutyl, CH2OH, CH2OCH3, CH2OCH2CH3, CH2NH2, CH2N3 or CH2NHC(O)OCH3, preferably R 9A Each occurrence is independently CH3, CH2CH3 or CH2CH2CH3, more preferably, R 9A In each occurrence it is CH2CH3.

[0320] Embodiment A16. A compound according to any one of Embodiments A13-A15, or a pharmaceutically acceptable salt thereof, wherein R 13 is hydrogen, C 1-4 alkyl (e.g., methyl, isopropyl, etc.), CN, OH, COOH, CONH2, methoxy, ethoxy, cyclopropyl, cyclobutyl, optionally substituted phenyl, or optionally substituted 5- or 6-membered heteroaryl having 1-3 ring heteroatoms independently selected from N, O, and S, wherein, when substituted, the optionally substituted phenyl or 5- or 6-membered heteroaryl is substituted with 1-3 substituents independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted with 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F C1-4 Heteroalkyl, and 3-4 membered rings optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), more preferably, R 13 It's hydrogen.

[0321] Embodiment A17. A compound according to any one of Embodiments A1-A12, or a pharmaceutically acceptable salt thereof, wherein L 2 Not present, or O or C(O).

[0322] Embodiment A18. A compound according to any one of Embodiments A1-A17, or a pharmaceutically acceptable salt thereof, wherein R 30 is an optionally substituted phenyl group or a 5-membered or 6-membered heteroaryl group (e.g., oxadiazolyl group (e.g., ), pyridyl (e.g., ) or pyrimidinyl (e.g. ), for example, when substituted, phenyl or 5-membered or 6-membered heteroaryl may be replaced by 1-3 (e.g., 1 or 2) R 22 Substituted, where R 22 Each occurrence is halogen (eg, F, Cl, or Br), CN, C optionally substituted with 1-3 F 1-4 Alkyl (such as CH3, CF3, etc.), C optionally substituted by 1-3 F 1-4 Alkoxy (such as OCH3, OCF3, etc.), SCF3, SF5, cyclopropyl, cyclobutyl or

[0323] Embodiment A19. A compound according to any one of Embodiments A1-A17, or a pharmaceutically acceptable salt thereof, wherein R 30 is a phenyl group consisting of 1 to 3 (e.g., 1 or 2) R 22 Substituted, where R 22 Each occurrence is independently halogen (eg, F, Cl, or Br), CN, OH, R M1 , OR M1 、SO2R M1 、P(O)(R M1 )2、SR M1 or SF5, where R M1 Each occurrence is independently optionally substituted C 1-4 alkyl or an optionally substituted 3-4 membered ring (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), wherein when substituted, the optionally substituted C 1-4 The alkyl group or the 3-4 membered ring is substituted by 1-3 substituents independently selected from the group consisting of halogen (preferably F or Cl), OH, CN, C optionally substituted by 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F C1-4 Heteroalkyl, and 3-4 membered rings optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), preferably R 22 Each occurrence is independently F, Cl, Br, CF3, OCF3, SCF3, SF5, OMe, CN, methyl, CHF2, CF2CH3, cyclopropyl, CH3SO2 and OCH2-(cyclopropyl).

[0324] Embodiment A20. A compound according to any one of Embodiments A1-A17, or a pharmaceutically acceptable salt thereof, wherein R 30 It is composed of 1-3 (e.g. 1 or 2) R 22 Substituted phenyl, wherein R 22 Each occurrence is independently F, Cl, CN, R M2 , OR M2 SR M2 or SF5, where R M2 Each occurrence is independently C optionally substituted with 1-3 F 1-4 Alkyl groups, such as CF3.

[0325] Embodiment A21. A compound according to any one of Embodiments A1-A17, or a pharmaceutically acceptable salt thereof, wherein R 30 is a 5-membered heteroaryl group (e.g., ) or pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Substitution, where valence permits, where R 22 Each occurrence is independently halogen (eg, F, Cl, or Br), CN, OH, R M1 , OR M1 、SO2R M1 、P(O)(R M1 )2、SR M1 or SF5, where R M1 Each occurrence is independently optionally substituted C 1-4 alkyl or an optionally substituted 3-4 membered ring (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), wherein when substituted, the optionally substituted C 1-4 The alkyl group or the 3-4 membered ring is substituted by 1-3 substituents independently selected from the group consisting of halogen (preferably F or Cl), OH, CN, C optionally substituted by 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F 1-4Heteroalkyl, 3-4 membered ring optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), preferably R 22 Each occurrence is independently F, Cl, Br, CF3, OCF3, SCF3, SF5, OMe, CN, methyl, CHF2, CF2CH3, cyclopropyl, CH3SO2 and OCH2-(cyclopropyl).

[0326] Embodiment A22. A compound according to any one of Embodiments A1-A17, or a pharmaceutically acceptable salt thereof, wherein R 30 is a 5-membered heteroaryl group (e.g., ) or pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Substitution, where valence permits, where R 22 Each occurrence is independently F, Cl, CN, R M2 , OR M2 SR M2 or SF5, where R M2 Each occurrence is independently C optionally substituted with 1-3 F 1-4 Alkyl groups, such as CF3.

[0327] Embodiment A23. A compound according to any one of Embodiments A1-A17, or a pharmaceutically acceptable salt thereof, wherein R 30 Having the structure according to S-1-A, S-1-B, S-1-C or S-1-D:

[0328]

[0329] where R 8 is C optionally substituted with 1-3 F 1-4 Alkyl (such as CH3, CF3, etc.), optionally substituted by 1-3 F 1-4 Alkoxy (such as OCH3, OCF3, etc.), SCF3, SF5, cyclopropyl, cyclobutyl, or

[0330] Embodiment A24. A compound according to any one of Embodiments A1-A17, or a pharmaceutically acceptable salt thereof, wherein R 30 Selected from:

[0331]

[0332] Embodiment A25. A compound according to any one of Embodiments A1-A17, or a pharmaceutically acceptable salt thereof, wherein R 30Selected from:

[0333]

[0334] Embodiment A26. A compound according to any one of Embodiments A1-A17, or a pharmaceutically acceptable salt thereof, wherein R 30 Select from the following:

[0335]

[0336] Embodiment A27. A compound according to any one of Embodiments A1-A17, or a pharmaceutically acceptable salt thereof, wherein R 30 Selected from:

[0337]

[0338] Embodiment A28. A compound according to any one of Embodiments A1-A17, or a pharmaceutically acceptable salt thereof, wherein R 30 Selected from:

[0339]

[0340] Embodiment A29. A compound according to any one of Embodiments A1-A17, or a pharmaceutically acceptable salt thereof, wherein R 30 Selected from:

[0341]

[0342] Embodiment A30. A compound according to any one of Embodiments A1-A17, or a pharmaceutically acceptable salt thereof, wherein R 30 Selected from:

[0343]

[0344] Embodiment A31. A compound according to any one of Embodiments A1-A4, or a pharmaceutically acceptable salt thereof, wherein L 1 -L 2 -R 30 Select from the following:

[0345]

[0346] Embodiment A32. A compound according to any one of Embodiments A1-A4, or a pharmaceutically acceptable salt thereof, wherein L 1 -L 2 -R 30 Select from the following:

[0347]

[0348]

[0349] Embodiment A33. A compound according to any one of Embodiments A1-A4, or a pharmaceutically acceptable salt thereof, wherein L 1 -L 2 -R 30 Select from the following:

[0350]

[0351]

[0352] Embodiment A34. A compound according to any one of Embodiments A1-A4, or a pharmaceutically acceptable salt thereof, wherein L 1 -L 2 -R 30 Select from the following:

[0353]

[0354] Or, L 1 -L 2 -R 30 Select from the following:

[0355]

[0356] Or, L 1 -L 2 -R 30 Select from the following:

[0357]

[0358] Embodiment A35. A compound according to any one of Embodiments A1-A12, or a pharmaceutically acceptable salt thereof, wherein L 2 -R 30 Selected from:

[0359]

[0360] Embodiment A36. A compound according to any one of Embodiments A1-A12, or a pharmaceutically acceptable salt thereof, wherein L 2 -R 30 Selected from:

[0361]

[0362] Embodiment A37. A compound of formula III-8, or a pharmaceutically acceptable salt thereof, wherein Ring C is an imidazole or triazole ring, wherein the variables X, Y, U, R1 、R 2 , L 1 , L 2 and R 30 As defined herein, including any of those defined in connection with Formula III-2 as shown in Embodiments A2-A36.

[0363] Embodiment A38. The compound of Embodiment A37, or a pharmaceutically acceptable salt thereof, characterized in that it has the structural formula according to III-8-A or III-8-B:

[0364]

[0365] Among them, variables X, Y, U, R 1 、R 2 , L 1 , L 2 and R 30 As defined herein, including any of those defined in connection with Formula III-2 shown in Embodiments A2-A36.

[0366] In some embodiments, the present disclosure provides the following listed exemplary embodiments B1-B45:

[0367] Implementation Plans B1-B45

[0368] Embodiment B1. A compound of formula III-3, or a pharmaceutically acceptable salt thereof,

[0369]

[0370] Among them, variables Y, U, Z, R 1 、R 2 、R 3 、R 9 、n1、L 2 and R 30 As defined herein.

[0371] Embodiment B2. The compound of Embodiment B1, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-3-A:

[0372]

[0373] Embodiment B3. A compound of formula III-4, or a pharmaceutically acceptable salt thereof,

[0374]

[0375] Among them, variables Y, U, Z, R 1 、R2 、R 3 、R 9 、n1、L 2 and R 30 As defined herein.

[0376] Embodiment B4. The compound of Embodiment B3, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-4-A:

[0377]

[0378] Embodiment B5. The compound of Embodiment B3, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-4-B:

[0379]

[0380] Embodiment B6. The compound of Embodiment B5, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-4-C or III-4-D:

[0381]

[0382] Embodiment B7. The compound of Embodiment B6, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1 or III-4-D-2:

[0383]

[0384]

[0385] Embodiment B8. The compound of any one of Embodiments B1-B7, or a pharmaceutically acceptable salt thereof, wherein (i) R 3 is an optionally substituted C 1-4 Alkyl, such as CH3, CD3, ethyl, isopropyl, CH2CHF2, etc., or R 3 is an optionally substituted 3-4 membered ring, such as cyclopropyl or cyclobutyl, etc., when substituted, C 1-4 The alkyl group or the 3-4 membered ring is usually substituted by 1-3 substituents which are independently deuterium, F or methyl, preferably R 3 is methyl or CD3; (ii) R 3 It's hydrogen.

[0386] Embodiment B9. The compound of any one of Embodiments B1-B8, or a pharmaceutically acceptable salt thereof, wherein (i) R1 is CN; (ii) R 1 is a halogen, such as F or Cl; (iii) R 1 yes (iv)R 1 is an optionally substituted 5- or 6-membered heteroaryl group having 1-4 ring heteroatoms independently selected from O, S and N, such as an optionally substituted pyrimidinyl group or an optionally substituted thiazolyl group, for example, R 1 for or (v)R 1 SR A1 , where R A1 are independently optionally substituted C 1-4 Alkyl groups, such as R 1 For SCH3.

[0387] Embodiment B10. The compound of any one of Embodiments B1-B9, or a pharmaceutically acceptable salt thereof, wherein R 9 Each occurrence is independently CH3, CH2CH3, CH2CH2CH3, fluorinated C 1-3 Alkyl (e.g., CF2H), cyclopropyl, cyclobutyl, CH2OH, CH2OCH3, CH2OCH2CH3, CH2NH2, CH2N3 or CH2NHC(O)OCH3, preferably, R 9 Each occurrence is independently CH3, CH2CH3 or CH2CH2CH3, more preferably, R 9 Each occurrence is independently CH2CH3.

[0388] Embodiment B11. A compound according to any one of Embodiments B1-B10, or a pharmaceutically acceptable salt thereof, wherein L 2 is an optionally substituted C 1-4 Alkylene.

[0389] Embodiment B12. A compound according to any one of Embodiments B1-B10, or a pharmaceutically acceptable salt thereof, wherein L 2 Select from the following:

[0390]

[0391] where R 13 As defined herein.

[0392] Embodiment B13. A compound according to any one of Embodiments B1-B10, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f:

[0393]

[0394] where R 13 As defined herein.

[0395] Embodiment B14. The compound of any one of Embodiments B1-B10, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-4-C-4a:

[0396]

[0397] where R 13 As defined herein.

[0398] Embodiment B15. A compound according to Embodiment B14, or a pharmaceutically acceptable salt thereof, which is substantially stereoisomerically pure, e.g., having an enantiomeric excess ("ee") of 80% or greater, such as 90% ee, 95% ee, 98% ee, 99% ee or greater, and is substantially free of the corresponding stereoisomer according to Formula III-4-C-4b.

[0399]

[0400] For example, having less than 5%, e.g., less than 2%, less than 1%, less than 0.5% or less than 0.1% of the corresponding stereoisomer according to Formula III-4-C-4b as determined by HPLC or SFC area % and / or weight.

[0401] Embodiment B16. The compound of any one of Embodiments B1-B10, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-4-C-4c:

[0402]

[0403] where R 13 As defined herein.

[0404] Embodiment B17. A compound according to Embodiment B16, or a pharmaceutically acceptable salt thereof, which is substantially stereoisomerically pure, e.g., having an enantiomeric excess ("ee") of 80% or greater, such as 90% ee, 95% ee, 98% ee, 99% ee or greater, and is substantially free of the corresponding stereoisomer according to Formula III-4-C-4d.

[0405]

[0406] For example, having less than 5%, e.g., less than 2%, less than 1%, less than 0.5% or less than 0.1% of the corresponding stereoisomer according to Formula III-4-C-4d as determined by HPLC or SFC area % and / or weight.

[0407] Embodiment B18. The compound of any one of Embodiments B1-B10, or a pharmaceutically acceptable salt thereof, characterized in that it has a structure according to Formula III-4-C-4e:

[0408]

[0409] where R 13 As defined herein.

[0410] Embodiment B19. A compound according to Embodiment B18, or a pharmaceutically acceptable salt thereof, which is substantially stereoisomerically pure, e.g., having an enantiomeric excess ("ee") of 80% or greater, such as 90% ee, 95% ee, 98% ee, 99% ee or greater, and is substantially free of the corresponding stereoisomer according to Formula III-4-C-4f.

[0411]

[0412] For example, having less than 5%, e.g., less than 2%, less than 1%, less than 0.5% or less than 0.1% of the corresponding stereoisomer according to Formula III-4-C-4f as determined by HPLC or SFC area % and / or weight.

[0413] Embodiment B20. A compound according to any one of Embodiments B12-B19, or a pharmaceutically acceptable salt thereof, wherein R 13 is hydrogen, CN, OH, COOH, CONH2, methoxy, ethoxy, cyclopropyl, cyclobutyl, optionally substituted phenyl, or optionally substituted 5- or 6-membered heteroaryl having 1-3 ring heteroatoms independently selected from N, O and S, wherein, when substituted, the optionally substituted phenyl or 5- or 6-membered heteroaryl is substituted by 1-3 substituents independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted with 1-3 F 1-4Alkyl, optionally substituted with 1-3 F C 1-4 Heteroalkyl, and a 3-4 membered ring optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), more preferably, R 13 It's hydrogen.

[0414] Embodiment B21. A compound according to any one of Embodiments B12-B19, or a pharmaceutically acceptable salt thereof, wherein R 13 is optionally composed of one or more independently selected from F, OH or C 1-4 Alkoxy substituents substituted C 1-4 Alkyl groups, such as R 13 It is methyl, ethyl, isopropyl, CH2OH, CH2OMe, etc.

[0415] Embodiment B22. A compound according to any one of Embodiments B12-B19, or a pharmaceutically acceptable salt thereof, wherein R 13 is phenyl, which is optionally substituted by 1-3 substituents, the substituents being independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted by 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F C 1-4 Heteroalkyl, and a 3-4 membered ring optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), for example, R 13 yes

[0416] Embodiment B23. A compound according to any one of Embodiments B12-B19, or a pharmaceutically acceptable salt thereof, wherein R 13 is a 5- or 6-membered heteroaryl group, such as It is optionally substituted with 1-3 substituents independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted with 1-3 F 1-4 Alkyl, optionally substituted with 1-3 F 1-4 Heteroalkyl, and 3-4 membered rings optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), for example, R 13 yes

[0417] Embodiment B24. A compound according to any one of Embodiments B1-B10, or a pharmaceutically acceptable salt thereof, wherein L 2 Not present, or O or C(O).

[0418] Embodiment B25. A compound according to any one of Embodiments B1 to B24, or a pharmaceutically acceptable salt thereof, wherein R 30 is an optionally substituted phenyl group or a 5- or 6-membered heteroaryl group (e.g., such as oxadiazolyl (e.g., ), pyridyl (e.g., ) or pyrimidinyl (e.g., ), for example, when substituted, a phenyl group or a 5- or 6-membered heteroaryl group may be substituted by 1-3 (e.g., 1 or 2) R 22 Substituted, where R 22 Each occurrence is halogen (eg, F, Cl, or Br), CN, C optionally substituted with 1-3 F 1-4 Alkyl (such as CH3, CF3, etc.), C optionally substituted by 1-3 F 1-4 Alkoxy (such as OCH3, OCF3, etc.), SCF3, SF5, cyclopropyl, cyclobutyl or

[0419] Embodiment B26. A compound according to any one of Embodiments B1-B24, or a pharmaceutically acceptable salt thereof, wherein R 30 is a phenyl group consisting of 1 to 3 (e.g., 1 or 2) R 22 Substituted, where R 22 Each occurrence is independently halogen (eg, F, Cl, or Br), CN, OH, R M1 , OR M1 、SO2R M1 、P(O)(R M1 )2、SR M1 or SF5, where R M1 Each occurrence is independently optionally substituted C 1-4 alkyl or an optionally substituted 3-4 membered ring (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), wherein when substituted, the optionally substituted C 1-4 The alkyl group or the 3-4 membered ring is substituted by 1-3 substituents independently selected from the group consisting of halogen (preferably F or Cl), OH, CN, C 1-4 Alkyl, optionally substituted with 1-3 F C 1-4 Heteroalkyl, and 3-4 membered rings optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), preferably R 22 Each occurrence is independently F, Cl, Br, CF3, OCF3, SCF3, SF5, OMe, CN, methyl, CHF2, CF2CH3, cyclopropyl, CH3SO2 and OCH2-(cyclopropyl).

[0420] Embodiment B27. A compound according to any one of Embodiments B1 to B24, or a pharmaceutically acceptable salt thereof, wherein R 30 is a phenyl group consisting of 1 to 3 (e.g., 1 or 2) R 22 Substitute, where R 22 Each occurrence is independently F, Cl, CN, R M2 , OR M2 SR M2 or SF5, where R M2 Each occurrence is independently C optionally substituted with 1-3 F 1-4 Alkyl groups, such as CF3.

[0421] Embodiment B28. A compound according to any one of Embodiments B1 to B24, or a pharmaceutically acceptable salt thereof, wherein R 30 is a 5-membered heteroaryl group (e.g., ) or pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Substitution, where valence permits, where R 22 Each occurrence is independently halogen (eg, F, Cl, or Br), CN, OH, R M1 , OR M1 、SO2R M1 、P(O)(R M1 )2、SR M1 or SF5, where R M1 Each occurrence is independently optionally substituted C 1-4 alkyl or an optionally substituted 3-4 membered ring (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), wherein when substituted, the optionally substituted C 1-4 The alkyl group or the 3-4 membered ring is substituted by 1-3 substituents independently selected from the group consisting of halogen (preferably F or Cl), OH, CN, C 1-4 Alkyl, optionally substituted with 1-3 F 1-4 Heteroalkyl, 3-4 membered ring optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), preferably R 22 Each occurrence is independently F, Cl, Br, CF3, OCF3, SCF3, SF5, OMe, CN, methyl, CHF2, CF2CH3, cyclopropyl, CH3SO2 and OCH2-(cyclopropyl).

[0422] Embodiment B29. A compound according to any one of Embodiments B1 to B24, or a pharmaceutically acceptable salt thereof, wherein R 30is a 5-membered heteroaryl group (e.g., ) or pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Substitution, where valence permits, where R 22 Each occurrence is independently F, Cl, CN, R M2 , OR M2 SR M2 or SF5, where R M2 Each occurrence is independently C optionally substituted with 1-3 F 1-4 Alkyl groups, such as CF3.

[0423] Embodiment B30. A compound according to any one of Embodiments B1 to B24, or a pharmaceutically acceptable salt thereof, wherein R 30 Having the structure according to S-1-A, S-1-B, S-1-C or S-1-D:

[0424]

[0425]

[0426] where R 8 is C optionally substituted with 1-3 F 1-4 Alkyl (such as CH3, CF3, etc.), C optionally substituted by 1-3 F 1-4 Alkoxy (such as OCH3, OCF3, etc.), SCF3, SF5, cyclopropyl, cyclobutyl, or

[0427] Embodiment B31. A compound according to any one of Embodiments B1-B24, or a pharmaceutically acceptable salt thereof, wherein R 30 Selected from:

[0428]

[0429] Embodiment B32. A compound according to any one of Embodiments B1-B24, or a pharmaceutically acceptable salt thereof, wherein R 30 Selected from:

[0430]

[0431] Embodiment B33. A compound according to any one of Embodiments B1-B24, or a pharmaceutically acceptable salt thereof, wherein R 30 Selected from:

[0432]

[0433] Embodiment B34. A compound according to any one of Embodiments B1-B24, or a pharmaceutically acceptable salt thereof, wherein R 30 Selected from:

[0434]

[0435] Embodiment B35. A compound according to any one of Embodiments B1-B24, or a pharmaceutically acceptable salt thereof, wherein R 30 Selected from:

[0436]

[0437] Embodiment B36. A compound according to any one of Embodiments B1-B24, or a pharmaceutically acceptable salt thereof, wherein R 30 Selected from:

[0438]

[0439] Embodiment B37. A compound according to any one of Embodiments B1-B24, or a pharmaceutically acceptable salt thereof, wherein R 30 Selected from:

[0440]

[0441] Embodiment B38. A compound according to any one of Embodiments B1-B10, or a pharmaceutically acceptable salt thereof, wherein L 2 -R 30 Selected from:

[0442]

[0443] Embodiment B39. A compound according to any one of Embodiments B1-B10, or a pharmaceutically acceptable salt thereof, wherein L 2 -R 30 Selected from:

[0444]

[0445] Embodiment B40. A compound according to any one of Embodiments B1-B10, or a pharmaceutically acceptable salt thereof, wherein L 2 -R 30 Selected from:

[0446]

[0447] Embodiment B41. A compound according to any one of Embodiments B1-B10, or a pharmaceutically acceptable salt thereof, wherein L 2 -R30 Selected from:

[0448]

[0449] Embodiment B42. A compound according to any one of Embodiments B1-B24, or a pharmaceutically acceptable salt thereof, wherein R 30 Selected from:

[0450]

[0451] Embodiment B43. A compound according to any one of Embodiments B1-B10, or a pharmaceutically acceptable salt thereof, wherein L 2 -R 30 Selected from:

[0452]

[0453] Embodiment B44. A compound according to any one of Embodiments B1-B10, or a pharmaceutically acceptable salt thereof, wherein L 2 -R 30 Selected from:

[0454]

[0455] Embodiment B45. A compound of formula III-6 or III-7, or a pharmaceutically acceptable salt thereof, wherein -JW- represents -CH2-O-CH2, -O-CH2-CH2-, -N(CH3)-C(O)-, -NH-C(O)-, -N(CH3)-CH2 or -NH-CH2, (from left to right, i.e., J is the first group from the left, such as CH2, O, NH or NCH3), wherein the variables Z, Y, U, R 1 、R 2 、R 3 、n1、R 9 、L 2 and R 30 As defined herein, including any of those defined in connection with Formula III-3 or III-4 shown in Embodiments B1-B44.

[0456] In some embodiments, the present disclosure also provides a compound selected from Compound Nos. 1-347, or a pharmaceutically acceptable salt thereof.

[0457] In some embodiments, the present disclosure further provides a compound selected from the compounds shown in Table A below, or a pharmaceutically acceptable salt thereof:

[0458] Table A. Compound List

[0459]

[0460] Table A. List of compounds (continued)

[0461]

[0462] Table A. List of compounds (continued)

[0463]

[0464] Table A. List of compounds (continued)

[0465]

[0466] Table A. List of compounds (continued)

[0467]

[0468] Table A. List of compounds (continued)

[0469]

[0470] Table A. List of compounds (continued)

[0471]

[0472] Table A. List of compounds (continued)

[0473]

[0474] Table A. List of compounds (continued)

[0475]

[0476] Table A. List of compounds (continued)

[0477]

[0478] Table A. List of compounds (continued)

[0479]

[0480] Table A. List of compounds (continued)

[0481]

[0482] Table A. List of compounds (continued)

[0483]

[0484] Table A. List of compounds (continued)

[0485]

[0486] Exemplary syntheses and characterizations of the above compounds are presented in the Examples section. The compounds can be prepared in racemic form, separated into two enantiomers including the drawn enantiomers with respect to one or more chiral centers, or prepared by chiral synthesis according to the present disclosure.

[0487] In some embodiments, the compound classes in the present disclosure also exclude, to the extent applicable, any compounds specifically prepared and disclosed prior to the present disclosure. In other words, the compound classes in the present disclosure may optionally have negative limitations to exclude one or more applicable compounds selected from any compound specifically prepared prior to the present disclosure.

[0488] In some embodiments, the presently disclosed genus of compounds includes any of the compounds set forth herein as original claims 1-63, Embodiments 1-49, Embodiments A1-A38, and Embodiments B1-B45.

[0489] Those skilled in the art can readily synthesize the disclosed compounds based on the present disclosure. Exemplary syntheses are also shown in the Examples section.

[0490] It will be apparent to those skilled in the art that conventional protecting groups may be required to prevent certain functional groups from undergoing undesirable reactions. Suitable protecting groups for various functional groups and suitable conditions for protecting and deprotecting specific functional groups are well known in the art. For example, in "Protective Groups in Organic Synthesis", 4 thMany protecting groups are described in ed. PGM Wuts; TW Greene, John Wiley, 2007, and references cited therein. The reagents used in the reactions described herein are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many reagents are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Sigma (St. Louis, Missouri, USA). Other reagents can be prepared by procedures described in standard reference texts, such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplemental (Elsevier Science Publishers, 1989), Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (Wiley, 7 th Edition) and Larock's Comprehensive Organic Transformations (Wiley-VCH, 1999), and any updated versions available as of the time of submission of this article.

[0491] Pharmaceutical composition

[0492] Certain embodiments relate to a pharmaceutical composition comprising one or more compounds of the present disclosure.

[0493] The pharmaceutical composition may optionally contain a pharmaceutically acceptable excipient. In some embodiments, a pharmaceutical composition includes a compound of the present disclosure (e.g., Formula III-1, III-2 (e.g., III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-1, III-2-D-2, III-2-D-3, III-2-D-4, III-2-E-1, III-2-E-2, III-2-E-3, III-2-E-1a, III-2-E-2a, III-2-E-3a, III-2-E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F-3a, or III-2-F-3b). ), III-3 (e.g., III-3-A), III-4 (e.g., III-4-A, III-4-B, III-4-C, III-4-D, III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1, III-4-D-2, III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e, or III-4-C-4f), III-5, III-6, III-7, III-8 (e.g., III-8-A or III-8-B), III-9, III-10, III-11, or III-12, any compound of 1-347, any compound selected from the group consisting of compounds shown in Table A herein, or a pharmaceutically acceptable salt thereof), and a pharmaceutically acceptable excipient. Pharmaceutically acceptable excipients are known in the art. Suitable non-limiting excipients include, for example, encapsulating materials or additives such as absorption enhancers, antioxidants, binders, buffers, carriers, coatings, colorants, diluents, disintegrants, emulsifiers, extenders, fillers, flavorings, humectants, lubricants, fragrances, preservatives, propellants, release agents, bactericides, sweeteners, solubilizers, wetting agents, and mixtures thereof. See also Remington's The Science and Practice of Pharmacy, 21st Edition, A.R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, Md., 2005; incorporated herein by reference), which discloses various excipients for formulating pharmaceutical compositions and known techniques for their preparation.

[0494] Pharmaceutical compositions may include any one or more compounds of the present disclosure. For example, in some embodiments, the pharmaceutical composition comprises, for example, a therapeutically effective amount of a compound of formula III-1, III-2 (e.g., III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-1, III-2-D-2, III-2-D-3, III-2-D-4, III-2-E-1, III-2-E-2, III-2-E-3, III-2-E-1a, III-2-E-2a, III-2-E-3a, III-2-E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F-3a, or III-2-E-1 -2-F-3b), III-3 (e.g., III-3-A), III-4 (e.g., III-4-A, III-4-B, III-4-C, III-4-D, III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1, III-4-D-2, III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f), III-5, III-6, III-7, III-8 (e.g., III-8-A or III-8-B), III-9, III-10, III-11 or III-12, any compound of 1-347, any compound selected from the group consisting of compounds shown in Table A herein, or a pharmaceutically acceptable salt thereof. In any of the embodiments described herein, the pharmaceutical composition may comprise a therapeutically effective amount of any compound selected from Compounds 1-347, or a pharmaceutically acceptable salt thereof. In any of the embodiments described herein, the pharmaceutical composition may comprise a therapeutically effective amount of a compound selected from the compounds shown in Table A herein, or a pharmaceutically acceptable salt thereof.

[0495] The pharmaceutical compositions may also be formulated for delivery by any known route of delivery, including but not limited to oral, parenteral, inhalation, and the like.

[0496] In some embodiments, the pharmaceutical composition can be formulated for oral administration. Oral formulations can be presented as discrete units, such as capsules, pills, cachets, lozenges, or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Excipients used to prepare orally administrable compositions are known in the art. Non-limiting suitable excipients include, for example, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomer, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, crospovidone, diglycerides, ethanol, ethylcellulose, ethyl laurate, ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, groundnut oil, hydroxypropyl methylcellulose, isopropyl alcohol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, oil), potassium phosphate, potato starch, povidone, propylene glycol, Ringer's solution, safflower oil, sesame oil, sodium carboxymethylcellulose, sodium phosphate, sodium lauryl sulfate, sodium sorbitol, soybean oil, stearic acid, stearyl fumarate, sucrose, surfactant, talc, tragacanth gum, tetrahydrofurfuryl alcohol, triglycerides, water and mixtures thereof.

[0497] In some embodiments, the pharmaceutical composition is formulated for parenteral administration (e.g., intravenous injection or infusion, subcutaneous or intramuscular injection). Parenteral formulations can be, for example, aqueous solutions, suspensions, or emulsions. Excipients for the preparation of parenteral formulations are known in the art. Non-limiting suitable excipients include, for example, 1,3-butylene glycol, castor oil, corn oil, cottonseed oil, glucose (dextrose), germ oil, peanut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, USP or isotonic sodium chloride solution, water, and mixtures thereof.

[0498] In some embodiments, the pharmaceutical composition is formulated for inhalation. For example, the inhalable formulation can be formulated into a nasal spray, dry powder or aerosol that can be administered by a metered dose inhaler. Excipients for the preparation of inhalation formulations are known in the art. Non-limiting suitable excipients include, for example, lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, and mixtures of these substances. Sprays can also include propellants, such as chlorofluorocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0499] Pharmaceutical compositions can include various amounts of the disclosed compounds, depending on factors such as the intended use and the potency and selectivity of the compound. In some embodiments, a pharmaceutical composition comprises a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of Formula III-1, III-2 (e.g., III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-1, III-2-D-2, III-2-D-3, III-2-D-4, III-2-E-1, III-2-E-2, III-2-E-3, III-2-E-1a, III-2-E-2a, III-2-E-3a, III-2-E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F-3a, or III-2-E-1). -4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f), III-5, III-6, III-7, III-8 (e.g., III-8-A or III-8-B), III-9, III-10, III-11 or III-12, any compound of Ill-1-347, any compound selected from the group consisting of compounds shown in Table A herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of the present disclosure and a pharmaceutically acceptable excipient. As used herein, a therapeutically effective amount of a compound of the present disclosure is an amount effective to treat a disease or condition described herein, which may depend on the recipient of the treatment, the disease or condition being treated and its severity, the composition containing the compound, the time of administration, the route of administration, the duration of treatment, the potency of the compound (e.g., for inhibiting DGKa and / or DGKz), its clearance rate, and whether it is co-administered with another drug.

[0500] For veterinary use, the compounds of the present disclosure can be administered as an appropriately acceptable formulation in accordance with normal veterinary practice. A veterinarian can readily determine the most appropriate dosing regimen and route of administration for a particular animal.

[0501] In some embodiments, all necessary components for treating DGKa and / or DGKz related diseases or conditions using the compounds of the present disclosure can be packaged into a kit, either alone or in combination with another agent or intervention traditionally used to treat such diseases. Specifically, in some embodiments, the present invention provides a kit for therapeutic intervention of a disease, comprising a set of packaged drugs comprising a compound disclosed herein and a buffer and other components for preparing a deliverable form of the drug, and / or a device for delivering such a drug, and / or any agent used in a combined therapy with a compound of the present disclosure (e.g., any of those described herein, such as an immuno-oncology agent as described herein, including, for example, a protein antagonist that inhibits T cell activation, a protein agonist that stimulates T cell activation, and the like, particularly one or more antibodies selected from anti-PD-1, anti-PD-L1, anti-CTLA-4, and combinations thereof), and / or instructions for treating the disease packaged with the drug. These instructions can be fixed in any tangible medium, such as printed paper, or computer-readable magnetic or optical media, or with reference to instructions from a remote computer data source (e.g., a global webpage accessible via the Internet).

[0502] Treatment

[0503] The compounds of the present disclosure can be used as therapeutically active substances for the treatment and / or prevention of diseases or conditions associated with the activity of DGKa, DGKz, or both DGKa and DGKz (e.g., DGK target inhibition in T cells). Such diseases or conditions include viral and other infections (e.g., skin infections, gastrointestinal infections, urinary tract infections, genitourinary system infections, systemic infections) and proliferative diseases (e.g., cancer).

[0504] In some embodiments, the present disclosure provides a method of inhibiting diacylglycerol kinase α and / or ζ (DGKa / z) activity in a cell, comprising contacting the cell with a therapeutically effective amount of one or more compounds of the present disclosure (e.g., Formula III-1, III-2 (e.g., III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, II I-2-D-1, III-2-D-2, III-2-D-3, III-2-D-4, III-2-E-1, III-2-E-2, III-2-E-3, III-2-E-1a, III-2 -E-2a, III-2-E-3a, III-2-E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, I -4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f), III-5, III-6, III-7, III-8 (e.g., III-8-A or III-8-B), III-9, III-10, III-11 or III-12, any compound of Ill-1-347, any compound selected from the group consisting of compounds shown in Table A herein, or a pharmaceutically acceptable salt thereof). As used herein, the term "cell" refers to a cell in vitro, ex vivo, or in vivo. In some embodiments, an ex vivo cell can be a portion of a tissue sample removed from an organism such as a mammal. In some embodiments, an in vitro cell can be a cell in cell culture. In some embodiments, an in vivo cell is a living cell of an organism such as a mammal. As used herein, the term "contacting" refers to bringing the parts together in an in vitro system or an in vivo system. For example, the "contacting" of DGKa and DGKz enzymes with a compound of the present disclosure includes: administering a compound of the present disclosure to a subject (e.g., a human) having DGKa and DGKz, and, for example, introducing a compound of the present disclosure into a sample of a cell preparation or purified preparation containing the DGKa and DGKz enzymes.The term "DGK inhibitor" (e.g., DGKa and / or DGKz inhibitor) refers to an agent that is capable of inhibiting the activity of diacylglycerol kinase alpha and / or diacylglycerol kinase zeta (DGKa and / or DGKz), for example, activity in T cells that results in T cell stimulation.

[0505] In some embodiments, the present disclosure provides a method for treating a disease associated with the activity or expression (including abnormal activity and / or overexpression) of DGKa and / or DGKz in a subject in need thereof, the method comprising administering to the subject an effective amount of one or more compounds of the present disclosure (e.g., Formula III-1, III-2 (e.g., III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-1-2-A, III-1-2-B, III-1-2-C, III-1-2-C-1, III-1-2-C-2, III-1 ...C-4, III-1-2- -2-C-4, III-2-D, III-2-D-1, III-2-D-2, III-2-D-3, III-2-D-4, III-2-E-1, III-2-E-2, III-2-E-3, I II-2-E-1a, III-2-E-2a, III-2-E-3a, III-2-E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F-3a or III-2-F-3b), III-3 (such as III-3-A), III-4 (such as III-4-A, III-4-B, III-4-C, III-4-D, III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1, III-4-D-2, III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f), III-5, III-6, III-7, III-8 (e.g., III-8-A or III-8-B), III-9, III-10, III-11 or III-12, any compound of Nos. 1-347, any compound selected from the group consisting of compounds shown in Table A herein, or a pharmaceutically acceptable salt thereof). Examples of diseases may include any disease, condition or symptom directly or indirectly related to the expression or activity (e.g., overexpression or abnormal activity) of the DGKa and / or DGKz enzyme. DGKa and / or DGKz-related diseases may also include any disease, condition or symptom that can be prevented, improved or cured by regulating the activity of the DGKa and / or DGKz enzyme. DGKa and / or DGKz-related diseases include cancer and viral infections, such as HIV infection, hepatitis B and hepatitis C. Examples of cancer include colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, kidney cancer, head and neck cancer, lymphoma, leukemia and / or melanoma.

[0506] In some embodiments, the present disclosure provides a method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of one or more compounds of the present disclosure (e.g., Formula III-1, III-2 (e.g., III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-1, III-2-D-2 , III-2-D-3, III-2-D-4, III-2-E-1, III-2-E-2, III-2-E-3, III-2-E-1a, III-2-E-2a, III-2-E-3a, III-2-E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F- -3a or III-2-F-3b), III-3 (e.g., III-3-A), III-4 (e.g., III-4-A, III-4-B, III-4-C, III-4-D, III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1, III-4-D-2, III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f), III-5, III-6, III-7, III-8 (e.g., III-8-A or III-8-B), III-9, III-10, III-11 or III-12, any compound of 1-347, any compound selected from the group consisting of compounds shown in Table A herein, or a pharmaceutically acceptable salt thereof), or a therapeutically effective amount of a pharmaceutical composition as described herein. In some embodiments, the cancer is colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, kidney cancer, head and neck cancer, lymphoma, leukemia and / or melanoma. Cancer types that can be treated with the compounds of the present disclosure include, but are not limited to, brain cancer, skin cancer, bladder cancer, ovarian cancer, breast cancer, stomach cancer, pancreatic cancer, prostate cancer, colon cancer, blood cancer, lung cancer and bone cancer.Examples of such cancer types include neuroblastoma, intestinal cancer (such as rectal cancer, colon cancer, familial adenomatous polyposis cancer and hereditary non-polyposis colorectal cancer), esophageal cancer, lip cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, gastric cancer, adenocarcinoma, medullary thyroid cancer, thyroid carcinoma, kidney cancer, renal parenchymal cancer, ovarian cancer, cervical cancer, uterine corpus cancer, endometrial cancer, choriocarcinoma, pancreatic cancer, prostate cancer, testicular cancer, breast cancer, urinary tract cancer, melanoma, brain tumors (such as glioblastoma, astrocytoma, meningioma, medulloblastoma and peripheral neuroectodermal tumor), Hodgkin lymphoma, non-Hodgkin lymphoma Lymphoma, Burkitt lymphoma, acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), adult T-cell leukemia lymphoma, diffuse large B-cell lymphoma (DLBCL), hepatocellular carcinoma, gallbladder cancer, bronchogenic carcinoma, small cell lung cancer, non-small cell lung cancer, multiple myeloma, basaloma, teratoma, retinoblastoma, choroidal melanoma, seminoma, rhabdomyosarcoma, craniopharyngioma, osteosarcoma, chondrosarcoma, myeloma, liposarcoma, fibrosarcoma, Ewing sarcoma and plasmacytoma.

[0507] In some embodiments, the present disclosure provides a method of treating a viral infection in a subject, comprising administering to the subject a therapeutically effective amount of one or more compounds of the present disclosure (e.g., Formula III-1, III-2 (e.g., III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-1, III-2-D-2 , III-2-D-3, III-2-D-4, III-2-E-1, III-2-E-2, III-2-E-3, III-2-E-1a, III-2-E-2a, III-2-E-3a, III-2-E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F- -3a or III-2-F-3b), III-3 (e.g., III-3-A), III-4 (e.g., III-4-A, III-4-B, III-4-C, III-4-D, III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1, III-4-D-2, III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f), III-5, III-6, III-7, III-8 (e.g., III-8-A or III-8-B), III-9, III-10, III-11 or III-12, any compound of Nos. 1-347, any compound selected from the group consisting of compounds shown in Table A herein, or a pharmaceutically acceptable salt thereof), or a therapeutically effective amount of a pharmaceutical composition as described herein. Treatable viral infections include, but are not limited to, diseases caused by the following viruses: hepatitis C virus (HCV), human papillomavirus (HPV), cytomegalovirus (CMV), herpes simplex virus (HSV), Epstein-Barr virus (EBV), varicella-zoster virus, coxsackie virus, human immunodeficiency virus (HIV). In some embodiments, parasitic infections (e.g., malaria) can also be treated by the above methods.

[0508] In some embodiments, the present disclosure provides a method of treating a disease or condition in a subject in need thereof, for example, a cancer associated with DGKa and / or DGKz. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a compound of the present disclosure (e.g., Formula III-1, III-2 (e.g., III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-1, III-2-D-2, III-2-D-3, III-2-D- 4. III-2-E-1, III-2-E-2, III-2-E-3, III-2-E-1a, III-2-E-2a, III-2-E-3a, III-2-E-1b, III-2 -E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F-3a or III-2-F-3 b), III-3 (e.g., III-3-A), III-4 (e.g., III-4-A, III-4-B, III-4-C, III-4-D, III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1, III-4-D-2, III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f), III-5, III-6, III-7, III-8 (e.g., III-8-A or III-8-B), III-9, III-10, III-11 or III-12, any compound of Nos. 1-347, any compound selected from the group consisting of compounds shown in Table A herein, or a pharmaceutically acceptable salt thereof), or a therapeutically effective amount of a pharmaceutical composition described herein. In some embodiments, the cancer comprises colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, kidney cancer, head and neck cancer, lymphoma, leukemia and / or melanoma. Other cancer types suitable for treatment with this method include the cancers described herein.

[0509] The compounds of the present disclosure can be used as monotherapy or for combination therapy. In some embodiments, combination therapy includes treating subjects with targeted therapeutic agents, chemotherapeutics, therapeutic antibodies, radiation, cell therapy and / or immunotherapy. In some embodiments, the compounds of the present disclosure can also be co-administered with another pharmaceutically active compound and administered to subjects in need simultaneously or sequentially in any order. In some embodiments, combination therapy includes treating subjects with one or more additional therapies, such as antivirals, chemotherapeutics or other anticancer agents, immunopotentiators, immunosuppressants, radiation, anti-tumor and antiviral vaccines, cytokine therapies (such as IL2 and GM-CSF) and / or tyrosine kinase inhibitors.

[0510] In some embodiments, the compounds of the present disclosure can be administered simultaneously or sequentially with immuno-oncology preparations in any order.Immuno-oncology preparations include, for example, small molecule drugs, antibodies or other biological preparations or small molecule preparations. Examples of biological immuno-oncology preparations include, but are not limited to, cancer vaccines, antibodies and cytokines. In some embodiments, immuno-oncology preparations are agonists of (i) stimulatory (including co-stimulatory) receptors or antagonists of inhibitory (including co-inhibitory) signals on (ii) T cells, both of which lead to the expansion of antigen-specific T cell responses (commonly referred to as immune checkpoint regulators). Certain stimulatory and inhibitory molecules are members of the immunoglobulin superfamily (IgSF). An important family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the B7 family, including B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA) and B7-H6. Another family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the TNF family of molecules that bind to cognate TNF receptor family members, including CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 (4-1BB), TRAIL / Apo2-L, TRAILR1 / DR4, TRAILR2 / DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR / Fn14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LTbR, LIGHT, DcR3, HVEM, VEGI / TL1A, TRAMP / DR3, EDAR, EDA1, XEDAR, EDA2, TNFR1, lymphotoxin a / TNFb, TNFR2, TNFa, LTbR, lymphotoxin a 1b2, FAS, FASL, RELT, DR6, TROY, NGFR.T cell responses can be stimulated by a combination of the compounds disclosed herein with one or more of the following: (i) an antagonist of a protein that inhibits T cell activation (e.g., an immune checkpoint inhibitor), such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4, and (ii) an agonist of a protein that stimulates T cell activation, such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3, and CD28H. Other preparations that can be combined with the compounds of the present disclosure for the treatment of cancer include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells. For example, the compounds of the present disclosure can be combined with KIR antagonists (such as lirilumab). Other preparations for combined therapy include preparations that inhibit or consume macrophages or monocytes, including but not limited to CSF-1R antagonists, such as CSF-1R antagonist antibodies, including RG7155 (WO11 / 70024, WO11 / 107553, WO11 / 131407, WO13 / 87699, WO13 / 119716, WO13 / 132044) or FPA-008 (WO11 / 140249; WO13169264; WO14 / 036357). In some embodiments, the compounds of the present disclosure may be used with one or more of the following: agonists that can bind to positive co-stimulatory receptors; blockers that can attenuate signals sent through inhibitory receptors; antagonists and one or more agents that can increase the frequency of anti-tumor T cells throughout the body; agents that can overcome unique immunosuppressive pathways in the tumor microenvironment (e.g., blocking inhibitory receptor engagement (such as PD-L1 / PD-1 interaction), depleting or inhibiting Tregs (such as using anti-CD25 monoclonal antibodies (such as daclizumab) or by in vitro anti-CD25 bead depletion), inhibiting metabolic enzymes such as IDO, or reversing / preventing T cell hypersensitivity or exhaustion), and agents that induce innate immune activation and / or inflammation at the tumor site. In some embodiments, the immuno-oncology agent is a CTLA-4 antagonist, such as an antagonist CTLA-4 antibody. Suitable CTLA-4 antibodies include, for example, YERVOY (ipilimumab) or tremelimumab, etc. In some embodiments, the immuno-oncology agent is a PD-1 antagonist, such as an antagonist PD-1 antibody.Suitable PD-1 antibodies include OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI-0680 (AMP-514; WO2012 / 145493). Immuno-oncology agents may also include pidilizumab (CT-011), but its specificity for binding to PD-1 has been questioned. Another approach to targeting the PD-1 receptor is a recombinant protein fused to the extracellular domain of PD-L2 (B7-DC) and the Fc portion of IgG1, called AMP-224. In some embodiments, the immuno-oncology agent is a PD-L1 antagonist, including, for example, an antagonist PD-L1 antibody. Suitable PD-L1 antibodies include, for example, MPDL3280A (RG7446; WO2010 / 077634), durvalumab (MEDI4736), BMS-936559 (WO2007 / 005874), and MSB0010718C (WO2013 / 79174). In some embodiments, the immuno-oncology preparation is a LAG-3 antagonist, such as an antagonistic LAG-3 antibody. Suitable LAG3 antibodies include, for example, BMS-986016 (WO10 / 19570, WO14 / 08218), or IMP-731 or IMP-321 (WO08 / 132601, WO09 / 44273). In some embodiments, the immuno-oncology preparation is a CD137 (4-1BB) agonist, such as an agonistic CD137 antibody. Suitable CD137 antibodies include, for example, urelumab and PF-05082566 (WO12 / 32433). In some embodiments, the immuno-oncology preparation is a GITR agonist, such as an agonist GITR antibody. Suitable GITR antibodies include, for example, BMS-986153, BMS-986156, TRX-518 (WO06 / 105021, WO09 / 009116) and MK-4166 (WO11 / 028683). In some embodiments, the immuno-oncology preparation is an IDO antagonist. Suitable IDO antagonists include, for example, INCB-024360 (WO2006 / 122150, WO07 / 75598, WO08 / 36653, WO08 / 36642), indoximod, BMS-986205, or NLG-919 (WO09 / 73620, WO09 / 1156652, WO11 / 56652, WO12 / 142237). In some embodiments, the immuno-oncology agent is an OX40 agonist, such as an agonistic OX40 antibody. Suitable OX40 antibodies include, for example, MEDI-6383 or MEDI-6469.In another aspect, the immuno-oncology formulation is an OX40L antagonist, such as an OX40 antagonist antibody. Suitable OX40L antagonists include, for example, RG-7888 (WO06 / 029879). In some embodiments, the immuno-oncology formulation is a CD40 agonist, such as an agonist CD40 antibody. In another embodiment, the immuno-oncology formulation is a CD40 antagonist, such as an antagonist CD40 antibody. Suitable CD40 antibodies include, for example, lucatumumab or dacetuzumab. In some embodiments, the immuno-oncology formulation is a CD27 agonist, such as an agonist CD27 antibody. Suitable CD27 antibodies include, for example, varlilumab. In some embodiments, the immuno-oncology formulation is MGA271 (to B7H3) (WO11 / 109400).

[0511] Combination therapy may also include the use of the above therapeutic agents in combination with other biologically active ingredients and / or non-drug therapies (such as surgery or radiation therapy).

[0512] Suitable antiviral agents contemplated for use in combination with the compounds of the present disclosure may include nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, and other antiviral drugs. Suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir; BCH-I0652; imicitabine [(-)-FTC]; β-L-FD4 (also known as β-L-D4C and designated β-L-2¢,3¢-dicleoxy-5-fluoro-cytidene); DAPD, ((-)-β-D-2,6-diaminopurine dioxolane); and lodenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delavirdine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (1-(ethoxy-methyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4(1H,3H)-pyrimidinedione); and (+)-calophylline A (NSC-675451) and B. Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK-639); nefuravir (AG-1343); amprenavir (141W94); lasinavir; DMP-450; BMS-2322623; ABT-378 and AG-1549. Other antiviral drugs include hydroxyurea, ribavirin, interleukin-2 (IL-2), interleukin-12 (IL-12), pentafuside, and Yissum Project No. 11607.

[0513] Additional combination therapies, such as additional immuno-oncology drugs, also include drugs suitable for use in combination with DGK inhibitors as described in any of the following published patent applications: WO2019005883; WO2020006016; WO2020006018; WO2021041588; WO2021105115; WO2021105116; WO2021105117; WO2021127554; WO2021130638; WO2021132422; WO2021133748; WO2021133749; WO2021133750; WO2021133751; WO2021133752; WO2021214019; or WO2021214020.

[0514] Administration herein is not limited to any specific route of administration. For example, in some embodiments, administration can be oral, nasal, transdermal, pulmonary, inhalation, oral, sublingual, intraperitoneal, subcutaneous, intramuscular, intravenous, rectal, intrapleural, intrathecal and parenteral administration. In some embodiments, administration is oral administration.

[0515] Dosage regimens, including dosages, can vary and be adjusted depending on the subject being treated, the disease or condition being treated and its severity, the composition containing the compound, the time of administration, the route of administration, the duration of treatment, the potency of the compound, its clearance rate, and whether it is co-administered with another drug.

[0516] definition

[0517] It is understood that proper valence is maintained for all moieties and combinations thereof.

[0518] It is also understood that one embodiment of a variable portion herein may be the same as or different from another embodiment having the same identifier.

[0519] The present disclosure includes all combinations of various aspects and / or embodiments disclosed herein. It should be understood that any and all embodiments of the present disclosure can be combined with any other embodiment or multiple embodiments to describe additional embodiments. It should also be understood that each individual element in the embodiments of the present invention can be combined with any and all other elements in any embodiment to describe additional embodiments.

[0520] The atoms or groups suitable for the variables herein are independently selected. The definitions of the variables can be combined. Taking Formula III-4 as an example, R 1 、R 2 、R 3 、R 9 、R 30 , U, Y, Z, n1 and L 2 Any of the definitions of one can be combined with R in formula III-4 1 、R 2 、R 3 、R 9 、R 30 , U, Y, Z, n1 and L 2 Any combination of the other definitions in the formulas III-1 to III-12. Such combinations are contemplated and are within the scope of the present disclosure. Non-limiting useful groups for the variables in compounds of Formulae III-1 to III-12, or subformulae thereof, include, as applicable, any of the corresponding groups shown in the examples or in the specific compounds described in Table A herein, alone or in any combination.

[0521] Although it is well understood in the art, it is to be understood that when a formula herein is referred to as a subformula of a broader formula, it is to be understood that, for variables defined in relation to the broader formula, such variables of the subformula may have the same definitions as any variables defined in the broader formula, and preferred definitions of such variables of the subformula may also include the same preferred definitions as any variables of the broader formula, unless clearly contrary to the context. Similarly, for variables defined in relation to a subformula, such variables of the broader formula or different subformulas of the broader formula may have the same definitions as any variables defined in the subformula, unless clearly contrary to the context.

[0522] When the symbol Perpendicular to (or otherwise crossing) a bond, it indicates the point at which the moiety is attached to the rest of the molecule. It should be noted that for a divalent structure (or multivalent structure), one or more groups or appropriate variables shown as directly attached in the general formula may be shown in the divalent structure (or multivalent structure) as symbols. To indicate the direction of attachment. When no direct-linked groups or variables are shown at both points of attachment in a bivalent structure, this indicates that any direction of attachment to the rest of the molecule is permitted unless otherwise stated or clearly contradicted by the context. Use "XAGB" to illustrate, for example, if G is defined as That is, the directly connected groups or variables are not shown, so the structure of "XAGB" can be On the other hand, if G is defined as Then the structure of "XAGB" should be understood as

[0523] Definitions of specific functional groups and chemical terms are described in more detail below. Chemical elements are identified according to the Periodic Table of the Elements, CAS edition, Handbook of Chemistry and Physics, 75th edition, inside cover, and specific functional groups are generally defined as described therein. In addition, general principles of organic chemistry as well as specific functional moieties and reactivities are described in: Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5 thEdition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3 rd Edition, Cambridge University Press, Cambridge, 1987. This disclosure is not intended to be limited in any way by the list of exemplary substituents described herein.

[0524] The compounds of the present disclosure may contain one or more asymmetric centers and / or axial chirality and may therefore exist in various isomeric forms, for example, enantiomers and / or diastereomers. For example, the compounds described herein may be in the form of individual enantiomers, diastereomers, atropisomers, or geometric isomers, or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers may be separated from the mixture by methods known to those skilled in the art, including chiral high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis. For example, see Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (ELE Liel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The present disclosure also includes the compounds described herein as individual isomers substantially free of other isomers, or as mixtures of various isomers, including racemic mixtures. In the embodiments herein, unless otherwise clearly contrary to the context, when stereochemistry is specifically drawn, it is understood that for that particular chiral center or axial chirality, the compound may exist primarily as the drawn stereoisomer, e.g., by weight, by HPLC or SFC area, or both, with less than 20%, less than 10%, less than 5%, less than 1%, or no detectable amount of other stereoisomers. For example, the compound may be characterized by an enantiomeric excess ("ee") greater than 60%, such as greater than 80% ee, greater than 90% ee, greater than 95% ee, greater than 98% ee, or greater than 99% ee. The presence and / or amount of stereoisomers can be determined by one of ordinary skill in the art based on this disclosure, including by using chiral HPLC or SFC. When the stereochemistry of a chiral center is not specifically drawn, it is understood that the structure or fragment thereof is intended to encompass all possible stereoisomers of that particular chiral center.

[0525] When a range of values ​​is listed, it is intended to include every value and subrange within the range. For example, "C 1–6" is intended to include C1, C2, C3, C4, C5, C6, C 1-6 、C 1-5 、C 1-4 、C 1-3 、C 1-2 、C 2-6 、C 2-5 、C 2-4 、C 2-3 、C 3-6 、C 3-5 、C 3-4 、C 4-6 、C 4-5 and C 5-6 .

[0526] As used herein, the term "compounds of the present disclosure" or "compounds of the invention" refers to compounds described herein according to Formula III-1, III-2 (e.g., III-2-A, III-2-B, III-2-C, III-2-C-1, III-2-C-2, III-2-C-3, III-2-C-4, III-2-D, III-2-D-1, III-2-D-2, III-2-D-3, III-2-D-4, III-2-E-1, III-2-E-2, III-2- E-3, III-2-E-1a, III-2-E-2a, III-2-E-3a, III-2-E-1b, III-2-E-2b, III-2-E-3b, III-2-F-1a, III-2-F-1b, III -2-F-2a, III-2-F-2b, III-2-F-3a or III-2-F-3b), III-3 (e.g. III-3-A), III-4 (e.g. III-4-A, III-4-B, III-4-C, III- 4-D, III-4-C-1, III-4-C-2, III-4-C-3, III-4-C-4, III-4-D-1, III-4-D-2, III-4-C-4a, III-4-C-4b, III-4-C-4 c, III-4-C-4d, III-4-C-4e or III-4-C-4f), III-5, III-6, III-7, III-8 (such as III-8-A or III-8-B), III-9, III-10, III Any compound of any of the compounds of Ill-11 or III-12, any compound of any of the compounds of Ill-347, any compound selected from the group consisting of compounds shown in Table A herein, isotopically labeled compounds thereof (e.g., deuterated analogs wherein one or more hydrogen atoms are replaced by deuterium atoms having an abundance greater than the natural abundance), possible stereoisomers thereof (including diastereomers, enantiomers, and racemic mixtures), geometric isomers thereof, atropisomers thereof, tautomers thereof, conformational isomers thereof, and / or pharmaceutically acceptable salts thereof (e.g., acid addition salts such as HCl salts or base addition salts such as Na salts). For the avoidance of doubt, compounds Ill-347 or compounds I-347 refer to compounds described herein labeled with integers 1, 2, 3, ..., 347, see, for example, the title compounds of the Examples and Table 1. For ease of description, starting materials or intermediates of the synthesis may be labeled with an integer (compound number) followed by a "-" and an additional numerical value, such as 2-1, 2-2, etc., see the Examples for details. Such labels of synthetic starting materials or intermediates should not be confused with compounds labeled with only integers without "-" and an additional number. Hydrates and solvates of the disclosed compounds are considered compositions of the disclosure wherein the compound is in combination with water or a solvent, respectively.In some embodiments, the compounds of the present disclosure may be any one of the definitions in original claims 1-63 herein. In some embodiments, the compounds of the present disclosure may be any one of the definitions in embodiments 1-49 herein. In some embodiments, the compounds of the present disclosure may be any one of the definitions in any one of enumerated embodiments A1-A38 and B1-B45.

[0527] The compounds of the present disclosure may exist in isotopically labeled or enriched forms, which contain one or more atoms having an atomic mass or mass number different from the atomic mass or mass number found most abundantly in nature. Isotopes may be radioactive or non-radioactive isotopes. Isotopes of atoms such as hydrogen, carbon, phosphorus, sulfur, fluorine, chlorine, and iodine include, but are not limited to, 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 32 P. 35 S. 18 F. 36 Cl and 125 I. Compounds containing other isotopes of these and / or other atoms are within the scope of this invention.

[0528] As used herein, the phrases "administering" a compound, "administering" a compound, or other variations thereof, means providing the compound or a prodrug of the compound to a subject in need of treatment.

[0529] As used herein, the term "alkyl" used alone or as part of another group refers to a straight or branched chain aliphatic saturated hydrocarbon. In some embodiments, an alkyl group may include one to twelve carbon atoms (i.e., C 1-12 In one embodiment, the alkyl group is a straight chain C 1-10 In another embodiment, the alkyl group is a branched C 3-10 In another embodiment, the alkyl group is a straight chain C 1-6 In another embodiment, the alkyl group is a branched C 3-6 In another embodiment, the alkyl group is a straight chain C 1-4 In one embodiment, the alkyl group is a C alkyl group selected from the group consisting of methyl, ethyl, propyl (n-propyl), isopropyl, butyl (n-butyl), sec-butyl, tert-butyl and isobutyl. 1-4Alkyl. As used herein, the term "alkylene," used alone or as part of another group, refers to a divalent radical derived from an alkyl group. For example, non-limiting straight-chain alkylene groups include -CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-, -CH2-CH2-, and the like.

[0530] As used herein, the term "alkenyl" when used alone or as part of another group refers to a straight or branched chain aliphatic hydrocarbon containing one or more, for example one, two or three, carbon-carbon double bonds. In one embodiment, alkenyl is C 2-6 In another embodiment, alkenyl is C 2-4 Non-limiting exemplary alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, and hexenyl.

[0531] As used herein, the term "alkynyl" used alone or as part of another group refers to a straight or branched chain aliphatic hydrocarbon containing one or more, for example one to three, carbon-carbon triple bonds. In one embodiment, the alkynyl group has one carbon-carbon triple bond. In one embodiment, the alkynyl group is C 2-6 In another embodiment, alkynyl is C 2-4 Alkynyl. Non-limiting exemplary alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl.

[0532] As used herein, the term "alkoxy" used alone or as part of another group refers to a radical of the formula OR a1 A group in which R a1 As used herein, the term "cycloalkoxy" when used alone or as part of another group refers to a cycloalkyl group of the formula OR a1 A group in which R a1 It is a cycloalkyl group.

[0533] As used herein, the term "haloalkyl" used alone or as part of another group refers to an alkyl group substituted with one or more fluorine, chlorine, bromine and / or iodine atoms. In preferred embodiments, haloalkyl refers to an alkyl group substituted with one or more fluorine atoms, or herein refers to a fluorine-substituted alkyl group substituted with one, two or three fluorine atoms. In one embodiment, haloalkyl is C 1-4 In one embodiment, the haloalkyl group is a fluorine-substituted C 1-4 alkyl.

[0534] As used herein, unless otherwise indicated, the term "heteroalkyl" alone or in combination with another term refers to a stable straight or branched chain alkyl group, for example, having 2 to 14 carbons, such as 2 to 10 carbons, in the chain, wherein one or more carbons has been replaced by a heteroatom selected from S, O, P, and N, and wherein the nitrogen, phosphorus, and sulfur atoms may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized. The heteroatoms S, O, P, and N may be located at any interior position of the heteroalkyl group or at the position where the alkyl group is attached to the rest of the molecule. When a heteroalkyl group is described as being substituted, a substituent may replace one or more hydrogen atoms attached to a carbon atom and / or a heteroatom in the heteroalkyl group. In some embodiments, the heteroalkyl group is C 1-4 Heteroalkyl refers to a heteroalkyl group as defined herein having 1 to 4 carbon atoms. 1-4 Examples of heteroalkyl groups include, but are not limited to, C4 heteroalkyl groups, such as -CH2-CH2-N(CH3)-CH3, C3 heteroalkyl groups, such as -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-S-CH2-CH3, -CH2-CH2-S(O)-CH3, -CH2-CH2-S(O)2-CH3, C2 heteroalkyl groups, such as -CH2-CH2-OH, -CH2-CH2-NH2, -CH2-NH(CH3), -O-CH2-CH3, and C1 heteroalkyl groups, such as -CH2-OH, -CH2-NH2, -O-CH3. Preferably, the C4 heteroalkyl groups herein are C3 heteroalkyl groups. 1-4 Heteroalkyl (or C 1-4 Heteroalkylene) contains 1 or 2 heteroatoms, such as one oxygen, one nitrogen, two oxygens, two nitrogens, or one oxygen and one nitrogen. Similarly, the term "heteroalkylene" itself or as part of another substituent refers to a divalent group derived from heteroalkyl, such as, but not limited to -CH2-CH2-O-CH2-CH2- and -O-CH2-CH2-NH-CH2-. For heteroalkylene, heteroatoms can also occupy one or both chain ends (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, etc.). In addition, for alkylene and heteroalkylene linking groups, the writing direction of the formula of the linking group does not imply the orientation of the linking group. When referring to "heteroalkylene", specific heteroalkyl groups, such as -NR'R" and the like are subsequently mentioned, it should be understood that the terms heteroalkylene and -NR'R" are not redundant or mutually exclusive. On the contrary, specific heteroalkylene is listed to add illustrativeness. Therefore, the term "heteroalkylene" should not be interpreted as excluding specific heteroalkylene, such as -NR'R" and the like in this article.

[0535] "Carbocyclyl" or "carbocyclic" used alone or as part of another group refers to a non-aromatic cyclic hydrocarbon radical having 3 to 10 ring carbon atoms and zero heteroatoms in the non-aromatic ring system ("Carbocyclyl"). 3-10"Carbocyclyl"). A carbocyclyl group may be a single ring (a "monocyclic carbocyclyl") or may contain fused, bridged, or spiro ring systems, such as a bicyclic ring system (a bicyclic carbocyclyl), and may be saturated or partially unsaturated. "Carbocyclyl" also includes ring systems in which a carbocycle as defined above is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is on the carbocycle, in which case the carbon number still refers to the number of carbons in the carbocyclyl system. Non-limiting exemplary carbocyclyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclopentenyl, and cyclohexenyl.

[0536] In some embodiments, a "carbocyclyl" is fully saturated, which is also referred to as a cycloalkyl. In some embodiments, a cycloalkyl group may have 3 to 10 ring carbon atoms ("C 3-10 In a preferred embodiment, the cycloalkyl group is a monocyclic ring.

[0537] "Heterocyclyl" or "heterocyclic" when used alone or as part of another group refers to a group having a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon ("3-10 membered heterocyclyl"). Heterocyclyl groups or heterocycles having a ring size different from that of a 3- to 10-membered heterocyclyl are represented by a different ring size designation when applicable. One of ordinary skill in the art will understand that such a heterocyclyl group of a different ring size is also a non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon. In heterocyclyl groups containing one or more nitrogen atoms, the point of attachment can be a carbon atom or a nitrogen atom, where valence permits. A heterocyclyl group can be a monocyclic ring (a "monocyclic heterocyclyl group") or a fused, bridged, or spiro ring system, such as a bicyclic ring system (a "bicyclic heterocyclyl"), and can be saturated or partially unsaturated. Heterocyclyl bicyclic ring systems may contain one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems in which a heterocycle, as defined above, is fused to one or more carbocyclic groups, where the point of attachment is on the carbocyclic or heterocyclic ring; or ring systems in which a heterocycle, as defined above, is fused to one or more aryl or heteroaryl groups, where the point of attachment is on the heterocycle, in which case the number of ring members continues to specify the number of ring members in the heterocycle system.

[0538] Exemplary 3-membered heterocyclic groups containing one heteroatom include, but are not limited to, aziridinyl, oxiranyl, and thioranyl. Exemplary 4-membered heterocyclic groups containing one heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclic groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxathiolanyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclic groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclic groups containing three heteroatoms include, but are not limited to, triazinyl. Exemplary 7-membered heterocyclic groups containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Exemplary 8-membered heterocyclic groups containing one heteroatom include, but are not limited to, azocanyl, oxocanyl, and thiocanyl. Exemplary 5-membered heterocyclic groups fused to a C6 aryl ring (also referred to herein as 5,6-bicyclic heterocycles) include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinone, and the like. Exemplary 6-membered heterocyclic groups fused to an aromatic ring (also referred to herein as 6,6-bicyclic heterocycles) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.

[0539] "Aryl" when used alone or as part of another group refers to a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in the cyclic array) having 6-14 ring carbon atoms and zero heteroatoms ("C 6-14 In some embodiments, an aryl group has six ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, an aryl group has ten ring carbon atoms ("C 10 In some embodiments, an aryl group has fourteen ring carbon atoms ("C 14 "Aryl" also includes ring systems in which an aryl ring as defined above is fused to one or more carbocyclic or heterocyclic groups, wherein the radical or point of attachment is on the aryl ring, in which case the number of carbon atoms refers to the number of carbon atoms in the aryl ring system.

[0540] "Aralkyl" used alone or as part of another group refers to an alkyl group substituted with one or more aryl groups, preferably an alkyl group substituted with one aryl group. Examples of aralkyl groups include benzyl, phenethyl, and the like. When an aralkyl group is referred to as optionally substituted, either the alkyl portion or the aryl portion of the aralkyl group may be optionally substituted.

[0541] "Heteroaryl" when used alone or as part of another group refers to a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in the cyclic array) having ring carbon atoms provided in the aromatic ring system and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-10 membered heteroaryl"). Heteroaryl groups having a ring size different from that of the 5-10 membered heteroaryl are designated by a different ring size designation when applicable. It will be understood by those skilled in the art that such heteroaryl groups of different ring sizes are also 4n+2 aromatic ring systems (e.g., having 6 or 10 π electrons shared in the cyclic array) having ring carbon atoms provided in the aromatic ring system and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur. In heteroaryl groups containing one or more nitrogen atoms, the point of attachment can be a carbon atom or a nitrogen atom if valence permits. Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings. "Heteroaryl" includes ring systems comprising a heteroaryl ring, as defined above, fused to one or more carbocyclic or heterocarbocyclic rings, wherein the point of attachment is on the heteroaryl ring, in which case the number of ring members continues to specify the number of ring members in the heteroaryl ring system. "Heteroaryl" also includes ring systems comprising a heteroaryl ring, as defined above, fused to one or more aryl groups, wherein the point of attachment is on the aryl or heteroaryl ring, in which case the number of ring members refers to the number of ring members in the fused (aryl / heteroaryl) ring system. In bicyclic heteroaryl groups in which one ring does not contain heteroatoms (e.g., indolyl, quinolinyl, etc.), the point of attachment can be on the ring with the heteroatom (e.g., 2-indolyl) or the ring without the heteroatom (e.g., 5-indolyl).

[0542] Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thienyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolyl, isoquinolyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

[0543] "Heteroaralkyl" used alone or as part of another group refers to an alkyl group substituted with one or more heteroaryl groups, preferably, an alkyl group substituted with one heteroaryl group. When a heteroaralkyl group is said to be optionally substituted, either the alkyl portion or the heteroaryl portion of the heteroaralkyl group may be optionally substituted.

[0544] As generally understood by those skilled in the art, alkylene, alkenylene, alkynylene, heteroalkylene, carbocyclylene, heterocyclylene, arylene and heteroarylene refer to the corresponding divalent radicals of alkyl, alkenyl, alkynyl, heteroalkyl, carbocyclyl, heterocyclyl, aryl and heteroaryl, respectively.

[0545] "Optionally substituted" groups, such as optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl and optionally substituted heteroaryl, refer to each group that is unsubstituted or substituted. Generally speaking, the term "substituted", whether or not there is the term "optional" in front, refers to at least one hydrogen present on a group (such as a carbon or nitrogen atom) being replaced by a substituent that is allowed, the substituent being allowed, for example, a substituent that can produce a stable compound after substitution, the stable compound being, for example, a compound that will not spontaneously transform, for example, by rearrangement, cyclization, elimination or other reactions. Unless otherwise stated, a "substituted" group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent at each position may be the same or different. Typically, when substituted, the optionally substituted group herein may be substituted by 1-5 substituents. If applicable, the substituent may be a carbon atom substituent, a nitrogen atom substituent, an oxygen atom substituent or a sulfur atom substituent.

[0546] Unless expressly stated to the contrary, combinations of substituents and / or variables are permissible only if such combinations are chemically permitted and result in stable compounds. A "stable" compound is one that can be prepared and isolated and whose structure and properties remain or can be caused to remain substantially unchanged for a period of time sufficient to allow the compound to be used for the purposes described herein (e.g., therapeutic administration to a subject).

[0547] In some embodiments, an "optionally substituted" alkyl, alkenyl, alkynyl, heteroalkyl, carbocyclic, cycloalkyl, alkoxy, cycloalkoxy, or heterocyclic group herein may be unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of: F, Cl, -OH, protected hydroxy, oxo (if applicable), NH2, protected amino, NH(C 1-4 Alkyl) or its protected derivatives, N(C 1-4 Alkyl)(C 1-4 Alkyl), C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6cycloalkyloxy, phenyl, 5- or 6-membered heteroaryl containing 1, 2 or 3 ring heteroatoms independently selected from O, S and N, 3-7 membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from O, S and N, wherein each of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxy, phenyl, heteroaryl and heterocyclyl is optionally substituted with 1, 2 or 3 substituents independently selected from: F, -OH, oxo (if applicable), C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl (such as CF3), C 1-4 Alkoxy and fluorine-substituted C 1-4 In some embodiments, the "optionally substituted" aryl or heteroaryl groups herein may be unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of: F, Cl, -OH, -CN, NH2, protected amino, NH(C 1-4 alkyl) or its protected derivatives, N(C 1-4 Alkyl)(C 1-4 alkyl), -S(=O)(C 1-4 Alkyl), -SO2(C 1-4 Alkyl), C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 cycloalkyloxy, phenyl, 5- or 6-membered heteroaryl containing 1, 2 or 3 ring heteroatoms independently selected from O, S and N, 3-7 membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from O, S and N, wherein each of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxy, phenyl, heteroaryl and heterocyclyl is optionally substituted with 1, 2 or 3 substituents independently selected from: F, -OH, oxo (if applicable), C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4 Alkoxy.

[0548] Exemplary carbon atom substituents include, but are not limited to, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa 、-ON(R bb )2、-N(R bb )2、-N(R bb )3 + X - 、-N(OR cc )R bb 、-SH、-SR aa、-SSR cc 、-C(=O)R aa 、-CO2H、-CHO、-C(OR cc )2、-CO2R aa 、-OC(=O)R aa 、-OCO2R aa 、-C(=O)N(R bb )2、-OC(=O)N(R bb )2、-NR bb C(=O)R aa 、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2、-C(=O)NR bb SO2R aa 、-NR bb SO2R aa 、-SO2N(R bb )2、-SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3、-OSi(R aa )3-C(=S)N(R bb )2、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa、-P(=O)(R aa )2、-P(=O)(OR cc )2、-OP(=O)(R aa )2、-OP(=O)(OR cc )2、-P(=O)(N(R bb )2)2、-OP(=O)(N(R bb) 2)2, -NR bb P(=O)(R aa )2、-NR bb P(=O)(OR cc )2、-NR bb P(=O)(N(R bb )2)2、-P(R cc )2、-P(OR cc )2、-P(R cc )3 + X - 、-P(OR cc )3 + X - 、-P(R cc )4、-P(OR cc )4、-OP(R cc )2、-OP(R cc )3 + X - 、-OP(OR cc )2、-OP(OR cc )3 + X - 、-OP(R cc )4、-OP(OR cc )4、-B(R aa )2、-B(OR cc )2, -BR aa (OR cc ), C 1-10 Alkyl, C 1-10 Halogenated alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently replaced by 0, 1, 2, 3, 4 or 5 R dd Group substitution; wherein X - is the counterion;

[0549] Or the two geminal hydrogen atoms on the carbon atom are replaced by groups =O, =S, =NN(R bb )2, =NNRbb C(=O)R aa 、=NNR bb C(=O)OR aa 、=NNR bb S(=O)2R aa 、=NR bb , or = NOR cc Replacement;

[0550] R aa Each instance of is independently selected from C 1-10 Alkyl, C 1-10 Halogenated alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, or two R aa The groups are connected to form a 3-14 membered heterocyclic group or a 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0551] R bb Each instance of is independently selected from hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc )2, -CO2R aa 、-SO2R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc )2, -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、-P(=O)(R aa )2、-P(=O)(OR cc )2、-P(=O)(N(R cc )2)2、C 1-10 Alkyl, C 1-10 Halogenated alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C6-14 Aryl and 5-14 membered heteroaryl, or two R bb The groups are connected to form a 3-14 membered heterocyclic group or a 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd Group substitution; wherein X - is the counterion;

[0552] R cc Each instance of is independently selected from hydrogen, C 1-10 Alkyl, C 1-10 Halogenated alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, or two R cc The groups are connected to form a 3-14 membered heterocyclic group or a 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0553] R dd Each instance of is independently selected from halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee 、-ON(R ff )2、-N(R ff )2、-N(R ff )3 + X - 、-N(OR ee )R ff 、-SH、-SR ee 、-SSR ee 、-C(=O)R ee 、-CO2H、-CO2R ee 、-OC (= O)R ee 、-OCO2R ee 、-C(=O)N(R ff )2、-OC(=O)N(R ff )2、-NR ff C(=O)R ee 、-NR ff CO2R ee 、-NR ff C(=O)N(R ff )2、-C(=NR ff )OR ee 、-OC(=NR ff)R ee 、-OC(=NR ff )OR ee 、-C(=NR ff )N(R ff )2、-OC(=NR ff )N(R ff )2、-NR ff C(=NR ff )N(R ff )2、-NR ff SO2R ee 、-SO2N(R ff )2, -SO2R ee 、-SO2OR ee 、-OSO2R ee 、-S(=O)R ee 、-Si(R ee )3、-OSi(R ee )3、-C(=S)N(R ff )2, -C(=O)SR ee 、-C(=S)SR ee 、-SC(=S)SR ee 、-P(=O)(OR ee )2、-P(=O)(R ee )2、-OP(=O)(R ee )2、-OP(=O)(OR ee )2、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently replaced by 0, 1, 2, 3, 4 or 5 R gg Group substitution, or two geminal R dd Substituents may be linked to form =O or =S; where X - is the counterion;

[0554] R ee Each instance of is independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic group, C 6-10Aryl, 3-10 membered heterocyclyl and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently replaced by 0, 1, 2, 3, 4 or 5 R gg group substitution;

[0555] R ff Each instance of is independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, or two R ff The groups are connected to form a 3-14 membered heterocyclic group or a 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R gg group substitution; and

[0556] R gg Each instance of is independently halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6 Alkyl, -ON(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + X - 、-NH(C 1-6 Alkyl)2 + X - 、-NH2(C 1-6 alkyl) + X - 、-NH3 + X - 、-N(OC 1-6 Alkyl)(C 1-6 Alkyl), -N(OH)(C 1-6 Alkyl), -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), -CO2H, -CO2(C 1-6 alkyl), -OC(=O)(C 1-6 Alkyl), -OCO2(C 1-6 alkyl), -C(=O)NH2, -C(=O)N(C 1-6 alkyl)2, -OC(=O)NH(C 1-6 alkyl), -NHC(=O)(C 1-6Alkyl), -N(C 1-6 alkyl)C(=O)(C 1-6 Alkyl), -NHCO2(C 1-6 alkyl), -NHC(=O)N(C 1-6 Alkyl)2, -NHC(=O)NH(C 1-6 alkyl), -NHC(=O)NH2, -C(=NH)O(C 1-6 alkyl), -OC(=NH)(C 1-6 alkyl), -OC(=NH)OC 1-6 Alkyl, -C(=NH)N(C 1-6 Alkyl)2, -C(=NH)NH(C 1-6 alkyl), -C(=NH)NH2, -OC(=NH)N(C 1-6 Alkyl)2, -OC(NH)NH(C 1-6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1-6 Alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 Alkyl), -SO2N(C 1-6 Alkyl)2, -SO2NH(C 1-6 alkyl), -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C 1-6 alkyl)3, -OSi(C 1-6 alkyl)3-C(=S)N(C 1-6 alkyl)2、C(=S)NH(C 1-6 alkyl), C(=S)NH2, -C(=O)S(C 1-6 alkyl), -C(=S)SC 1-6 Alkyl, -SC(=S)SC 1-6 Alkyl, -P(=O)(OC 1-6 alkyl)2, -P(=O)(C 1-6 alkyl)2, -OP(=O)(C 1-6 alkyl)2, -OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic group, C 6-10 Aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl; or two geminal R ggSubstituents may be linked to form =O or =S; where X - It is a counter ion.

[0557] A "counterion" or "anionic counterion" is a negatively charged group that is bound to a positively charged group to maintain electrical neutrality. Anionic counterions can be monovalent (i.e., include one negative formal charge). Anionic counterions can also be multivalent (i.e., include more than one negative formal charge), such as divalent or trivalent. Exemplary counterions include halides (e.g., F - 、Cl - Br - , I - )、NO3 - 、ClO4 - OH - 、H2PO4 - 、HSO4 - , sulfonate ions (e.g., methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate, 10-camphorsulfonate, naphthalene-2-sulfonate, naphthalene-1-sulfonic acid-5-sulfonate, ethane-1-sulfonic acid-2-sulfonate, etc.), carboxylate ions (e.g., acetate, propionate, benzoate, glycerate, lactate, tartrate, glycolate, gluconate, etc.), BF4 - PF4 - PF6 - 、AsF6 - 、SbF6 - 、B[3,5-(CF3)2C6H3]4] - , BPh4 - 、Al(OC(CF3)3)4 - and carborane anions (e.g. CB 11 H 12 - or (HCB 11 Me5Br6) - ). Exemplary counterions that may be multivalent include CO3 2- 、HPO4 2- PO4 3- 、B4O7 2- 、SO4 2- 、S2O3 2- , carboxylate anions (e.g., tartrate, citrate, fumarate, maleate, malate, malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate, azelaate, sebacate, salicylate, phthalate, aspartate, glutamate, etc.), and carborane.

[0558] "Halo" or "halogen" refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodo, -I).

[0559] "Acyl" refers to a group selected from -C(=O)R aa 、-CHO、-CO2R aa 、-C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-C(=NR bb )N(R bb )2, -C(=O)NR bb SO2R aa 、-C(=S)N(R bb )2, -C(=O)SR aa or -C(=S)SR aa The part in which R aa and R bb As defined herein.

[0560] The nitrogen atoms may be substituted or unsubstituted where valence permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc )2, -CO2R aa 、-SO2R aa 、-C(=NR bb )R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc )2, -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、-P(=O)(OR cc )2、-P(=O)(R aa )2、-P(=O)(N(R cc )2)2、C 1-10 Alkyl, C 1-10 Halogenated alkyl, C2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, or two R groups connected to the nitrogen atom cc The groups are connected to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substituted, and wherein R aa 、R bb 、R cc and R dd As defined above.

[0561] In certain embodiments, the substituent present on the nitrogen atom is a nitrogen protecting group (also known as an amino protecting group). Nitrogen protecting groups are well known in the art and are included in Protective Groups in Organic Synthesis, TW Greene and PGM Wuts, 3 rd Edition, John Wiley & Sons, 1999, which is incorporated herein by reference. Exemplary nitrogen protecting groups include, but are not limited to, those that form carbamates, such as benzyloxycarbonyl (Cbz) groups, p-methoxybenzylcarbonyl (Moz or MeOZ) groups, tert-butoxycarbonyl (BOC) groups, Troc, 9-fluorenylmethoxycarbonyl (Fmoc) groups, and the like, those that form amides, such as acetyl, benzoyl, and the like, those that form benzylamines, such as benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, and the like, those that form sulfonamides, such as tosyl (tosyl), nitrobenzenesulfonyl (Nosyl), and the like, and others, such as p-methoxyphenyl.

[0562] Exemplary oxygen atom substituents include, but are not limited to, -R aa 、-C(=O)SR aa 、-C(=O)R aa 、-CO2R aa 、-C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-S(=O)R aa 、-SO2R aa 、-Si(R aa )3、-P(Rcc )2、-P(R cc )3 + X - 、-P(OR cc )2、-P(OR cc )3 + X - 、-P(=O)(R aa )2、-P(=O)(OR cc )2 and -P(=O)(N(R bb )2)2, where X - 、R aa 、R bb and R cc As defined herein. In certain embodiments, the oxygen atom substituent present on the oxygen atom is an oxygen protecting group (also known as a hydroxy protecting group). Oxygen protecting groups are well known in the art and are included in Protective Groups in Organic Synthesis, TW Greene and PGM Wuts, 3 rd Edition, John Wiley & Sons, 1999, which is incorporated herein by reference. Exemplary oxygen protecting groups include, but are not limited to, alkyl ethers or substituted alkyl ethers, such as methyl, allyl, benzyl, substituted benzyl (e.g., 4-methoxybenzyl), methoxymethyl (MOM), benzyloxymethyl (BOM), 2-methoxyethoxymethyl (MEM), and the like, silyl ethers, such as trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBDMS), and the like, acetals or ketals, such as tetrahydropyran (THP), esters, such as formates, acetates, chloroacetates, dichloroacetates, trichloroacetates, trifluoroacetates, methoxyacetates, and the like, carbonates, sulfonates, such as methanesulfonate (mesylate), benzylsulfonate, tosylate (Ts), and the like.

[0563] The term "leaving group" is given its common meaning in the field of synthetic organic chemistry, for example, it can refer to an atom or group that can be replaced by a nucleophilic reagent. For example, referring to Smith, March Advanced Organic Chemistry 6th ed. (501-502). The example of a suitable leaving group includes but is not limited to halogen (for example F, Cl, Br or I (iodine)), alkoxycarbonyloxy, aryloxycarbonyloxy, alkanesulfonyloxy, arylsulfonyloxy, alkyl-carbonyloxy (for example acetoxy), arylcarbonyloxy, aryloxy, methoxyl group, N, O-dimethylhydroxylamino, 9-phenylxanthenyl (pixyl) and haloformate.

[0564] The term "pharmaceutically acceptable salt" refers to salts that are suitable for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic response, or the like, and are commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment. Pharmaceutically acceptable salts are well known in the art.

[0565] The term "tautomer" or "tautomers" refers to two or more interconvertible compounds resulting from at least one formal migration of a hydrogen atom and at least one valence change (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa). The exact ratio of tautomers depends on a variety of factors, including temperature, solvent, and pH. Tautomerism (i.e., reactions that provide tautomeric pairs) can be catalyzed by acids or bases. Exemplary tautomerism reactions include keto-enol, amide-imide, lactam-lactim, enamine-imine, and enamine-(different enamine) tautomerism.

[0566] As used herein, the term "subject" (or "patient" herein) refers to an animal, preferably a mammal, and most preferably a human, who is the object of treatment, observation, or experiment.

[0567] As used herein, the terms "treat," "treating," "treatment," and the like refer to eliminating, reducing, or ameliorating a disease or condition, and / or symptoms associated therewith. Although not excluded, treating a disease or condition does not require complete elimination of the disease, condition, or symptoms associated therewith. As used herein, the terms "treat," "treating," "treatment," and the like may include "prophylactic treatment," which refers to reducing the likelihood of redevelopment of a disease or condition, or the likelihood of recurrence of a previously controlled disease or condition, in a subject who does not have the disease or condition but is at risk of redeveloping the disease or condition or recurrence of the disease or condition or is susceptible to redevelopment of the disease or condition or recurrence of the disease or condition. The terms "treating" and synonyms contemplate administering a therapeutically effective amount of a compound described herein to a subject in need of such treatment.

[0568] As used herein, the singular forms "a," "an," and "the" include plural references unless expressly stated otherwise or unambiguously clear from the context.

[0569] As used herein, the term "and / or" in phrases such as "A and / or B" is intended to include A and B; A or B; A (alone); and B (alone). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0570] The headings and subheadings are used for convenience and / or formal compliance only, do not limit the subject technology, and are not related to the interpretation of the subject technology description. In various embodiments, the features described under one heading or one subheading of the present disclosure can be combined with the features described under other headings or subheadings. In addition, all features under a single heading or a single subheading are not necessarily used together in an embodiment.

[0571] Example

[0572] The starting materials, intermediates, and compounds of the various preferred embodiments can be isolated and purified, where appropriate, using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation, and chromatography. These compounds can be characterized using conventional methods, such as by melting point, mass spectrometry, nuclear magnetic resonance, and other various spectroscopic analyses. These examples are provided for illustrative purposes only and do not limit the claimed invention in any way.

[0573] Exemplary embodiments for carrying out the steps for synthesizing the products described herein are described in greater detail below. Some of the examples discussed herein can be prepared by separating the corresponding racemic mixtures. As will be appreciated by one of ordinary skill in the art, the compounds described in the Examples exist as racemates and / or mixtures of stereoisomers prior to the subsequent chiral separation step (e.g., by supercritical fluid chromatography (SFC)). It should be understood that the enantiomeric excess ("ee") and / or diastereomeric excess ("de") reported in these Examples represent exemplary procedures herein and are not intended to be limiting; one of ordinary skill in the art will appreciate that, given the present disclosure, enantiomers and / or diastereomers having different ee and / or de, e.g., higher ee and / or de, can be obtained. Typically, when a pair of diastereomers (differing at only one chiral center) are isolated from the corresponding diastereomeric mixture, the "de" value is reported. In this case, the "de" value indicates the degree of enrichment of one diastereomer.

[0574] Unless otherwise specified or clearly contradicted by the context, the abbreviations used in the Examples section should be understood to have their common meanings in the art. Shown below are some of the abbreviations used in the Examples section herein.

[0575]

[0576]

[0577]

[0578] Example 1 Synthesis of Compound 1

[0579]

[0580] Step 1: To a solution of 1-1 (2.5 g, 10.4 mmol) in dioxane (20 mL) were added tert-butyl 2,8-diazaspiro[4.5]decane-8-carboxylate (3.0 g, 12.45 mmol), Cs2CO3 (6.76 g, 20.75 mmol) and RuPhos Pd G3 (867.6 mg, 1.4 mmol). The resulting mixture was degassed with N2 for 10 minutes and then stirred at 120°C for 4 hours. After cooling to room temperature, the mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 3 / 1) to give 1-2.

[0581] Step 2: To a solution of 1-2 (2.8 g, 7 mmol) in dioxane (20 mL) was added HCl (4.3 mL, 43 mmol). The reaction mixture was stirred at room temperature for 5 hours. The pH was adjusted to 6 by the addition of saturated NaHCO₃. The mixture was extracted with ethyl acetate. The organic layer was dried over Na₂SO₄, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 0 / 1) to provide 1-3.

[0582] Step 3: To a solution of 1-4 (24 g, 144.4 mmol) in acetonitrile (250 mL) was added NBS (28.3 g, 158.9 mmol) at room temperature. The mixture was stirred at room temperature for 1 hour. Water was added and the mixture was extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 0 / 1) to provide 1-5.

[0583] Step 4: To a solution of 2-cyanoacetic acid (16.6 g, 195.2 mmol) in DMF (400 mL) was added HATU (1.39 g, 3.7 mmol) and triethylamine (45.2 mL, 325.4 mmol) at room temperature. The mixture was stirred at room temperature for 15 minutes. 1-5 (31.9 g, 130.2 mmol) was then added. The mixture was stirred at room temperature for 12 hours. Water was added to the reaction mixture. The solid was collected by filtration to obtain 1-6.

[0584] Step 5: To a solution of 1-6 (21.5 g, 68.9 mmol) in THF (300 mL) was added KHMDS (1 M in THF, 89.6 mL, 89.6 mmol) at room temperature. The mixture was stirred at room temperature for 12 hours, and HCl (1 N) was added until the pH value was 4. The solid was collected by filtration to give 1-7.

[0585] Step 6: To a solution of 1-7 (15.8 g, 59.4 mmol) in DMF (200 mL) was added portionwise NaH (9.5 g, 60%, 237.6 mmol) at 0°C. The mixture was stirred at 0°C for 30 minutes. CH3I (14.8 mL, 237.6 mmol) was added. The reaction was stirred at room temperature for 12 hours and then quenched with water. The pH of the reaction mixture was adjusted to 3 with HCl (1 N). The solid was collected by filtration to give 1-8.

[0586] Step 7: To a solution of 1-8 (17.3 g, 61.8 mmol), triethylamine (25.8 mL, 185.3 mmol) and DMAP (0.8 g, 6.2 mmol) in dichloromethane (200 mL) was added Tf O (34.9 g, 123.5 mmol) at 0°C. The mixture was stirred at 0°C for 0.5 hours, then quenched with water and extracted with dichloromethane. The combined organic layers were dried over Na SO , filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 2 / 1) to give 1-9.

[0587] Step 8: To a mixture of 1-9 (300 mg, 0.73 mmol) and 1-3 (327.9 mg, 1.1 mmol) in acetonitrile (10 mL) was added DIPEA (0.36 mL, 2.18 mmol). The mixture was stirred at 85°C for 2 hours. The reaction was quenched with water. The aqueous layer was extracted with ethyl acetate. The organic layers were combined and washed with brine, dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give 1-10.

[0588] Step 9: To a solution of 1-10 (210 mg, 0.37 mmol) in NMP (8 mL) was added Zn(CN)2 (87.7 mg, 0.75 mmol), Zn (4.9 mg, 0.075 mmol), Pd2(dba)3 (34.2 mg, 0.037 mmol) and dppf (12.6 mg, 0.022 mmol) under N2. The reaction mixture was stirred at 80 ° C for 1 hour. The reaction was quenched with water. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and the filtrate was concentrated. The residue was purified by reverse phase HPLC (reverse phase HPLC (acetonitrile / water: 5-95%) to give 1. LCMS (ESI, m / z): [M+H] + =509.4; 1 H NMR (400MHz, DMSO-d6, ppm): δ8.25(d,J=8.8Hz,1H),8.14(d,J=8.8Hz,1H),7.12(d,J=8.4Hz,2H),6.58(d,J=9.2H z,2H),3.90-3.85(m,4H),3.52(s,3H),3.38-3.34(m,2H),3.25(s,2H),1.99(t,J=6.8Hz,2H),1.86-1.80(m,4H).

[0589] Example 2 Synthesis of Compound 2

[0590]

[0591] Step 1: To a solution of 2-1 (19 g, 106.7 mmol), tert-butyl 4-hydroxypiperidine-1-carboxylate (21.5 g, 106.7 mmol) and PPh (30.8 g, 117.3 mmol) in THF (85 mL) was added DEAD (18.6 mL, 117.3 mmol) at 0° C. under N2. The mixture was stirred at 20° C. under N2 for 16 hours. The mixture was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 4 / 1) to give 2-2.

[0592] Step 2: To a solution of 2-2 (22.1 g, 61.2 mmol) in dichloromethane (20 mL) was added a solution of HCl in dioxane (4 M, 61.2 mL, 244.8 mmol) at 20° C. The mixture was stirred at 20° C. for 16 hours. The mixture was concentrated under reduced pressure to give 2-3.

[0593] Step 3: To a mixture of 1-9 (600 mg, 1.46 mmol) and 2-3 (456.4 mg, 1.75 mmol) in acetonitrile (10 mL) was added DIPEA (564.4 mg, 4.37 mmol) at room temperature. The mixture was stirred at 85 ° C for 1 hour. The mixture was concentrated and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 10 / 1) to give 2-4.

[0594] Step 4: Rh(PPh 3 ) 3 Cl (53.0 mg, 0.057 mmol) was added to a toluene solution (15 mL) of 2-4 (300 mg, 0.57 mmol) and acetaldehyde oxime (609.5 mg, 10.3 mmol) at room temperature. The mixture was then heated at 110° C. for 12 hours. The mixture was concentrated and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 0 to 10 / 1) to give 2-5.

[0595] Step 5: To a mixture of 2-5 (250 mg, 0.46 mmol), Zn (6.0 mg, 0.09 mmol) and Zn(CN)2 (108.5 mg, 0.92 mmol) in NMP (4 mL) was added Pd2(dba)3 (42.3 mg, 0.046 mmol) and dppf (12.8 mg, 0.023 mmol) at room temperature. The mixture was then stirred at 90 ° C for 1 hour. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered and the filtrate was concentrated. The residue was purified by reverse phase HPLC (acetonitrile / 0.05% TFA in water: 5%-80%) to give 2 as 0.2 equivalents of TFA salt. LCMS (ESI, m / z): [M+H] + =488.4; 1 HNMR (400MHz, DMSO-d6, ppm): δ8.17(d,J=8.8Hz,1H),8.08(d,J=8.9Hz,1H),7.65(s,1H),7.50(s,1H),7.27(d,J=8.6Hz,2H ),7.13-7.08(m,2H),4.73-4.65(m,1H),3.63(s,2H),3.55(s,3H),3.34-3.29(m,2H),2.13-2.10(m,2H),1.86-1.83(m,2H). 19 F NMR (376MHz, DMSO-d6, ppm): δ-57.25 (3F), -74.58 (0.6F, TFA).

[0596] Example 3 Synthesis of Compound 3

[0597]

[0598] Step 1: 3-1 (10 g, 81.2 mmol) and piperidine-4-carboxylic acid (10.5 g, 81.2 mmol) were added to PPA (53.4 g, 81.2 mmol), and the mixture was stirred at 180°C for 2 hours. The reaction mixture was cooled to 90°C, and then water was added to quench the reaction. The pH value of the mixture was adjusted to 12 with 50% KOH. The mixture was extracted with CH2Cl2. The organic layer was dried over Na2SO4, filtered and concentrated to give 3-2.

[0599] Step 2: Compound 3-3 was prepared from compound 3-2 according to the synthesis procedure of compound 1-10 in Example 1.

[0600] Step 3: Compound 3 was prepared from compound 3-3 according to the synthesis procedure of compound 1 in Example 1. LCMS (ESI, m / z): [M+H] + =425.2; 1 H NMR(400MHz,DMSO-d6,ppm)δ8.27-8.24(m,1H),8.16-8.13(m,1H),7.54-7.56(m,1H),7.51(s,1H),7.17-7.15(m,1H),4.2 8-4.24(m,2H),3.67(t,J=11.2Hz,2H),3.53(s,3H),3.50-3.46(m,1H),2.40(s,3H),2.30-2.28(m,2H),2.16-2.08(m,2H).

[0601] Example 4 Synthesis of Compound 4

[0602]

[0603] Step 1: To a solution of 4-1 (2.5 g, 10.37 mmol) in dioxane (20 mL) were added Cs2CO3 (6.8 g, 20.75 mmol), Pd2(dba)3 (0.9 g, 1.04 mmol), BINAP (1.3 g, 2.08 mmol) and tert-butyl 2,6-diazaspiro[3.4]octane-6-carboxylate (2.64 g, 12.45 mmol). The resulting mixture was degassed for 10 minutes and then stirred at 120 ° C for 4 hours. The mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 3 / 1) to give 4-2.

[0604] Step 2: To a solution of 4-2 (2.9 g, 7.8 mmol) in dichloromethane (20 mL) was added TFA (5 mL, 805.6 mmol). The reaction mixture was then stirred at 25°C for 3 hours. The pH was adjusted to 6 with aqueous NaHCO₃ solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over Na₂SO₄, filtered, and concentrated to afford 4-3.

[0605] Step 3: Compound 4-4 was prepared from compound 4-3 according to the synthesis procedure of compound 1-10 in Example 1.

[0606] Step 4: Compound 4 was prepared from compound 4-4 according to the synthesis procedure of compound 1 in Example 1 as 0.33 equivalents of TFA salt. LCMS (ESI, m / z): [M+H] + =481.2; 1 H NMR (400MHz, DMSO-d6, ppm) δ8.24-8.22(m,1H),8.08-8.05(m,1H),7.16-7.13(m,2H),6.49-6.47( m,2H),4.40(s,2H),4.24(t,J=6.7Hz,2H),3.87-3.81(m,4H),3.49(s,3H),2.24(t,J=6.9Hz,2H). 19 F NMR(376MHz,DMSO-d6,ppm)δ-57.34(3F),-73.62(1F,TFA).

[0607] Example 5 Synthesis of Compound 5

[0608]

[0609] Step 1: To a solution of 5-1 (46 g, 250.6 mmol) in concentrated hydrochloric acid (170 mL) and EtOH (510 mL) was added Fe powder (42.0 g, 751.8 mmol) in portions at 40°C. The mixture was then stirred at 80°C for 1 hour. The mixture was filtered and the filtrate was concentrated. The pH of the mixture was adjusted to 8 with ammonia. The mixture was then filtered and the filtrate was extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered, and the filtrate was concentrated to afford 5-2.

[0610] Step 2: Pyridine (56.6 mL, 703.3 mmol), DMAP (2.9 g, 23.4 mmol) and TFAA (73.9 g, 351.6 mmol) were slowly added to a solution of 5-2 (36 g, crude product) in THF (400 mL) at 0 ° C. The mixture was then stirred at room temperature for 0.5 hours. The mixture was concentrated. Water was added to the residue. The mixture was extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 2 / 1) to give 5-3.

[0611] Step 3: To a solution of 5-3 (47 g, 188.3 mmol) in DMF (450 mL) was added KCO (78.1 g, 565 mmol) and CHI (35.2 mL, 565 mmol) at room temperature. The mixture was stirred at room temperature for 12 h and then quenched with water. The mixture was extracted with ethyl acetate. The combined organic layers were dried over NaSO, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 2 / 1) to give 5-4.

[0612] Step 4: To a mixture of 5-4 (49.0 g, 175.4 mmol) and K2CO3 (72.7 g, 526.3 mmol) in DMSO (500 mL) was slowly added H2O2 (30%, 59.7 g, 526.3 mmol) at 0°C. The mixture was stirred at room temperature for 2 hours. Water was added to the mixture and the mixture was extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 2 / 1) to give 5-5.

[0613] Step 5: To a solution of 5-5 (27 g, 87.3 mmol) in DMF (300 mL) was added NaH (60%, 7.0 g, 174.6 mmol) portionwise at 0°C. The mixture was stirred at 0°C for 1 hour, and CDI (21.2 g, 130.9 mmol) was added to the reaction mixture. The mixture was then stirred at 70°C for 2 hours. The solid was collected by filtration and washed with ethyl acetate and methanol to afford 5-6.

[0614] Step 6: To a solution of 5-6 (1.5 g, 7.09 mmol) in toluene (15 mL) was added POCl (5.27 mL, 56.71 mmol) and DIPEA (2.93 mL, 17.72 mmol) at room temperature. The mixture was then stirred at 110° C. for 12 hours. The mixture was concentrated to afford 5-7, which was used directly in the next step without further purification.

[0615] Step 7: To a solution of 5-7 (crude, 1.2 g) and DIPEA (2.5 mL, 15.1 mmol) in acetonitrile (10 mL) was added 2-3 (500 mg, 1.68 mmol) at room temperature. The mixture was then stirred at 80° C. for 1 hour. The mixture was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 1 / 4) to give 5-8.

[0616] Step 8: To a solution of 5-8 (98 mg, 0.22 mmol) in NMP (6 mL) was added dppf (11.9 mg, 0.022 mmol), Zn (5.6 mg, 0.088 mmol), Zn(CN)2 (50.6 mg, 0.43 mmol) and Pd2(dba)3 (19.7 mg, 0.022 mmol) at room temperature. The mixture was then stirred at 90°C for 3 hours. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered, and the filtrate was concentrated under vacuum. The residue was purified by reverse phase HPLC (acetonitrile / 0.05% TFA in water: 5%-90%) to afford 5 as 0.4 equivalents of the TFA salt. LCMS (ESI, m / z): [M+H] + =446.4; 1 H NMR (400MHz, DMSO-d6, ppm): δ8.26(d,J=9.2Hz,1H),8.02(d,J=9.2Hz,1H),7.35-7.26(m,2H),7.18-7 .06(m,2H),4.82-4.71(m,1H),3.96-3.79(m,4H),3.46(s,3H),2.20-2.05(m,2H),1.86-1.70(m,2H). 19 F NMR (376MHz, DMSO-d6, ppm): δ-57.23 (3F), -74.35 (1.2F, TFA).

[0617] Example 6 Synthesis of Compound 12

[0618]

[0619] Step 1: To a solution of 12-1 (7.4 g, 34 mmol) in DMSO (100 mL) were added 4-bromo-1H-pyrazole (5.0 g, 34 mmol), K3PO4 (21.7 g, 102 mmol), CuO (0.2 g, 1.7 mmol) and N1, N2-bis(furan-2-ylmethyl)oxamide (0.4 g, 1.7 mmol). The reaction mixture was degassed with nitrogen three times, and then the reaction mixture was stirred at 120 ° C for 14 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layer was washed with water and brine, dried and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to obtain 12-2.

[0620] Step 2: To a solution of tert-butyl 4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine 1-carboxylate (4.7 g, 15.2 mmol) in dioxane (60 mL) were added 12-2 (3 g, 12.7 mmol) and K2CO3 (5.2 g, 38 mmol). The reaction mixture was degassed with nitrogen three times, and then Pd(dppf)Cl2 (0.9 g, 1.27 mmol) and water (20 mL) were added to the reaction mixture. The reaction mixture was stirred at 80 ° C for 14 hours. The reaction mixture was diluted with water and then extracted with ethyl acetate. The combined organic layer was washed with water and brine, dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to give 12-3.

[0621] Step 3: To a solution of 12-3 (973 mg, 2.9 mmol) in dichloromethane (10 mL) was added Pd / C (10%, 97.6 mg). The reaction mixture was degassed with H2 three times. The reaction mixture was stirred under H2 atmosphere at room temperature for 14 hours. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to obtain 12-4.

[0622] Step 4: To a solution of 12-4 (826 mg, 2.4 mmol) in dichloromethane (5 mL) was added a solution of HCl in ethyl acetate (4 M, 5 mL, 20 mmol), and the reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure to give 12-5, which was used directly in the next step without further purification.

[0623] Compound 12 was prepared from compound 12-5 according to the synthetic procedure of compound 5 in Example 5. LCMS (ESI, m / z): [M+H] + =426.2; 1H NMR (400MHz, methanol-d4, ppm) δ8.11(d,J=8.9Hz,1H),8.03(d,J=8.9Hz,1H),7.74(s,1H),7.68(s,1H),7.39-7.36(m,2H),7.33-7.30( m,2H),3.61(s,3H),3.36-3.34(m,2H),3.32-3.29(m,2H),3.17-3.11(m,1H),2.28-2.21(m,2H),2.20(s,3H),1.94-1.81(m,2H).

[0624] Example 7 Synthesis of Compounds 16 and 17

[0625]

[0626] Step 1: To a solution of 16-1 (1.9 g, 8.36 mmol) in methanol (12 mL) was added NaBH4 (0.2 g, 10.87 mmol) at 0°C. The mixture was stirred at 20°C for 16 hours. The mixture was quenched with water and concentrated. The residue was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 2 / 1) to give 16-2 and 16-3.

[0627] Step 2: To a solution of 16-2 (604 mg, 2.63 mmol), 16-4 (563 mg, 3.16 mmol) and PPh (1.04 g, 3.95 mmol) in toluene (6 mL) was added DIAD (0.78 mL, 3.95 mmol) at 0°C under N2. The mixture was stirred at 110°C under N2 for 5 hours. The mixture was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to give 16-5.

[0628] Step 3: To a solution of 16-5 (923 mg, 2.37 mmol) in dichloromethane (5 mL) was added HCl in ethyl acetate (4 M, 2.37 mL, 9.5 mmol) at 25° C. The mixture was stirred at 25° C. for 3 hours. The mixture was concentrated to afford 16-6, which was used in the next step without further purification.

[0629] Step 4: Compound 16-7 was prepared from compound 16-6 according to the synthesis procedure of compound 5 in Example 5.

[0630] Step 5: Purification by SFC (column: DAICELCHIR A OZ, methanol (+0.1% 7.0 mol / l ammonia methanol solution) / supercritical CO2 = 40 / 60) 16-7 (70 mg) to give 16 (31.8 mg) and 17 (7.02 mg), respectively. 16: SFC analysis: 99.52% ee; retention time: 1.87 min; chromatographic column: DAICELCHIR A OZ, methanol (0.1% DEA) in CO2, 40%; pressure: 1800 psi; flow rate: 1.5 mL / min. LCMS (ESI, m / z): [M+H] + =474.2; 1 H NMR (400MHz, DMSO-d6, ppm): δ8.28-8.23(m,1H),8.04-7.99(m,1H),7.33 -7.29(m,2H),7.11-7.07(m,2H),4.85-4.77(m,1H),3.47-3.43(m,4H),3. 37–3.29(m,2H),2.17-2.02(m,3H),2.01-1.89(m,3H),0.87-0.79(m,3H). 19 F NMR (376 MHz, DMSO-d6, ppm): δ-57.23 (3F). 17: SFC analysis: 96.6% ee; retention time: 2.14 min; chromatographic column: DAICELCHIR A OZ, methanol (0.1% DEA) in CO2, 40%; pressure: 1800 psi; flow rate: 1.5 mL / min. LCMS (ESI, m / z): [M+H] + =474.2; 1 H NMR (400MHz, DMSO-d6, ppm): δ8.28-8.23(m,1H),8.04-7.99(m,1H),7.33 -7.29(m,2H),7.11-7.07(m,2H),4.85-4.77(m,1H),3.47-3.43(m,4H),3. 37-3.29(m,2H),2.17-2.02(m,3H),2.01-1.89(m,3H),0.87-0.79(m,3H). 19 F NMR (376MHz, DMSO-d6, ppm): δ-57.23 (3F).

[0631] Example 8 Synthesis of Compound 21

[0632]

[0633] Step 1: Compound 21-1 was prepared from compound 2-3 according to the synthesis procedure of compound 5-8 in Example 5.

[0634] Step 2: To a mixture of 21-1 (730 mg, 1.61 mmol) and (tert-butoxy)formylhydrazide (640 mg, 4.8 mmol) in dioxane (10 mL) was added Pd2(dba)3 (147.0 mg, 0.16 mmol), Cs2CO3 (1.57 g, 4.8 mmol) and t-BuBrettPhos (77.8 mg, 0.16 mmol) at room temperature. The mixture was then stirred at 80°C for 1 hour. The mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 1 / 0 to 10 / 1) to give 21-2.

[0635] Step 3: To a solution of 21-2 (310 mg, 0.56 mmol) in methanol (5 mL) was added 4 M HCl in ethyl acetate (3 mL) at room temperature. The mixture was then stirred at room temperature for 0.5 hours. The mixture was concentrated to afford 21-3.

[0636] Step 4: To a solution of 21-3 (250 mg, crude product) in methanol (6 mL) was added CH(OCH3)3 (3 mL, 0.56 mmol) at room temperature. The mixture was then heated at 100°C for 12 hours. The mixture was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 1 / 0 to 10 / 1) to give 21. LCMS (ESI, m / z): [M+H] + =461.4; 1 H NMR(400MHz,DMSO-d6,ppm)δ9.49(d,J=3.3Hz,1H),8.26(d,J=10.1Hz,1H),7.77(d,J=10.1Hz,1H),7.33-7.26(m,2H),7.15-7 .08(m,2H),4.73-4.65(m,1H),3.68-3.50(m,5H),3.44-3.36(m,1H),3.29-3.22(m,1H),2.17-1.87(m,3H),1.78-1.65(m,1H). 19 F NMR (376MHz, DMSO-d6, ppm): δ-57.23 (3F).

[0637] Example 9 Synthesis of Compounds 23, 24 and 25

[0638]

[0639] Step 1: To a solution of LDA in THF (20 mL) (2M in THF, 1.57 mL, 3.15 mmol) was added dropwise 23-1 (550 mg, 2.42 mmol) at -68 ° C. After 30 minutes, a solution of 1,1,1-trifluoro-N-phenyl-N-trifluoromethanesulfonylmethanesulfonamide (864.44 mg, 2.42 mmol) in THF (5 mL) was added. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with saturated NH4Cl and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 1 / 1) to give 23-2.

[0640] Step 2: To a solution of 12-2 (1.0 g, 4.22 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (1.39 g, 5.48 mmol) in dioxane (20 mL) were added KOAc (0.8 g, 8.44 mmol) and Pd(dppf)Cl2 (0.3 g, 0.42 mmol). The mixture was stirred at 100°C under N2 atmosphere for 16 hours. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 1 / 1) to provide 23-3.

[0641] Step 3: To a solution of 23-2 (500 mg, 1.39 mmol) and 23-3 (395.4 mg, 1.39 mmol) in dioxane (20 mL) and water (5 mL) were added Pd(dppf)Cl2 (113.6 mg, 0.14 mmol) and Na2CO3 (295 mg, 2.78 mmol). The mixture was stirred at 90°C under N2 atmosphere for 16 hours. The mixture was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 1 / 1) to give 23-4.

[0642] Step 4: To a solution of 23-4 (310 mg, 0.84 mmol) in methanol (10 mL) was added 10% Pd / C (179.5 mg). The mixture was degassed with H2 several times. The mixture was then stirred at 25°C under a H2 atmosphere (1 atm) for 16 hours. The mixture was filtered and the filtrate was concentrated to give 23-5, which was used directly in the next step without further purification.

[0643] Step 5: To a solution of 23-5 (240 mg, crude) in dichloromethane (4 mL) was added TFA (1 mL). The mixture was stirred at 25° C. for 1 hour. The mixture was concentrated to give 23-6, which was used in the next step without further purification.

[0644] Step 6: Compound 23-7 was prepared from compound 23-6 according to the synthesis procedure of compound 5 in Example 5.

[0645] Step 7: Use preparative SFC (chromatographic column: DAICELCHIR A 23-7 (120 mg, 0.26 mmol) was purified by AS, methanol (+0.1% 7.0 mol / l ammonia methanol solution) / supercritical CO2 = 40 / 60) to give 23 (25.05 mg), 24 (3.11 mg) and 25 (9.99 mg). 23: SFC analysis: retention time: 1.795 minutes; column: DAICELCHIR A AS, methanol (0.1% DEA) in CO2, 40%; pressure: 1800 psi; flow rate: 1.5 mL / min; LCMS (ESI, m / z): [M+H] + =454.4, 1 HNMR (400 MHz, methanol-d4, ppm): δ8.13-8.06 (m, 1H), 8.06-7.98 (m, 1H), 7.76-7.69 (m, 1H), 7.69-7.63 (m, 1H), 7.39-7.33 (m, 2H), 7.33-7.25 (m, 2H), 6.12-5.00 (m, 2H), 3.72-3.35 (m, 4H), 3.00-2.48 (m, 1H), 2.35-1.69 (m, 9H), 1.16-0.94 (m, 3H). 24: SFC analysis: 99.76% de; retention time: 2.300 min; column: DAICELCHIR A AS, methanol (0.1% DEA) in CO2, 40%; pressure: 1800 psi; flow rate: 1.5 mL / min; LCMS (ESI, m / z): [M+H] + =454.4, 1H NMR (400 MHz, methanol-d4, ppm): δ8.16-8.05 (m, 1H), 8.05-7.96 (m, 1H), 7.70 (s, 1H), 7.65 (s, 1H), 7.39-7.33 (m, 2H), 7.33-7.25 (m, 2H), 6.05-5.03 (m, 2H), 3.58 (s, 3H), 3.36 (s, 1H), 2.28-2.10 (m, 6H), 2.11-1.99 (m, 1H), 1.95-1.86 (m, 1H), 1.85-1.72 (m, 1H), 1.36-1.27 (m, 1H), 1.11-0.97 (m, 3H).25: SFC analysis: 100% de; retention time: 2.422 min; column: DAICELCHIR A AS, methanol (0.1% DEA) in CO2, 40%; pressure: 1800 psi; flow rate: 1.5 mL / min; LCMS (ESI, m / z): [M+H] + =454.4, 1 H NMR (400 MHz, methanol-d4, ppm): δ 8.19-8.06 (m, 1H), 8.05-7.96 (m, 1H), 7.75-7.70 (m, 1H), 7.67 (s, 1H), 7.40-7.34 (m, 2H), 7.34-7.27 (m, 2H), 5.17 (s, 2H), 3.61-3.55 (m, 3H) ,3.55-3.44(m,1H),3.00-2.81(m,1H),2.65-2.51(m,1H),2.36-2.22(m,1H),2.22- 2.16(m,3H),2.14-1.98(m,1H),2.01-1.85(m,2H),1.78(s,1H),1.13-0.97(m,3H).

[0646] Example 10 Synthesis of Compounds 26 and 27

[0647]

[0648] Step 1: To a mixture of 26-1 (10 g, 46.29 mmol) and potassium trifluoro(vinyl)borate (7.44 g, 55.55 mmol) in THF (160 mL) and water (40 mL) was added 1,1'-bis(di-tert-butylphosphino)ferrocenepalladium dichloride (3.0 g, 4.63 mmol) and K3PO4 (24.6 g, 115.73 mmol) under N2. The mixture was then stirred at room temperature for 16 hours. Water was added to quench the mixture. The aqueous layer was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 5 / 1) to give 26-2.

[0649] Step 2: To a mixture of methyl ester 26-2 (7.8 g, 47.8 mmol) in AcOH (100 mL) was added PtO2 (2.2 g, 9.56 mmol). The mixture was degassed with H2 several times, and then the mixture was stirred at 80°C under H2 atmosphere (1 atm) for 16 hours. The mixture was filtered and the filtrate was concentrated to give 26-3, which was used directly in the next step without further purification.

[0650] Step 3: To a mixture of 26-3 (8 g, 46.72 mmol) in THF (80 mL) and water (80 mL) was added NaHCO (39.2 g, 467.18 mmol) and (Boc) O (21.47 mL, 93.44 mmol). The mixture was then stirred at room temperature for 3 hours. The mixture was quenched by adding water and the aqueous layer was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, and then concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 5 / 1) to give 26-4.

[0651] Step 4: To a mixture of 26-4 (9.6 g, 35.38 mmol) in THF (60 mL) and water (60 mL) was added LiOH (7.4 g, 176.89 mmol). The mixture was then stirred at room temperature for 16 hours. The pH value of the mixture was adjusted to 4 with 1N HCl and the aqueous layer was extracted with ethyl acetate. The organic extracts were combined, washed with brine, dried over anhydrous Na2SO4, and concentrated to give 26-5, which was used directly in the next step without further purification.

[0652] Step 5: A mixture of 26-5 (4.55 g, crude) and PPA (100 mL) was stirred at 180°C for 2 hours. After cooling to 90°C, the reaction was quenched with water. The pH of the filtrate was adjusted to approximately 12 with 50% aqueous potassium hydroxide solution and extracted with dichloromethane. The organic layer was dried over Na2SO4, filtered, and concentrated to afford 26-6, which was used directly in the next step without further purification.

[0653] Step 6: Compound 26-7 was prepared from compound 26-6 according to the synthesis procedure of compound 5 in Example 5.

[0654] Step 7: 26-7 (150 mg, 0.35 mmol) was separated by reverse phase HPLC (acetonitrile / water, 5-95%) to give 26 (24.47 mg) and 27 (54.71 mg). 26: Analytical HPLC: Retention time: 1.85 min; Column: Waters ACQUITY BEH C18 2.1*50 mm, 1.7 um; Mobile phase A: Water (0.05% TFA); Mobile phase B: Acetonitrile (0.05% TFA); Flow rate: 1.0 mL / min; Run time: 5 min; 95 to 5% A for 3 minutes, 5% A for 2 minutes. LCMS (ESI, m / z): [M+H] + =429.4; 1 HNMR (400 MHz, DMSO-d6, ppm): δ8.27-8.23 (m, 1H), 8.01 (d, J = 9.2 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.47 (s, 1H), 7.18-7.15 (m, 1H), 5.77-5.44 (m, 1H), 5.34-4.80 (m, 1H), 3.68-3.61 (m, 2H), 3.45 (s, 3H), 2.40 (s, 3H), 2.29-2.16 (m, 2H), 2.05-1.78 (m, 4H), 1.00-0.89 (m, 3H). 27: Analytical HPLC: Retention time: 1.85 min; Column: Waters ACQUITY BEH C18 2.1*50mm, 1.7um; Mobile phase A: Water (0.05% TFA); Mobile phase B: Acetonitrile (0.05% TFA); Flow rate: 1.0mL / min; Run time: 5min; 95% to 5% A over 3 minutes, 5% A over 2 minutes. LCMS (ESI, m / z): [M+H] + =429.4; 1H NMR (400MHz, DMSO-d6, ppm): δ8.26(d,J=8.8Hz,1H),8.00(d,J=9.2Hz,1H),7.57(d,J=8.4Hz,1H),7.47(s,1H),7.18-7.15(m,1H),5.37-4.81(m, 2H),3.49-3.46(m,2H),3.45(s,3H),2.42(s,3H),2.37-2.25(m,3H),2.2 4-2.15(m,1H),1.79-1.64(m,1H),1.53-1.45(m,1H),0.92-0.81(m,3H).

[0655] Example 11 Synthesis of Compounds 28 and 29

[0656]

[0657] Step 1: To a -30°C solution of 28-1 (4.5 g, 19.38 mmol) in THF (30 mL) was added C2H5MgBr (29.07 mL, 29.07 mmol, 1 M THF solution). The mixture was stirred at room temperature for 2 hours. The reaction was quenched with saturated aqueous ammonium chloride. The organic phase was separated, dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 4 / 1) to afford 28-2.

[0658] Step 2: To a 0°C solution of 28-2 (1 g, 3.81 mmol) in dichloromethane (10 mL) was added DMF (0.029 mL, 0.38 mmol) and SOCl2 (0.42 mL, 5.72 mmol). The reaction was stirred at room temperature for 18 hours. The reaction mixture was concentrated and the residue was purified by silica gel column chromatography (petroleum ether) to afford 28-3.

[0659] Step 3: To a stirred solution of 28-4 (100 g, 651 mmol) in dry CH2Cl2 (1.5 mmol) were added benzaldehyde (67.5 mL, 664 mmol), K2CO3 (90.0 g, 651 mmol) and Na2SO4 (92.5 g, 651 mmol). The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was cooled with an ice-water bath and NaBH(OAc)3 (207.0 g, 976 mmol) was added portionwise over 30 minutes. The mixture was then stirred at room temperature for 16 hours. The solid was filtered and the filtrate was concentrated. The residue was washed with 1N HCl and extracted with ethyl acetate. The aqueous layer was adjusted to pH=8.0 with NaHCO3. The mixture was then extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to give 28-5, which was used in the next step without further purification.

[0660] Step 4: To a solution of (2R)-2-{[(tert-butoxy)carbonyl]amino}butanoic acid (124 g, crude) in DMF (1 L) was added DIPEA (137 mL, 832 mmol) and HATU (253 g, 666 mmol). The reaction was stirred at 0°C for 10 minutes, and then 28-5 (115 g, 555 mmol) was added to the mixture. The resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous Na2SO4, filtered, and evaporated to afford 28-6, which was used directly in the next step without further purification.

[0661] Step 5: To a solution of 28-6 (300 g, crude) in dichloromethane (1 L) was added TFA (500 mL, 764 mmol) and the reaction was stirred at room temperature for 16 hours. The solvent was removed to give 28-7, which was used directly in the next step without further purification.

[0662] Step 6: 28-7 (500 g, crude product) was dissolved in methanol (1.5 L), and the reaction mixture was heated at 70° C. for 16 hours. The solvent was removed, and the residue was dissolved in dichloromethane and washed with saturated aqueous NaHCO 3 . The combined organic layers were dried over anhydrous Na 2 SO 4 , filtered, and concentrated. The residue was dissolved in propan-2-ol (500 mL) and heated at 70° C. for 1 hour. The mixture was filtered, the solution was cooled to -10° C., the solid was filtered, and dried to give 28-8.

[0663] Step 7: To a stirred solution of 28-8 (20 g, 76.82 mmol) in dry THF (500 mL) was slowly added BH3.THF (1 M, 768 mL, 768 mmol) at 0°C. The reaction mixture was heated at 70°C for 16 hours. The reaction was quenched with methanol and 1.5 N HCl. The solvent was removed, and the residue was dissolved in dichloromethane and washed with saturated aqueous NaHCO3. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated to afford 28-9, which was used directly in the next step without further purification.

[0664] Step 8: To a stirred solution of 28-9 (23 g, crude product) in THF (100 mL) and water (100 mL) were added NaHCO (16.6 g, 198 mmol) and (Boc) O (34.1 mL, 148.5 mmol). The reaction mixture was stirred at room temperature for 4 hours. The mixture was diluted with ethyl acetate, washed with water and brine, dried over anhydrous NaSO, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1 to 10 / 1) to give 28-10.

[0665] Step 9: To a stirred solution of 28-10 (20 g, 60.15 mmol) in ethanol (200 mL) was added Pd / C (10%, 10 g). The reaction mixture was stirred at room temperature under a H2 atmosphere for 18 hours. The reaction mixture was filtered and the solvent removed. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 1 / 0 to 10 / 1) to afford 28-11.

[0666] Step 10: To a solution of 5-7 (1.63 g, crude product) and DIPEA (7 mL, 42.5 mmol) in acetonitrile (40 mL) was added 28-11 (1.37 g, 5.66 mmol) at room temperature, and the mixture was stirred at 80° C. for 1 hour. The mixture was then concentrated, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 1 / 4) to give 28-12.

[0667] Step 11: To a solution of 28-12 (800 mg, 1.84 mmol) in NMP (8 mL) was added dppf (207.2 mg, 0.37 mmol), zinc (120.0 mg, 1.84 mmol), Zn(CN)2 (431.0 mg, 3.67 mmol), and Pd2(dba)3 (168.0 mg, 0.18 mmol) at room temperature. The mixture was then heated at 90°C for 12 hours. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 1 / 4) to afford 28-13.

[0668] Step 12: To a solution of 28-13 (570 mg, 1.34 mmol) in dichloromethane (5 mL) was added TFA (2 mL, 1.34 mmol) at room temperature. The mixture was then stirred at room temperature for 1 hour. The mixture was concentrated to afford 28-14, which was used directly in the next step without further purification.

[0669] Step 13: A mixture of 28-14 (220 mg, 0.67 mmol), 28-3 (283.8 mg, 1.01 mmol), DIPEA (1.11 mL, 6.74 mmol) and NaI (151.5 mg, 1.01 mmol) in acetonitrile (10 mL) was stirred at 90° C. for 24 h. The solvent was removed and the residue was purified by reverse phase HPLC (acetonitrile in water containing 0.05% TFA: 10% to 70%) to give 28-15.

[0670] Step 14: SFC (170 mg) (column: DAICELCHIR A IG, methanol (+0.1% 7.0 mol / l ammonia methanol solution) / supercritical CO2 = 40 / 60) to purify 28-15 to give 28 (28 mg) and 29 (18 mg), respectively. 28: SFC analysis: 96.44% de; retention time: 4.29 min; chromatographic column: DAICELCHIR A IB, methanol (0.1% DEA) in CO2, 5% to 40%; pressure: 1800 psi; flow rate: 1.5 mL / min. LCMS (ESI, m / z): [M+H] + =571.5. 1 H NMR (400MHz, DMSO-d6, ppm) δ8.23(d,J=8.32Hz,1H),7.98(d,J=8.86Hz,1H),7.89(d,J=8.52H z,2H),7.56(d,J=6.04Hz,2H),5.85-5.47(m,1H),4.97-4.85(m,1H),3.71-3.62(m,1H),3.66 (s,3H),3.09(d,J=12.24Hz,1H),2.93-2.76(m,2H),2.44-2.24(m,1H),2.22-2.06(m,1H),2. 05-1.80(m,3H),1.62-1.54(m,1H),1.53-1.39(m,1H),0.97-0.91(m,3H),0.70-0.52(m,6H); 19F NMR (376 MHz, DMSO-d6, ppm): δ87.99 (1F), 64.42 (4F)29: SFC analysis: 97.86% de; retention time: 4.44 min; chromatographic column: DAICELCHIR A IB, methanol (0.1% DEA) in CO2, 5% to 40%; pressure: 1800 psi; flow rate: 1.5 mL / min. LCMS (ESI, m / z): [M+H] + =571.5. 1 H NMR (400MHz, DMSO-d6, ppm): δ8.27-8.19(m,1H),8.01-7.95(m,1H),7.87(d ,J=7.88Hz,2H),7.58(d,J=8.28Hz,2H),6.05-5.28(m,1H),5.09-4.75(m,1 H),3.64-3.50(m,2H),3.43(s,3H),3.18-3.07(m,1H),2.21-2.12(m,1H),2 .04-1.95(m,1H),1.83-1.39(m,6H),1.00-0.91(m,3H),0.65-0.54(m,6H). 19 FNMR (376MHz, DMSO-d6, ppm): δ88.00 (1F), 64.37 (4F).

[0671] Example 12 Synthesis of Compound 30

[0672]

[0673] Step 1: To a solution of 30-1 (5 g, 26.3 mmol) and NaOH (1.6 g, 39.5 mmol) in EtOH (30 mL) and water (15 mL) was added hydroxylamine hydrochloride (2.2 g, 31.6 mmol) at 25° C. The mixture was stirred at 25° C. for 16 hours. Ice was added to the reaction mixture, the solid was filtered, and the filter cake was washed with water and dried to give 30-2.

[0674] Step 2: A solution of 30-2 (1.6 g, 7.8 mmol) and NCS (1.1 g, 8.6 mmol) in DMF (15 mL) was stirred at 25° C. for 16 hours. The mixture was concentrated, and the residue was diluted with ethyl acetate and washed with water. The organic layer was dried over Na2SO4, filtered, and concentrated to afford 30-3.

[0675] Step 3: To a solution of 30-3 (800 mg, 3.3 mmol) and tert-butyl 3-vinylpyrrolidine-1-carboxylate (795.5 mg, 4.3 mmol) in THF (20 mL) was added triethylamine (0.93 mL, 6.7 mmol) at 25° C. The mixture was stirred at 25° C. for 4 hours. The mixture was concentrated and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 4 / 1) to obtain 30-4.

[0676] Step 4: To a solution of 30-4 (300 mg, 0.78 mmol) in dichloromethane (5 mL) was added HCl (4 M ethyl acetate solution, 2.0 mL) at 25° C. The mixture was stirred at 25° C. for 2 hours. The mixture was concentrated to give 30-5.

[0677] Step 5: Compound 30 was prepared from compound 30-5 according to the synthetic procedure of compound 5 in Example 5. LCMS (ESI, m / z): [M+H] + =471.2; 1 H NMR (400MHz, DMSO-d6, ppm): δ8.33-8.20(m,1H),8.06-7.94(m,1H),7.88-7.76(m,2H),7.55-7.43(m,2H),4.69-4.49 (m,1H),4.44-4.19(m,1H),4.12-3.93(m,1H),3.90-3.68(m,2H),3.64-3.52(m,1H),3.46(s,3H),2.45-2.15(m,2H). 19 F NMR (376MHz, DMSO-d6, ppm): δ-56.74 (3F).

[0678] Example 13 Synthesis of Compounds 32 and 33

[0679]

[0680] Step 1: To a solution of 32-1 (15 g, 99.25 mmol) in acetonitrile (100 mL) was added CH3NH2 (200 mL, 3.56 mmol, 40% in water). The reaction mixture was then stirred at 80°C for 16 hours. The reaction mixture was quenched with water. The mixture was extracted with ethyl acetate. The combined organic layers were washed with water. The organic layer was dried over Na2SO4, filtered, and the filtrate was concentrated to afford 32-2.

[0681] Step 2: To a solution of 32-2 (8.2 g, 50.56 mmol) in acetonitrile (150 mL) was added NCS (7.4 g, 55.61 mmol), and the reaction mixture was stirred at 60 ° C for 70 minutes. The mixture was quenched by adding water. The aqueous layer was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to give 32-3.

[0682] Step 3: To a solution of 32-3 (5.0 g, 25.43 mmol) in DMSO (60 mL) were added KCO (5.3 g, 38.14 mmol) and HO (17.3 g, 30%, 152.6 mmol). The reaction mixture was then stirred at 25°C for 16 hours. The reaction mixture was quenched with water. The mixture was extracted with ethyl acetate. The combined organic layers were washed with water. The organic layer was dried over NaSO, filtered, and the filtrate was concentrated to afford 32-4.

[0683] Step 4: To a stirred solution of 32-4 (5 g, 23.29 mmol) in DMF (70 mL) at 0°C was added NaH (1.9 g, 46.59 mmol) in portions. After stirring at 0°C for 0.5 h, CDI (5.7 g, 34.94 mmol) was added to the mixture, which was then stirred at 60°C for 16 h. The reaction mixture was quenched with water. The mixture was extracted with ethyl acetate. The combined organic layers were washed with water. The organic layer was dried over Na2SO4, filtered, and the filtrate was concentrated to afford 32-5.

[0684] Step 5: To a solution of 32-5 (1 g, 4.16 mmol) in toluene (10 mL) was added DIPEA (1.2 g, 9.14 mmol) and POCl3 (3.2 g, 20.78 mmol). The mixture was stirred at 90°C for 3 hours. The reaction mixture was concentrated to give 32-6.

[0685] Step 6: A mixture of 32-6 (1.0 g, 3.86 mmol), 3-2 (1.00 g, 4.63 mmol) and DIPEA (7.5 g, 57.9 mmol) in propan-2-ol (15 mL) was stirred at 90° C. for 5 hours. The mixture was cooled to room temperature. The precipitate was collected by filtration to give 32-7.

[0686] Step 7: To a solution of 32-7 (1.0 g, 2.28 mmol) in dichloromethane (10 mL) was added dropwise BBr (5.7 g, 22.8 mmol) at -78°C under N2. After the addition was complete, the mixture was stirred at room temperature for 16 hours. Ice water was added to the reaction mixture, and the precipitate was collected by filtration, washed with water, and dried to afford 32-8.

[0687] Step 8: To a mixture of 32-8 (300 mg, 0.71 mmol) in DMF (10 mL) was added CsCO (690 mg, 2.12 mmol) and 3-bromooxolane (213.2 mg, 1.41 mmol). The mixture was then stirred at 85°C for 1 hour. The solvent was removed under vacuum. The residue was purified by reverse phase HPLC (acetonitrile / water: 5% to 42%) to afford 32-9.

[0688] Step 9: Use SFC (chromatographic column: DAICELCHIR A IC, ethanol (+0.1% 7.0 mol / L ammonia methanol solution) purified 32-9 (100 mg) to give 32 (14.80 mg) and 33 (15.23 mg), respectively. 32: SFC analysis: 100% ee; retention time: 9.164 min; column: DAICELCHIR A IC, ethanol in CO2 (+0.1% 7.0 mol / L ammonia in methanol), 40% to 60%; pressure: 100 bar; flow rate: 1.0 mL / min; LCMS (ESI, m / z): [M+H] + =495.4; 1 H NMR (400MHz, DMSO-d6, ppm): δ7.79 (s, 1H), 7.56 (d, J = 8.0Hz, 1H), 7.50 (s, 1H), 7.20-7.16 (d,J=8.0Hz,1H),6.91(s,1H),5.44-5.42(m,1H),4.22-4.15(m,2H),4.05-3.95(m,1H),3. 95-3.78 (m, 3H), 3.51-3.49 (m, 3H), 3.49-3.38 (m, 2H), 2.41 (s, 3H), 2.39-2.30 (m, 2H), 2.22-2.18 (m, 2H), 2.09-1.94 (m, 3H). 33: SFC analysis: 98.89% ee; retention time: 10.858 min; column: DAICELCHIR A IC, ethanol in CO2 (+0.1% 7.0 mol / L ammonia in methanol), 40% to 60%; pressure: 100 bar; flow rate: 1.0 mL / min; LCMS (ESI, m / z): [M+H] + =495.4; 1H NMR (400MHz, DMSO-d6, ppm): δ7.79 (s, 1H), 7.56 (d, J = 8.0Hz, 1H), 7.50 (s, 1H), 7. 20-7.16(d,J=8.0Hz,1H),6.91(s,1H),5.44-5.41(m,1H),4.23-4.15(m,2H),4.0 1-3.95(m,1H),3.91-3.86(m,2H),3.83-3.78(m,1H),3.51-3.49(m,3H),3.41-3. 95(m,2H),2.41(s,3H),2.39-2.30(m,2H),2.22-2.18(m,2H),2.07-1.96(m,3H).

[0689] Example 14 Synthesis of Compounds 34 and 35

[0690]

[0691] Step 1: Compound 34-2 was prepared from compound 34-1 according to the synthesis procedure of compound 28-3 in Example 11.

[0692] Step 2: A mixture of 34-2 (3.2 g, 14.3 mmol), 28-9 (4.0 g, 17.2 mmol), K2CO3 (5.9 g, 43.0 mmol), NaI (0.2 g, 1.4 mmol) and TBAI (0.5 g, 1.4 mmol) in acetonitrile (80 mL) was stirred at 90 ° C for 66 hours. The reaction mixture was filtered and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to give 34-3.

[0693] Step 3: To a stirred solution of 34-3 (450 mg, 1.1 mmol) in isopropanol (10 mL) was added Pd / C (10%, 45 mg) at 25° C. The mixture was degassed with H2 several times, and then the mixture was stirred at 25° C. under H2 for 21 hours. The reaction mixture was filtered and the filtrate was concentrated to give 34-4.

[0694] Step 4: To a mixture of 5-2 (1.0 g, 6.54 mmol) and K2CO3 (2.7 g, 19.54 mmol) in DMSO (10 mL) was slowly added H2O2 (2.2 g, 19.54 mmol) at 0°C. The mixture was then stirred at room temperature for 2 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1 to 2 / 1) to give 34-5.

[0695] Step 5: To a solution of 34-5 (5.0 g, 29.2 mmol) in NMP (100 mL) was added Zn (0.4 g, 5.84 mmol), Zn(CN) (6.9 g, 58.4 mmol), dppf (1.0 g, 1.75 mmol) and Pd(dba) (2.7 g, 2.92 mmol) under N. The reaction mixture was stirred at 120°C for 2 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to give 34-6.

[0696] Step 6: To a solution of 34-6 (0.5 g, 3.08 mmol) in dioxane (20 mL) was added triphosgene (457.5 mg, 1.54 mmol) under N2. The reaction mixture was stirred at 100°C for 3 hours. The resulting mixture was cooled to room temperature, filtered and dried to afford 34-7.

[0697] Step 7: To a solution of 34-7 (255 mg, 1.36 mmol) in toluene (10 mL) was added POCl3 (1.26 mL, 13.6 mmol) and DIPEA (0.67 mL, 4.06 mmol). The reaction mixture was stirred at 100°C for 16 hours. The reaction mixture was concentrated to give 34-8, which was used directly in the next step without further purification.

[0698] Step 8: To a solution of 34-8 (300 mg, crude) in THF (10 mL) was added DIPEA (2.2 mL, 13.3 mmol) and 34-4 (437.8 mg, 1.33 mmol). The reaction mixture was stirred at 50°C for 4 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to give 34-9.

[0699] Step 9: To a solution of 34-9 (240 mg, 0.46 mmol) in dioxane (15 mL) were added (tert-butyloxy)formylhydrazide (184 mg, 1.39 mmol), Cs2CO3 (453.8 mg, 1.39 mmol), t-Bubrettphos (22.5 mg, 0.046 mmol) and Pd2(dba)3 (42.5 mg, 0.046 mmol). The reaction mixture was stirred at 80°C for 2 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to give 34-10.

[0700] Step 10: To a solution of 34-10 (240 mg, 0.39 mmol) in dichloromethane (6 mL) was added TFA (3 mL). The reaction mixture was stirred at 25° C. for 1 hour. The mixture was concentrated to afford 34-11, which was used in the next step without further purification.

[0701] Step 11: A mixture of 34-11 (180 mg crude product) and CH(OCH3)3 (5 mL) was stirred at 80°C for 1 hour. The mixture was concentrated and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1 to 0 / 1) to give 34-12.

[0702] Step 12: 34-12 (90 mg) was purified by SFC (chromatographic column: DAICELCHIR A Compounds 34 (31.64 mg) and 35 (8.09 mg) were purified by HPLC with EtOH (+0.1% 7.0 mol / l ethanolic ammonia solution) / supercritical CO2 = 40 / 60. 34: SFC analysis: 100% de; retention time: 4.35 min; column: DAICELCHIR A AD, ethanol (0.1% DEA) in CO2, 5% to 40%; pressure: 1800 psi; flow rate: 1.5 mL / min. LCMS (ESI, m / z): [M+H] + =523.5. 1 H NMR (400 MHz, methanol-d4, ppm): δ9.32 (s, 1H), 8.77–8.75 (m, 1H), 8.31–8.29 (m, 1H), 7.69–7.67 (m, 2H), 7.67–7.55 (m, 2H), 5.96–5.53 (m, 1H), 3.68–3.65 (m, 1H), 3.48–3.39 ( m,2H),3.12-3.05(m,1H),2.96–2.92(m,1H),2.46(s,1H),2.23(s,1H),2.06–2.00( m,2H),1.73–1.65(m,1H),1.58–1.53(m,2H),1.09–1.06(m,3H),0.78–0.69(m,6H). 19 F NMR (376 MHz, methanol-d4, ppm): δ-63.83 (3F).35: SFC analysis: 97.18% de; retention time: 4.94 min; chromatographic column: DAICELCHIR A AD, ethanol (0.1% DEA) in CO2, 5% to 40%; pressure: 1800 psi; flow rate: 1.5 mL / min. LCMS (ESI, m / z): [M+H] + =523.5. 1 H NMR (400MHz, methanol-d4, ppm): δ9.32(s,1H),8.77-8.75(m,1H),8.30-8.28(m,1H),7.65-7.63(m,2H),7.60-7.58(m,2H),5.32(s,1H),3.66-3.47 (m,3H),2.70-2.66(m,1H),2.37-2.33(m,1H),2.20-2.16(m,1H),2.07 -1.90(m,3H),1.70-1.56(m,3H),1.13-1.03(m,3H),0.71-0.65(m,6H). 19 F NMR (376 MHz, methanol-d4, ppm): δ-63.82 (3F).

[0703] Example 15 Synthesis of Compounds 36 and 37

[0704]

[0705] Step 1: A mixture of LiAlH4 (0.30 g, 8.2 mmol) in THF (20 mL) was stirred at 0°C under N2 for 0.5 h. 36-1 (1 g, 4.1 mmol) was then added and the mixture was stirred at 25°C for 16 h. The mixture was diluted with THF, quenched with saturated Na2SO4 (1.5 mL) and filtered. The filtrate was concentrated to give 36-2, which was used directly in the next step without further purification.

[0706] Step 2: A solution of 36-2 (700 mg, crude), 4-(trifluoromethoxy)benzoic acid (626.5 mg, 3.04 mmol), HATU (1733.5 mg, 4.56 mmol), and DIPEA (0.75 mL, 4.56 mmol) in DMF (12 mL) was stirred at 25° C. for 3 hours. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with water and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 2 / 1) to provide 36-3.

[0707] Step 3: To a solution of 36-3 (580 mg, 1.39 mmol) in dichloromethane (8 mL) was added DAST (0.28 mL, 2.08 mmol) at 0°C. The mixture was then stirred at 20°C for 1 hour. The mixture was quenched with aqueous NaHCO3 and extracted with dichloromethane. The organic phase was concentrated and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 3 / 1) to give 36-4.

[0708] Step 4: To a solution of 36-4 (588 mg, 1.47 mmol) in dichloromethane (6 mL) was added HCl in ethyl acetate (4 M, 2.5 mL) at 20° C. The mixture was stirred at 20° C. for 1.5 hours. The mixture was concentrated under reduced pressure to give 36-5.

[0709] Step 5: A solution of 5-7 (250 mg, 0.87 mmol), 36-5 (208.9 mg, 0.67 mmol) and DIPEA (1.50 mL, 9.1 mmol) in acetonitrile (10 mL) was stirred at 85°C under N2 for 3 hours. The mixture was concentrated. The residue was dissolved in ethyl acetate and washed with water. The organic phase was concentrated. The residue was purified by reverse phase HPLC (acetonitrile / water: 5%-80%) to give 37. LCMS (ESI, m / z): [M+H] + =494.2. 1 H NMR (400MHz, DMSO-d6, ppm): δ8.28-8.23(m,1H),8.09-7.92(m,3H),7.55-7.42(m,2H),4.75-3.90(m,6H),3.46(s,3H),1.98-1.78(m,4H). 19 F NMR (376MHz, DMSO-d6, ppm): δ-56.68 (3F).

[0710] Step 6: A solution of 37 (100 mg, 0.20 mmol), dppf (22.5 mg, 0.040 mmol), Zn (13.2 mg, 0.20 mmol), Zn(CN)2 (47.6 mg, 0.41 mmol) and Pd2(dba)3 (18.5 mg, 0.02 mmol) in NMP (8 mL) was stirred at 90°C under N2 for 16 h. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with water and concentrated. The residue was purified by reverse phase HPLC (acetonitrile / water: 5%-80%) to afford 36. LCMS (ESI, m / z): [M+H] + =485.2. 1HNMR (400MHz, DMSO-d6, ppm): δ8.13-7.89(m,3H),7.85-7.78(m,1H),7.54-7.43(m,2H),4.80-3.90(m,6H),3.45(s,3H),1.94-1.75(m,4H). 19 FNMR (376MHz, DMSO-d6, ppm): δ-56.68 (3F).

[0711] Example 16 Synthesis of Compounds 39 and 42

[0712]

[0713] Step 1: To a stirred solution of 39-1 (1 g, 4.71 mmol) in NMP (10 mL) was added ZnBr (10.6 g, 47.15 mmol), Pd (dppf) Cl (0.3 g, 0.47 mmol), DIPEA (15.59 mL, 94.3 mmol) and ethynylcyclopropane (3.12 g, 47.15 mmol) under N. The reaction mixture was stirred at 120 ° C for 2 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine. The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 20 / 1) to give 39-2.

[0714] Step 2: To a solution of 5-7 (583 mg, 2.53 mmol) in acetonitrile (5 mL) were added 39-2 (500 mg, 2.53 mmol) and DIPEA (983 mg, 7.6 mmol). The reaction was stirred at room temperature under N2 for 3 hours. The reaction mixture was concentrated and the residue was purified by reverse phase HPLC (acetonitrile / water, 5% to 50%) to give 39. LCMS (ESI, m / z): [M+H] + =391.2; 1 H NMR (400MHz, DMSO-d6, ppm): δ7.98(d,J=8.0Hz,1H),7.75(d,J=8.0Hz,1H),7.14-7.10(m,1H),6.97-6.90(m,2H),4.06-4 .02(m,2H),3.50(s,3H),2.84-2.80(m,2H),1.99-1.93(m,2H),1.63-1.56(m,1H),0.96-0.94(m,2H),0.93-0.91(m,2H).

[0715] Step 3: To a solution of 39 (140 mg, 0.36 mmol) in DMF (1.5 mL) were added Zn(CN)2 (420 mg, 3.58 mmol) and Pd(PPh3)4 (206.8 mg, 0.18 mmol). The reaction mixture was then stirred at 110°C under N2 for 1 hour. The reaction mixture was concentrated and the residue was purified by reverse phase HPLC (acetonitrile / water: 5% to 50%) to afford 42. LCMS (ESI, m / z): [M+H] + =382.2; 1 H NMR (400MHz, DMSO-d6, ppm): δ8.19(d,J=8.0Hz,1H),8.05(d,J=8.0Hz,1H),7.17-7.13(m,1H),6.96-6.94(m,2H),4.08-4 .03(m,2H),3.50(s,3H),2.85-2.82(m,2H),2.01-1.95(m,2H),1.62-1.58(m,1H),0.95-0.93(m,2H),0.92-0.91(m,2H).

[0716] Example 17 Synthesis of Compounds 44 and 45

[0717]

[0718] Step 1: To a solution of N1,N1,N2,N2-tetramethylethane-1,2-diamine (5.8 g, 56.28 mmol) in THF (80 mL) was added dropwise n-BuLi (40 mL, 64 mmol, 1.6 mol / L THF solution) at -40°C under N2. The reaction was stirred at -40°C for 40 minutes. 44-1 (7 g, 40.2 mmol) was then added to the mixture over 5 minutes. The mixture was stirred at -40°C for 30 minutes. A second portion of n-BuLi (25.328 mL, 40.525 mmol, 1.6 mol / L THF solution) was added dropwise over 5 minutes, and the reaction mixture was then stirred at -40°C for 2 hours. The cooling bath was removed, CuBr (7.5 g, 52.26 mmol) was added to the mixture, and the reaction mixture was stirred at 25°C for another hour. The reaction was cooled to -30 ° C, and a solution of 3-bromoprop-1-ene (9.73 g, 80.4 mmol) in THF (10 mL) was added dropwise over 5 minutes, and the reaction mixture was stirred at -40 ° C for 2 hours. The reaction was quenched by adding methanol. The pH value of the mixture was adjusted to 6 with HCl (6 M). The reaction mixture was filtered and the filter cake was washed with ethyl acetate. The mixture was extracted with ethyl acetate. The combined organic layer was washed with brine. The combined organic layer was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 3 / 1) to give 44-2.

[0719] Step 2: To a solution of 44-2 (5 g, 23.34 mmol) in THF (50 mL) was added allylmagnesium bromide (25.68 mL, 25.68 mmol) and the reaction was stirred at -40 ° C for 1 hour. The reaction was quenched with saturated NH4Cl aqueous solution. The reaction mixture was extracted with ethyl acetate. The combined organic layer was washed with brine and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 2 / 1) to give 44-3.

[0720] Step 3: To a solution of 44-3 (2.0 g, 7.8 mmol) in dichloromethane (160 mL) was added Grubbs second-generation catalyst (331 mg, 0.39 mmol). The reaction was stirred at 20°C under N2 for 18 hours. The reaction mixture was diluted with water. The organic layer was separated, washed with brine, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 2 / 1) to provide 44-4.

[0721] Step 4: To a solution of 44-4 (1.36 g, 5.96 mmol) in EtOH (25 mL) was added 10% Pd / C (0.1 g). The suspension was degassed under vacuum and purged with H2 three times, and then the mixture was stirred at 25°C under H2 for 1 hour. The suspension was filtered and the filter cake was washed with EtOH (20 mL). The combined filtrates were concentrated to give 44-5.

[0722] Step 5: To a solution of 44-5 (1 g, 4.34 mmol) in dichloromethane (25 mL) was added SOCl2 (0.47 mL, 6.51 mmol) and the reaction was stirred at 0°C for 1.5 hours. The reaction was quenched with water. The aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine. The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 10 / 1) to give 44-6.

[0723] Step 6: To a solution of 28-14 (250 mg, 0.77 mmol) in acetonitrile (10 mL) were added DIPEA (0.25 mL, 1.53 mmol), NaI (344 mg, 2.3 mmol) and 44-6 (380 mg, 1.53 mmol). The reaction mixture was stirred at 80°C for 24 hours. Another batch of 44-6 (190 mg, 0.76 mmol) was then added to the reaction mixture, and the reaction was stirred at 80°C for another 24 hours. The reaction mixture was concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 1 / 0 to 10 / 1) to give 44-7.

[0724] Step 7: Purification of 44-7 (150 mg, 0.28 mmol) by reverse phase HPLC (acetonitrile / 0.1% TFA in water: 75%) afforded 44 (10.43 mg) and 45 (4.01 mg). 44: Analytical HPLC: Retention time: 1.85 min; Column: Waters ACQUITY BEH C18 2.1*50 mm, 1.7 μm; Mobile phase A: Water (0.05% TFA); Mobile phase B: Acetonitrile (0.05% TFA); Flow rate: 1.0 mL / min; Run time: 5 min; 95 to 5% A for 3 min, 5% A for 2 min. LCMS (ESI, m / z): [M+H] + =539.4; 1 H NMR (400MHz, CDCl3): δ7.89-7.77(m,1H),7.63-7.54(m,1H),7.40-7.30(m,2H),7.25-7.20(m,1 H),6.16-5.54(m,1H),5.34-5.09(m,1H),3.75-3.67(m,1H),3.64-3.34(m,5H),3.12-2.97(m,1H ),2.74-2.63(m,1H),2.63-2.52(m,1H),2.18-2.11(m,1H),2.06-1.90(m,4H),1.87-1.75(m,2H) ,1.73-1.63(m,1H),1.49-1.36(m,2H),1.31-1.25(m,1H),1.09-0.90(m,3H),0.74-0.60(m,3H). 19 FNMR (376 MHz, CDCl3, ppm): δ-62.33 (3F).45: Analytical HPLC: Retention time: 1.85 min; Column: Waters ACQUITY BEH C18 2.1*50 mm, 1.7 μm; Mobile phase A: Water (0.05% TFA); Mobile phase B: Acetonitrile (0.05% TFA); Flow rate: 1.0 mL / min; Run time: 5 min; 95 to 5% A over 3 minutes, 5% A over 2 minutes. LCMS (ESI, m / z): [M+H] + =539.4; 1H NMR (400MHz, CDCl3): δ7.89-7.77(m,1H),7.64-7.54(m,1H),7.46-7.29(m,2H),7.24-7.16(m,1H),6.03-4.80(m,2H),3.77-3.07(m,6H),2.95-2 .80(m,1H),2.78-2.53(m,2H),2.30-2.10(m,4H),2.08-1.90(m,2H),1.7 4-1.67(m,2H),1.41-1.29(m,3H),1.05-0.96(m,3H),0.69-0.37(m,3H). 19 F NMR (376MHz, CDCl3, ppm): δ-62.34 (3F).

[0725] Example 18 Synthesis of Compound 50

[0726]

[0727] Step 1: To a solution of methyltriphenylphosphine bromide (4.4 g, 12.19 mmol) in THF (25 mL) was added potassium tert-butoxide (12.19 mL, 12.19 mmol) at 20°C. The mixture was stirred at 55°C under N2 for 2 hours. 50-1 (1.3 g, 6.09 mmol) was then added, and the mixture was stirred at 55°C for 16 hours. The mixture was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 10 / 1) to give 50-2.

[0728] Step 2: Compound 50 was prepared from 50-2 according to the synthetic procedure of compound 30 in Example 12. LCMS (ESI, m / z): [M+H] + =499.2; 1 H NMR (400MHz, DMSO-d6, ppm): δ8.30-8.23(m,1H),8.06-7.98(m,1H),7.88-7.72(m,2H),7.53-7.42(m,2H),5.60-5.35(m,1H),5.25-4.80 (m,1H),3.70-3.60(m,1H),3.46(s,3H),3.42-3.35(m,1H),3.34-3.30(m,1H),2.24-2.10(m,1H),2.07-1.79(m,3H),1.56-1.36(m,3H). 19 F NMR (376MHz, DMSO-d6, ppm): δ-56.75 (3F).

[0729] Example 19 Synthesis of Compounds 57 and 58

[0730]

[0731] Step 1: To a stirred solution of 57-1 (45 g, 276 mmol) in EtOH (450 mL) was added thiourea (22.06 g, 290 mmol) at room temperature. The resulting mixture was stirred at 80°C under N2 for 15 hours. The solvent was removed under reduced pressure. The residue was diluted with water and neutralized with NaHCO3 to a pH of 8-9, and then dichloromethane was added to the mixture. The mixture was extracted with dichloromethane. The combined organic layers were washed with saturated NaHCO3 and brine, dried over anhydrous Na2SO4, and concentrated to afford 57-2.

[0732] Step 2: To a stirred solution of 57-2 (6 g, 19.9 mmol) and CuBr (4.3 g, 29.9 mmol) in acetonitrile (80 mL) was added t-BuONO (3.59 mL, 29.9 mmol) at 0-5°C. The resulting mixture was stirred at room temperature for 30 hours. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 6 / 1) to give 57-3.

[0733] Step 3: To a stirred solution of 57-3 (1.0 g, 4.9 mmol) in THF (20 mL) was added n-BuLi (2.55 mL, 6.37 mmol) below -60°C under N2. The resulting mixture was stirred at this temperature for 1 hour. A solution of 4-((trifluoromethyl)thio)benzaldehyde (1313.4 mg, 6.37 mmol) in THF (20 mL) was added to the above reaction mixture below -60°C. The resulting mixture was stirred at room temperature for 30 minutes. The reaction mixture was quenched with saturated NH4Cl and diluted with water. The mixture was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to give 57-4.

[0734] Step 4: To a stirred solution of 57-4 (450 mg, 1.36 mmol) in dichloromethane (6 mL) was added SOCl2 (0.15 mL, 2.04 mmol) at 25° C. The resulting mixture was stirred at 25° C. for 15 hours. The reaction mixture was concentrated to give 57-5, which was used in the next step without further purification.

[0735] Step 5: To a stirred solution of 57-5 (1.15 g, 2.63 mmol) and 28-14 (0.86 g, 2.63 mmol) in acetonitrile (10 mL) was added DIPEA (1.83 mL, 10.52 mmol) at 25°C. The resulting mixture was stirred at 90°C for 15 hours. The reaction mixture was concentrated. The residue was purified by reverse phase HPLC (acetonitrile / 0.05% aqueous TFA, 0-60%) to afford 57 (11.65 mg) and 58 (6.24 mg). 57: Analytical HPLC: Retention time: 1.85 min; Column: Waters ACQUITY BEH C18 2.1*50 mm, 1.7 μm; Mobile phase A: Water (0.05% TFA); Mobile phase B: Acetonitrile (0.05% TFA); Flow rate: 1.0 mL / min; Run time: 5 min; 95% to 5% A: 3 min, 5% A: 2 min. LCMS (ESI, m / z): [M+H] + =640.2; 1 HNMR (400MHz, methanol-d4, ppm): δ8.09-8.03(m,1H),8.02-7.95(m,1H),7.75-7.66(m,4H) ,7.06(s,1H),6.19-5.51(m,1H),5.22-5.12(m,1H),3.68-3.33(m,1H),3.56(s,3H),2 .93-2.82(m,1H),2.76-2.64(m,2H),2.46-2.31(m,1H),2.12-1.97(m,3H),1.55-1.4 0(m,2H),0.98-0.84(m,6H),0.80-0.73(m,2H),0.69-0.65(m,1H),0.58-0.54(m,1H). 19 F NMR (376 MHz, methanol-d4, ppm): δ -44.64 (3F). 58: Analytical HPLC: Retention time: 1.85 min; Column: Waters ACQUITY BEH C18 2.1*50 mm, 1.7 μm; Mobile phase A: Water (0.05% TFA); Mobile phase B: Acetonitrile (0.05% TFA); Flow rate: 1.0 mL / min; Run time: 5 min; 95 to 5% A over 3 minutes, 5% A over 2 minutes. LCMS (ESI, m / z): [M+H] + =640.2; 1HNMR (400MHz, CDCl3, ppm): δ7.86-7.81(m,1H),7.65-7.57(m,5H),6.85(s,1H),6.07-5.62(m,1H),5.68-5.56(m,1H),3.73-3.41(m,1H),3.58 (s,3H),2.76-2.55(m,2H),2.52-2.42(m,1H),2.16-1.93(m,4H),1.50 -1.39(m,2H),0.93-0.90(m,2H),0.86-0.81(m,6H),0.78-0.67(m,2H). 19 F NMR (376MHz, CDCl3, ppm): δ-42.58 (3F).

[0736] Example 20 Synthesis of Compound 59

[0737]

[0738] Step 1: Compound 59-2 was prepared from compound 59-1 according to the synthesis procedure of compound 30-5 in Example 12.

[0739] Step 2: To a mixture of 59-3 (4.9 g, 25.4 mmol) and methyl 2-hydroxyacetate (2.74 g, 30.4 mmol) in DMF (50 mL) was added NaH (1.22 g, 60%, 30.5 mmol) at 0°C. The mixture was then stirred at room temperature for 1 hour. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 2 / 1) to give 59-4.

[0740] Step 3: To a solution of 59-4 (4.9 g, 19.87 mmol) in EtOH (50 mL) and HOAc (20 mL) was added Fe (5.6 g, 100 mmol) at room temperature. The mixture was then stirred at 80°C for 2 hours. The mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 1 / 0 to 20 / 1) to give 59-5.

[0741] Step 4: To a solution of 59-5 (2.6 g, 14.09 mmol) in THF (20 mL) was added BH3·THF (1 M, 65 mL, 65 mmol) at room temperature. The mixture was then stirred at 80°C for 2 hours. The mixture was quenched with methanol and stirred at 80°C for 30 minutes. The mixture was then concentrated to afford 59-6, which was used directly in the next step without further purification.

[0742] Step 5: To a solution of 59-6 (1.0 g, crude) and (Boc)2O (4.04 mL, 17.59 mmol) in THF (15 mL) was added DMAP (1.43 g, 11.72 mmol) and triethylamine (0.82 mL, 5.86 mmol) at room temperature. The mixture was then stirred at 80°C for 12 hours. The mixture was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 1 / 0 to 20 / 1) to give 59-7.

[0743] Step 6: To a solution of 59-7 (1.5 g, 5.54 mmol) in CHCl 3 (20 mL) was added mCPBA (2.25 g, 11.08 mmol) at room temperature. The mixture was then stirred at 80° C. for 12 hours. The mixture was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol) = 1 / 0 to 10 / 1) to give 59-8.

[0744] Step 7: To a solution of 59-8 (1.2 g, 4.19 mmol) in acetonitrile (20 mL) was added TMSCN (1.25 g, 12.56 mmol) and triethylamine (1.75 mL, 12.56 mmol) at room temperature. The mixture was then stirred at 80° C. for 12 hours. The mixture was concentrated and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 4 / 1) to give 59-9.

[0745] Step 8: To a solution of 59-9 (620 mg, 2.1 mmol) and KCO (870 mg, 6.29 mmol) in DMSO (10 mL) was added HO (30%, 713.0 mg, 6.29 mmol) at 0°C. The mixture was then stirred at room temperature for 1 hour. The solid was collected by filtration and washed with dichloromethane. The solid was suspended in water and concentrated HCl was added until the pH was 4-5. The solid was collected by filtration to give 59-10.

[0746] Step 9: Compound 59 was prepared from 59-10 according to the synthesis procedure of compound 5 in Example 5. LCMS (ESI, m / z): [M+H] + =513.2; 1 H NMR (400MHz, DMSO-d6, ppm): δ7.89(s,1H),7.84-7.76(m,2H),7.53-7.44(m,2H),5.06-4.58(m ,1H),4.55-4.46(m,2H),4.48-4.06(m,2H),4.05-3.68(m,3H),3.35(s,2H),2.06-1.82(m,4H). 19F NMR (376MHz, DMSO-d6, ppm): δ-56.75 (3F).

[0747] Example 21 Synthesis of Compound 64

[0748]

[0749] Step 1: To a suspension of 64-1 (950 mg, 3.62 mmol) in CCl4 (20 mL) were added NBS (709.4 mg, 3.99 mmol) and AIBN (89.2 mg, 0.54 mmol). The mixture was then stirred at 85°C for 3 hours. The mixture was concentrated and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 1 / 0 to 10 / 1) to give 64-2.

[0750] Step 2: To a mixture of 64-2 (500 mg, 1.17 mmol) and 28-14 (421.05 mg, 1.29 mmol) in acetonitrile (15 mL) was added DIPEA (0.97 mL, 5.86 mmol) and NaI (351.6 mg, 2.35 mmol). The mixture was then stirred at 85°C for 3 hours. The mixture was extracted with ethyl acetate. The organic layer was washed with water and brine (20 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by reverse phase HPLC (acetonitrile / 0.05% TFA in water: 0-60%) to give 64-3 and 64-4.

[0751] Step 3: To a mixture of 64-3 (75 mg, 0.13 mmol) and cyclopropylcarboxamide oxime (14.08 mg, 0.14 mmol) in DMSO (2 mL) was added DIPEA (58.3 mg, 0.15 mmol) and HATU (58.3 mg, 0.15 mmol). The mixture was stirred at room temperature for 30 minutes, then heated to 90 ° C and stirred for 30 minutes. The mixture was cooled and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by reverse phase HPLC (acetonitrile / 0.05% TFA aqueous solution: 0-70%) to give 64 as 3.3 equivalents of TFA salt. LCMS (ESI, m / z): [M + H] + =651.4; 1HNMR (400MHz, DMSO-d6, ppm): δ8.24 (d, J=8.8Hz, 1H), 8.02-7.98 (m, 3H), 7.88-7.81 (m,2H),6.00-5.37(m,2H),4.98-4.91(m,1H),3.65-3.56(m,0.5H),3.44(s,3H),3.3 0-3.18(m,1H),2.90-2.82(m,0.5H),2.2-2.57(m,1H),2.40-2.21(m,2H),2.17-2.12 (m,1H),2.04-1.78(m,2H),1.63-1.39(m,2H),1.11-1.04(m,2H),0.90-0.69(m,7H). 19 F NMR (376MHz, DMSO-d6, ppm): δ87.41-86.60 (1F), 64.20-63.80 (4F), -73.59 (9.9F, TFA).

[0752] Example 22 Synthesis of Compound 67

[0753]

[0754]

[0755] Step 1: To a stirred solution of 67-1 (25 g, 150.4 mmol) in acetonitrile (250 mL) was added NBS (28.1 g, 158 mmol) in portions at 25-40°C. The reaction mixture was stirred at 25-40°C for 2 hours. The precipitate was filtered and the filter cake was washed with acetonitrile. The filter cake was collected and dried to give 67-2.

[0756] Step 2: To a stirred solution of 67-2 (20 g, 81.6 mmol) in THF (100 mL) was added acetoacetate (24.14 mL, 257.06 mmol) dropwise at 25°C. The reaction mixture was stirred at 75°C for 19 hours. The reaction mixture was concentrated. The residue was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na2SO4 and concentrated to afford 67-3.

[0757] Step 3: To a solution of 67-3 (20.9 g, 72.8 mmol) and Cs2CO3 (52.2 g, 160.15 mmol) in DMF (150 mL) was added dropwise CH3I (7.7 mL, 123.7 mmol) at 5-15°C. The reaction mixture was stirred at 25°C for 67 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layers were combined, washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 1 / 4) to give 67-4.

[0758] Step 4: A solution of KHMDS in THF (1 M, 54.6 mL, 54.6 mmol) was added to THF (200 mL) at -10°C under N2, and then a solution of 67-4 (13.7 g, 45.5 mmol) in THF (400 mL) was added to the solution at -60°C to -50°C under N2. The reaction mixture was then stirred at 20°C for 1.5 hours. The reaction was quenched with water, and the mixture was extracted with ethyl acetate. The aqueous layer was acidified with HCl (2N) to a pH of 3-4. The precipitate was filtered, washed with water, and dried to give 67-5.

[0759] Step 5: To a stirred solution of 67-5 (2 g, 7.84 mmol) in AcOH (20 mL) was added HNO3 (1.3 mL, 31.74 mmol) at 25°C. The reaction mixture was stirred at 80°C for 15 hours. The reaction mixture was cooled to 25°C and diluted with water. The mixture was stirred for 10 minutes, and the precipitate was filtered and dried to afford 67-6.

[0760] Step 6: To a stirred solution of 67-6 (1.4 g, 4.67 mmol) in toluene (28 mL) was added DIPEA (4.06 mL, 23.33 mmol) and POCl3 (2.17 mL, 23.33 mmol) at 25°C. The reaction mixture was stirred at 110°C under N2 for 3 hours. The reaction mixture was concentrated to afford 67-7, which was used in the next step without further purification.

[0761] Step 7: To a stirred solution of 67-8 (34.9 g, 292.99 mmol) in methanol (250 mL) was added triethylamine (42.76 mL, 307.63 mmol) and benzaldehyde (31.27 mL, 307.63 mmol) at 5-10°C. The reaction mixture was stirred at this temperature for 3 hours. The reaction mixture was then cooled to 0°C and NaBH4 (22.2 g, 585.964 mmol) was added portionwise to the reaction mixture. The reaction mixture was stirred at 0-20°C for 2.5 hours. The reaction mixture was quenched with HCl (3N) and extracted with ethyl acetate. The organic layer was washed with HCl (3N). The aqueous layers were combined and neutralized with NaHCO3 powder. The aqueous layer was concentrated. The residue was dissolved in dichloromethane / methanol (10:1) and filtered. The organic layer was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol = 1 / 0 to 10 / 1) to give 67-9.

[0762] Step 8: To a solution of 67-9 (32.86 g, 157.04 mmol) and (2R)-2-{[(tert-butoxy)carbonyl]amino}butanoic acid (31.92 g, 157.04 mmol) in DMF (350 mL) was added dropwise DIPEA (82.06 mL, 471.11 mmol) at 25°C, followed by the addition of HATU (89.6 g, 235.56 mmol) at 5-15°C. The reaction mixture was stirred at 25°C for 48 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layers were combined, washed with water and brine, dried over anhydrous Na2SO4, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 0 / 1) to afford 67-10.

[0763] Step 9: To a stirred solution of 67-10 (28.9 g, 73.26 mmol) in methanol (280 mL) was added HCl in ethyl acetate (4 M, 50 mL) at 25-35° C. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated to afford 67-11.

[0764] Step 10: A solution of 67-11 (25.4 g, 69.14 mmol) in DIPEA (35 mL, 200.93 mmol) and methanol (300 mL) was stirred at 70° C. for 15 hours. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 1 / 0 to 10 / 1) to give 67-12.

[0765] Step 11: To a stirred solution of 67-12 (21 g, 80.06 mmol) in THF (100 mL) was added BH 3 ·THF (1 M in THF, 22.9 mL, 22.9 mmol) at 0° C. under N 2 . The reaction mixture was stirred at 70° C. for 18 hours. The reaction mixture was cooled to 0-10° C. and then quenched with methanol and HCl (2N). The resulting mixture was stirred at 70° C. for 2 hours. The reaction mixture was concentrated. The residue was diluted with water (100 mL) and basified with NaHCO 3 to pH=8-9. The mixture was concentrated to dryness. The residue was dissolved in 10% methanol in dichloromethane and the suspension was filtered. The filtrate was concentrated to give 67-13, which was used directly in the next step without further purification.

[0766] Step 12: To a stirred solution of 67-13 (27.7 g, crude), DMAP (0.9 g, 7.09 mmol), and triethylamine (19.72 mL, 141.85 mmol) in dichloromethane (280 mL) was added (Boc)2O (14.66 mL, 63.83 mmol) at 0-10°C. The reaction mixture was stirred at room temperature for 15 hours. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 2 / 1) to afford 67-14.

[0767] Step 13: To a stirred solution of 67-14 (5 g, 14.95 mmol) in methanol (30 mL) was added HCl in ethyl acetate (4 M, 30 mL) at 25° C. The reaction mixture was stirred for 15 hours at 25° C. The reaction mixture was concentrated to give 67-15, which was used in the next step without further purification.

[0768] Step 14: A mixture of 67-15 (4.5 g, 14.61 mmol), 34-2 (8.13 g, 36.53 mmol), DIPEA (10.18 mL, 58.44 mmol), KCO (8.1 g, 58.44 mmol), and KI (4.9 g, 29.22 mmol) in CHCN (100 mL) was stirred at 90° C. for 48 hours. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 2 / 3) to give 67-16 and 67-17.

[0769] Step 15: To a stirred solution of 67-16 (1.93 g, 4.59 mmol) in isopropanol (60 mL) was added Pd / C (5%, 450 mg) at 25° C. The reaction mixture was degassed with H2 several times, and then the mixture was stirred at 60° C. under H2 for 15 hours. The reaction mixture was filtered and the filtrate was concentrated to give 67-18.

[0770] Step 16: A solution of 67-18 (1.6 g, 4.84 mmol), 67-7 (1.46 g, crude) and DIPEA (8.44 mL, 48.43 mmol) in CHCN (30 mL) was stirred at 90° C. for 15 hours. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 1 / 4) to give 67-19.

[0771] Step 17: To a stirred solution of 67-19 (700 mg, 1.14 mmol), Zn(CN)2 (268.5 mg, 2.29 mmol), Zn (15.0 mg, 0.23 mmol) and DPPF (38.0 mg, 0.069 mmol) in NMP (7 mL) was added Pd2(dba)3 (104.7 mg, 0.114 mmol) at 25°C. The reaction mixture was degassed with N2 for a period of time and stirred at 90°C for 15 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layers were combined, washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 1 / 4) to give 67-20.

[0772] Step 18: To a stirred solution of 67-20 (180 mg, 0.31 mmol) in DMF (1.8 mL) was added DBU (139.8 mg, 0.92 mmol) at 25°C. The reaction mixture was stirred at 130°C for 15 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 0 / 1) and then by reverse phase HPLC (MeCN / 0.1% TFA in water: 0-60%) to give 67. Analytical HPLC: Retention time: 1.69 minutes; Column: Waters ACQUITY BEHC18 2.1*50 mm, 1.7 μm; Mobile phase A: Water (0.05% TFA); Mobile phase B: Acetonitrile (0.05% TFA); Flow rate: 1.0 mL / min; Run time: 5 minutes; 95% to 5% A in 3 minutes, 5% A in 2 minutes. LCMS (ESI, m / z): [M+H] + =512.2; 1H NMR (400 MHz, methanol-d4, ppm): δ8.06-7.99 (m, 1H), 7.89-7.85 (m, 1H), 7.68-7.62 (m, 2H), 7.59-7.53 (m, 2H), 5.13-5.08 (m, 1H), 4.41-4.35 (m, 1H), 4.08-4.04 (m, 1H), 3.82-3.74 (m, 1H), 3.71 ( s,3H),3.63-3.52(m,1H),3.16-3.09(m,1H),3.09-3.02(m,1H),2.74-2.65(m,1H),2.52-2.4 3(m,1H),2.12-2.01(m,1H),1.81-1.59(m,3H),0.81(t,J=7.4Hz,3H),0.69(t,J=7.3Hz,3H). 19 F NMR (376 MHz, methanol-d4, ppm): δ-63.86 (3F).

[0773] Example 23 Synthesis of Compounds 72 and 73

[0774]

[0775] Step 1: To a mixture of the methyl ester of 72-1 (500 mg, 2.31 mmol) in 2-methoxyethyl ether (10 mL) were added 2,2'-bipyridine (542 mg, 3.47 mmol), AgSCF3 (725.4 mg, 3.47 mmol), and CuI (661 mg, 3.47 mmol). The mixture was then stirred at 130°C under N2 for 24 hours. Water was added to quench the mixture, and the aqueous layer was extracted with ethyl acetate. The organic extracts were combined, washed with brine, dried over anhydrous Na2SO4, and the mixture was concentrated. The residue was purified by reverse phase HPLC (MeCN / water (0.05% TFA), 5-95%) to provide 72-2.

[0776] Step 2: NaBH4 (0.7 g, 18.55 mmol) was added to a solution of 72-2 (2.2 g, 9.28 mmol) in MeOH (2 mL) at 0 ° C. and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with DCM and saturated NH4Cl solution. The organic layer was separated and concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1) to give 72-3.

[0777] Step 3: To a solution of 72-3 (1.12 g, 5.35 mmol) in DCM (15 mL) was added Dess-Martin periodinane (3.0 g, 6.96 mmol) at 0°C and the reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1) to give 72-4.

[0778] Step 4: 4-fluorophenylmagnesium bromide (0.32 mL, 0.32 mmol) was added to a solution of 72-4 (460 mg, 2.21 mmol) in THF (10 mL) at -78 ° C, and the reaction mixture was then stirred at room temperature for 30 minutes. The reaction mixture was diluted with ethyl acetate and saturated NH4Cl solution. The organic layer was separated and washed with saturated NaCl solution, and then the organic layer was concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=4 / 1) to give 72-5.

[0779] Step 5: To a solution of 72-5 (580 mg, 1.91 mmol) in DCM (12 mL) was added DMF (0.01 mL, 0.13 mmol) and SOCl2 (378 mg, 3.82 mmol) at 0°C, and the reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated in vacuo to afford 72-6, which was used in the next step without further purification.

[0780] Step 6: Compounds 72 and 73 were prepared from compound 72-6 according to the synthetic procedure of compound 28-15 in Example 11. The product was obtained by reverse phase HPLC (MeCN / water (0.05% TFA), 0-80%). 72: 2.23 TFA salt, LCMS (ESI, m / z): [M+H] + =598.4; 1 H NMR (400 MHz, methanol-d4, ppm): δ 8.98 (s, 1H), 8.22 (dd, J = 8.0, 2.0 Hz, 1H), 8.14-8.01 (m, 2H), 7.76-7.60 (m, 3H), 7.25 (t, J = 8.4 Hz, 2H), 6.43-5.91 (m, 2H), 5.42-5.32 (m, 1H), 4.10-3.99 (m, 1H), 3.60 (s, 3H), 3.20-3.02 (m, 2H), 1.91-1.59 (m, 5H), 1.39-1.28 (m, 1H), 0.85 (t, J = 7.2 Hz, 3H). 19F NMR (376 MHz, methanol-d4, ppm): δ -44.15 (3F), -77.27 (6.7F, TFA), -111.5 (1F). 73:1.48 TFA salt LCMS (ESI, m / z): [M+H] + =598.4; 1 H NMR (400MHz, methanol-d4, ppm): δ8.93 (s, 1H), 8.21 (dd, J = 8.0, 2.0Hz, 1H), 8.10 ( d,J=8.8Hz,1H),8.03(d,J=8.8Hz,1H),7.81-7.67(m,3H),7.18(t,J=8.4Hz, 2H),6.34-5.96(m,1H),5.55-5.23(m,2H),4.10-3.85(m,1H),3.59(s,3H), 3.28-3.15(m,1H),3.10-2.90(m,1H),1.65-1.28(m,6H),0.78-0.64(m,3H). 19 F NMR (376 MHz, methanol-d4, ppm): δ -4.24 (3F), -77.38 (4.45F, TFA), -111.5 (1F).

[0781] Example 24 Synthesis of Compounds 77 and 78

[0782]

[0783] Step 1: To a mixture of 64-3 (80 mg, 0.14 mmol) in THF (10 mL) was added CDI (44.2 mg, 0.27 mmol). After stirring at room temperature for 16 hours, NaBH4 (5.2 mg, 0.14 mmol) was added to the mixture. The mixture was then stirred at room temperature for 20 minutes. Water was added to quench the mixture, and the aqueous layer was extracted with ethyl acetate. The organic layers were combined and washed with brine and dried over anhydrous Na2SO4. The solvent was concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH=10 / 1) to give 77. LCMS (ESI, m / z): [M+H] + =573.3; 1H NMR (400MHz, DMSO-d6, ppm): δ8.30-8.18(m,1H),8.01-7.91(m,1H),7.90-7.78( m,2H),7.65-7.06(m,2H),6.12-5.57(m,0.5H),5.62-5.53(m,0.5H),5.11-4.71 (m,2H),3.81-3.64(m,5H),3.06-2.72(m,3H),2.61-2.53(m,1H),2.37-2.11(m, 1H),2.09-1.47(m,2H),1.2-1.41(m,2H),1.07-0.84(m,3H),0.79-0.56(m,3H). 19 FNMR (376MHz, DMSO-d6, ppm): δ88.41 (1F), 64.39 (4F).

[0784] Step 2: To a mixture of 77 (50 mg, 0.087 mmol) in THF (2 mL) were added NaH (7.0 mg, 0.17 mmol) and iodomethane (37.0 mg, 0.26 mmol). The mixture was then stirred at 0°C for 3 hours. The reaction mixture was quenched with water and the aqueous layer was extracted with ethyl acetate. The organic layers were combined and washed with brine and dried over anhydrous Na2SO4. The solvent was concentrated. The residue was purified by reverse phase HPLC (MeCN / water from 1 / 0 to 2 / 3) to give 78. LCMS (ESI, m / z): [M+H] + =587.3; 1 HNMR (400MHz, DMSO-d6, ppm): δ8.31-8.17(m,1H),8.03-7.94(m,1H),7.96-7.83(m,2H) ,7.70-7.58(m,2H),6.09-5.78(m,0.5H),5.53-5.26(m,0.5H),5.09-4.75(m,1H),3.98- 3.80(m,1H),3.69–3.48(m,3H),3.43(s,3H),3.20(d,J=5.2Hz,3H),3.14-2.81(m,2H),2 .37-2.16(m,1H),2.13-1.70(m,2H),1.56-1.31(m,2H),1.01–0.83(m,3H),0.77-0.55(m 3H). 19 FNMR (376MHz, DMSO-d6, ppm): δ88.66 (1F), 64.36 (4F).

[0785] Example 25 Synthesis of Compound 84

[0786]

[0787] Step 1: To a solution of 34-8 (2.39 g, 10.62 mmol) in MeCN (50 mL) was added DIPEA (14.04 mL, 84.97 mmol) and 28-11 (2.57 g, 10.62 mmol) at room temperature. The mixture was then stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 10 / 1) to give 84-1.

[0788] Step 2: To a solution of 84-1 (3.66 g, 8.49 mmol) in THF (30 mL) was added N2H4.H2O (5 mL), and the mixture was stirred at 50°C for 1 hour. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 0 to 0 / 1) to give 84-2.

[0789] Step 3: 84-2 (3.6 g, 8.44 mmol) was dissolved in trimethoxymethane (30 mL), and the mixture was stirred at 100° C. under N 2 for 16 hours. The mixture was concentrated under reduced pressure to give the product 84-3.

[0790] Step 4: To a solution of 84-3 (3.65 g, 8.36 mmol) in DCM (30 mL) was added TFA (10 mL) at room temperature and stirred for 5 hours. The mixture was concentrated under reduced pressure, and the residue was dissolved in DCM and washed with saturated NaHCO 3 . The combined organic layers were dried over anhydrous Na 2 SO 4 , filtered and concentrated to give 84-4.

[0791] Step 5: To a solution of 4-(trifluoromethyl)benzoic acid solution (100 mg, 0.53 mmol) in DMF (5 mL) was added DIPEA (0.13 mL, 0.79 mmol) and HATU (240.0 mg, 0.63 mmol), and the mixture was stirred at 0 ° C for 10 minutes, and then 84-4 (176.9 mg, 0.53 mmol) was added to the mixture. The resulting mixture was stirred at room temperature for 16 hours. The resulting mixture was purified by reverse phase HPLC (MeCN / water from 0 / 1 to 1 / 1) to give 84. LCMS (ESI, m / z): [M+H] + =509.2;. 1HNMR(400MHz,DMSO-d6,ppm)δ9.55(s,1H),9.02-8.88(m,1H),8.67-8.50(m,1H),7.93-7.81(m,2H),7.74-7.59(m,2H ),5.87-4.23(m,3H),3.78-3.42(m,2H),3.38-3.12(m,1H),2.03-1.54(m,4H),1.11-0.88(m,3H),0.77-0.50(m,3H). 19 F NMR(377MHz,DMSO-d6,ppm)δ-61.21(3F).

[0792] Example 26 Synthesis of Compounds 91 and 92

[0793]

[0794] Step 1: To a solution of 91-1 (15 g, 99.25 mmol) in MeCN (100 mL) was added CH3NH2 (200 mL, 3.56 mmol, 40% in water). The reaction mixture was then stirred at 80°C for 16 hours. The reaction mixture was quenched with water. The mixture was extracted with ethyl acetate. The combined organic layers were washed with water. The organic layer was dried over Na2SO4, filtered, and concentrated to afford 91-2.

[0795] Step 2: To a solution of 91-2 (8.2 g, 50.56 mmol) in MeCN (150 mL) was added NCS (7.4 g, 55.61 mmol), and the reaction mixture was stirred at 60 ° C for 70 minutes. The mixture was quenched with water. The aqueous layer was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to give 91-3.

[0796] Step 3: Compounds 91-4 and 91-5 were prepared from compound 91-3 according to the synthesis procedure of compound 5-8 in Example 5, and the products were obtained by reverse phase HPLC (MeCN / water, 55%-65%).

[0797] Step 4: 91-4 (1.2 g) was purified by SFC (column: REGIS (S,S) WHELK-O1, 250 × 25 mm ID, 10 μm, A is CO₂, B is ethanol) to give 91-6 (200 mg) and 91-7 (250 mg), respectively. 91-6: SFC analysis: 100.00% ee; retention time: 5.932 min; column: ChiralPak AD, 250 × 30 mm ID, 10 μm, A is CO₂, B is ethanol, 40%; pressure: 100 bar; flow rate: 70 mL / min. 91-7: SFC analysis: 98.76% ee; retention time: 7.760 min; column: ChiralPak AD, 250 × 30 mm ID, 10 μm, A is CO₂, B is ethanol, 40%; pressure: 100 bar; flow rate: 70 mL / min.

[0798] Step 5: To a solution of 91-6 (180 mg, 0.39 mmol) in DCM (1 mL) was added dropwise BBr (3.86 mL, 3.86 mmol) at -78°C under N2. After the addition was complete, the mixture was stirred at room temperature for 16 hours. Ice water was added to the mixture to quench the reaction and the precipitate was collected by filtration, washed with water, and dried to afford 91-8.

[0799] Step 6: A mixture of 91-8 (160 mg, 0.35 mmol), 3-bromotetrahydrofuran (67.84 mg, 0.45 mmol) and CsCO (266.2 mg, 0.82 mmol) in DMF (5 mL) was stirred at 100° C. for 6 hours. The mixture was then washed with water and extracted with ethyl acetate. The organic layer was dried over NaSO, filtered and concentrated to afford 91-9.

[0800] Step 7: Purify 91-9 (110 mg) by SFC (Chromatographic column: ChiralPak AD, 250×30 mm ID, 10 μm, A is CO2, B is ethanol) to give 91 (26 mg) and 92 (15 mg), respectively. 91: SFC analysis: 100.00% ee; retention time: 2.519 min; Chromatographic column: ChiralPak AD, 250×30 mm ID, 10 μm, A is CO2, B is ethanol, 35%; Pressure: 100 bar; Flow rate: 80 mL / min. LCMS (ESI, m / z): [M+H]+ = 523.4; 1HNMR (400MHz, DMSO-d6, ppm): δ7.77(s,1H),7.57(d,J=8.4Hz,1H),7.52(s,1H),7.19(d,J=8.4Hz,1H),6.91( s,1H),5.45-5.40(m,1H),4.18-4.12(m,1H),3.99-3.93(m,1H),3.89-3.85(m,3H),3.82-3.71(m,2H),3.48( s, 3H), 3.45-3.40 (m, 2H), 2.38-2.32 (m, 2H), 2.30-2.26 (m, 2H), 2.21-2.17 (m, 1H), 2.15-1.97 (m, 3H), 1.58-1.52 (m, 1H), 1.45-1.33 (m, 1H), 0.71 (t, J = 7.6 Hz, 3H). 92: SFC analysis: 100.00% ee; retention time: 2.012 min; chromatographic column: ChiralPak AD, 250×30 mm ID, 10 μm, A is CO2, B is ethanol, 35%; pressure: 100 bar; flow rate: 80 mL / min. LCMS (ESI, m / z): [M+H]+ = 523.4; 1 HNMR (400MHz, DMSO-d6, ppm): δ7.77 (s, 1H), 7.61-7.48 (m, 2H), 7.19 (d, J = 8.0Hz, 1H), 6 .91(s,1H),5.92-5.30(m,1H),4.20-4.15(m,1H),3.98-3.92(m,1H),3.92-3.84(m,3H), 3.80-3.70(m,2H),3.55-3.45(m,5H),2.38-2.32(m,2H),2.30-2.26(m,2H),2.21-2.15 (m,1H),2.15-1.98(m,3H),1.60-1.52(m,1H),1.43-1.34(m,1H),0.71(t,J=7.0Hz,3H).

[0801] Example 27 Synthesis of Compound 95

[0802]

[0803] Step 1: To a solution of 84-4 (179.8 mg, 0.53 mmol) in DCM (2 mL) was added dropwise a solution of 1-isocyanato-4-(trifluoromethyl)benzene (100 mg, 0.53 mmol) in DCM (2 mL). The resulting mixture was stirred at room temperature for 16 hours. The resulting mixture was concentrated, and the residue was purified by silica gel column chromatography (DCM / MeOH = 10 / 1) to give 95. LCMS (ESI, m / z): [M+H] + =524.2;. 1 H NMR(400MHz,DMSO-d6,ppm)δ9.55(s,1H),8.98-8.91(m,2H),8.63-8.55(m,1H),7.75-7.66(m,2H),7.64-7.57(m,2H),5 .51-4.83(m,2H),4.41(m,1H),4.20-4.07(m,1H),3.58(m,1H),3.33-3.13(m,1H),1.86-1.63(m,4H),0.97-0.85(m,6H). 19 F NMR(377MHz,DMSO-d6,ppm)δ-59.99(s,3F).

[0804] Example 28 Synthesis of Compounds 98 and 99

[0805]

[0806] Step 1: Compound 98-1 was prepared from compound 28-12 according to the synthesis procedure of compound 28-14 in Example 11.

[0807] Step 2: To a 0°C solution of 98-2 (4 g, 17.08 mmol) in DCM (100 mL) were added triethylamine (5.18 g, 51.24 mmol), DMAP (357.2 mg, 1.71 mmol), and 4-methylbenzenesulfonyl chloride (4.88 g, 25.62 mmol). The reaction mixture was then stirred at room temperature for 4 hours. The reaction was quenched with water and extracted with DCM. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to afford 98-3.

[0808] Step 3: To a solution of 98-3 (3.8 g, 9.78 mmol) in THF (100 mL) was added TBAF (1 M in THF, 14.7 mL, 14.7 mmol) and TMSCN (1.16 g, 11.74 mmol). The reaction mixture was stirred at 60°C for 1 hour. The reaction was then quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 4 / 1) to provide 98-4.

[0809] Step 4: To a solution of 98-4 (1 g, 4.11 mmol) in acetone (20 mL) was added KCO (1.14 g, 8.22 mmol) and HO (4 mL). The mixture was then stirred at 40°C for 48 hours. The reaction was then quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous NaSO, filtered, and concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH = 1 / 0 to 10 / 1) to afford 98-5.

[0810] Step 5: To a solution of 98-5 (670 mg, 2.56 mmol) in CCl4 (10 mL) was added AIBN (42 mg, 0.26 mmol) and NBS (683.44 mg, 3.84 mmol). The reaction mixture was then stirred at 90°C for 16 hours. The reaction was then quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH = 1 / 0 to 10 / 1) to afford 98-6.

[0811] Step 6: To a solution of 98-6 (200 mg, 0.59 mmol) in MeCN (4 mL) were added 98-1 (265.5 mg, 0.59 mmol), DIPEA (380 mg, 2.94 mmol) and NaI (105.8 mg, 0.71 mmol). The reaction was stirred at 90°C for 2 hours. The solvent was removed under vacuum and the residue was purified by reverse phase HPLC (MeCN / H2O, 5-80%) to give 98-7.

[0812] Step 7: To a solution of 98-7 (110 mg, 0.19 mmol) in THF (4 mL) was added Lawesson's reagent (74.83 mg, 0.19 mmol). The reaction mixture was then stirred at 50° C. for 30 hours. The solvent was removed under vacuum and the residue was purified by reverse phase HPLC (MeCN / H 2 O, 5-80%) to afford 98-8.

[0813] Step 8: To a solution of 98-8 (30 mg, 0.049 mmol) in EtOH (1 mL) was added 2-bromo-1-cyclopropylethane-1-one (16 mg, 0.098 mmol). The reaction mixture was then stirred at 80°C for 2 hours. The solvent was removed in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 2 / 3) to afford 98-9.

[0814] Step 9: To a mixture of 98-9 (20 mg, 0.03 mmol) in DMF (1 mL) was added Zn(CN)2 (10.6 mg, 0.09 mmol) and Pd(PPh3)4 (3.5 mg, 0.003 mmol). The mixture was then stirred at 130°C for 2 hours under microwave conditions. The reaction mixture was purified by reverse phase HPLC (MeCN / H2O (0.05% TFA), 5-80%) to give 98 (5 mg) and 99 (7 ​​mg). 98: LCMS (ESI, m / z): [M+H] + =666.4; 1 H NMR (400MHz, DMSO-d6, ppm): δ8.23 (d, J=8.8Hz, 1H), 8.01-7.88 (m, 3H), 7.79-7.70 (m, 2H), 7 .25(s,1H),5.96-5.82(m,0.5H),5.42-5.38(m,0.5H),5.22(s,1H),4.98-4.83(m,1H),3.62 -3.58(m,0.5H),3.43(s,3H),3.38-3.32(m,0.5H),2.80-2.71(m,1H),2.23-2.18(m,1H),2. 05-1.88(m,3H),1.49-1.38(m,3H),0.86-0.77(m,6H),0.70-0.64(m,1H),0.62-0.45(m,3H). 19 F NMR (376MHz, DMSO-d6, ppm): δ87.47 (1F), 64.17 (4F).99: LCMS (ESI, m / z): [M+H] + =666.4; 1H NMR (400MHz, DMSO-d6, ppm): δ8.28-8.19(m,1H),8.02-7.88(m,3H),7.82-7.7 3(m,2H),7.30(s,1H),5.95-5.82(m,0.5H),5.43-5.38(m,0.5H),5.27(s,1H), 5.01-4.85(m,1H),3.62-3.58(m,0.5H),3.49-3.42(m,3.5H),2.20-2.11(m,1H ),2.08-1.84(m,4H),1.73-1.37(m,3H),0.90-0.82(m,2H),0.79-0.61(m,8H). 19 F NMR (376MHz, DMSO-d6, ppm): δ87.33 (1F), 64.18 (4F).

[0815] Example 29 Synthesis of Compound 102

[0816]

[0817] Step 1: To a mixture of 102-1 (400 mg, 2.48 mmol), 2-ethyl-4-oxopiperidine-1-carboxylic acid tert-butyl ester (564.3 mg, 2.48 mmol) in THF (10 mL) was added dropwise TiCl4 (235.4 mg, 1.24 mmol) at room temperature. The mixture was stirred for another 30 minutes, then sodium triacetoxyborohydride (1052.3 mg, 4.97 mmol) was added and the mixture was stirred at room temperature for 12 hours. The mixture was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 4 / 1) to give 102-2.

[0818] Step 2: To a mixture of 102-2 (646 mg, 1.74 mmol) and acetaldehyde (382.1 mg, 8.68 mmol) in THF (10 mL) was added TiCl4 (164.5 mg, 0.87 mmol) dropwise at room temperature. The mixture was stirred for an additional 30 minutes, then sodium triacetoxyborohydride (735.2 mg, 3.47 mmol) was added and the mixture was stirred at room temperature for 12 hours. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1 to 3 / 1) to give 102-3.

[0819] Step 3: To a solution of 102-3 (345 mg, 0.86 mmol) in DCM (5 mL) was added ethyl acetate / HCl (0.43 mL) and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated to dryness to give 102-4, which was used directly in the next step without further purification.

[0820] Step 4: Compound 102 was prepared from compound 102-4 according to the synthetic procedure of compound 84-3 in Example 25. LCMS (ESI, m / z): [M+H] + =495.3; 1 H NMR (400MHz, DMSO-d6, ppm): δ9.52 (s, 1H), 8.95-8.93 (d, J = 8.8Hz, 1H), 8.58-8.56 (d, J = 8.8Hz, 1H), 7.39-7.37 (d, J = 8.8Hz, 2H), 6.83-6.81 (d, J = 8.8Hz,2H),4.75-4.69(m,2H),4.05-4.03(m,1H),3.72-3.71(m,1H),3.4 5-3.34(m,2H),2.34-2.33(m,1H),2.14-1.75(m,5H),1.17-0.98(m,6H). 19 F NMR (376MHz, DMSO-d6, ppm): δ-58.90 (3F).

[0821] Example 30 Synthesis of Compound 103

[0822]

[0823] Step 1: To a mixture of 103-1 (9.50 g, 26.79 mmol) and ethyl (2E)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2-enoate (7.87 g, 34.83 mmol) in dioxane (95 mL) and water (9.5 mL) was added Pd(dppf)Cl2 (2.0 g, 2.68 mmol) and Na2CO3 (5.7 g, 53.59 mmol) at room temperature. The mixture was then heated at 100°C for 12 hours. The mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 1 / 4) to give 103-2.

[0824] Step 2: To a mixture of 103-2 (12 g, 25.71 mmol) and CoCl2·6H2O (0.6 g, 2.57 mmol) in MeOH (360 mL) and THF (180 mL) was added NaBH4 (5.8 g, 154.23 mmol) in portions at 0°C. The mixture was then stirred at room temperature for 1 hour. Water was added to the reaction mixture. The mixture was extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered, and the filtrate was concentrated under vacuum. The residue was purified by silica gel column chromatography (DCM) to afford 103-3.

[0825] Step 3: A solution of 103-3 (7.6 g, 23.12 mmol) in HCl / ethyl acetate (100 mL) was stirred at room temperature for 1 hour. The mixture was concentrated under vacuum to afford 103-4.

[0826] Step 4: Compound 103 was prepared from compound 103-4 according to the synthesis procedure of compound 59 in Example 20. LCMS (ESI, m / z): [M+H] + =511.2; 1 H NMR (400MHz, DMSO-d6, ppm): δ8.07(s,1H),7.82-7.77(m,2H),7.49-7.47(m,2H),4.9 2-4.17(m,4H),3.91-3.83(m,2H),3.35(s,2H),2.96-2.89(m,2H),2.02-1.90(m,6H). 19 F NMR (376MHz, DMSO-d6, ppm): δ-56.75 (3F).

[0827] Example 31 Synthesis of Compound 104

[0828]

[0829] Step 1: A mixture of 104-1 (5.0 g, 44.59 mmol), 1-(pyridin-3-yl)propan-1-one (7.23 g, 53.51 mmol), AgNO3 (2.27 g, 13.38 mmol), H2SO4 (9.75 g, 89.18 mmol) and ammonium persulfate (10.17 g, 44.59 mmol) in water (70 mL) and DCM (70 mL) was flushed with N2 for 0.5 min, and then the mixture was stirred at 25°C for 18 hours. The mixture was quenched by adding saturated NaHCO3 solution, and the aqueous layer was extracted with DCM. The organic extracts were combined, washed with brine, and dried over anhydrous Na2SO4. The solvent was concentrated, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to give 104-2.

[0830] Step 2: To a solution of 104-2 (560 mg, 2.78 mmol) in MeOH (10 mL) was added NaBH4 (12.3 mg, 3.34 mmol) at 0°C and the reaction mixture was stirred at room temperature for 2 hours. The mixture was quenched by adding water and the aqueous layer was extracted with ethyl acetate. The organic extracts were combined, washed with brine, dried over anhydrous Na2SO4, and concentrated to afford 104-3.

[0831] Step 3: To a solution of 104-3 (580 mg, 2.85 mmol) in DCM (15 mL) was added DMF (21.0 mg, 0.29 mmol) and SOCl2 (509 mg, 4.28 mmol) at 0°C, and the reaction mixture was stirred at room temperature for 3 hours. The solvent was removed under reduced pressure to give 104-4, which was used in the next step without further purification.

[0832] Step 4: A mixture of 28-9 (100 mg, 0.43 mmol), 104-4 (239 mg, 1.08 mmol), DIPEA (0.29 mL, 1.72 mmol) and NaI (129 mg, 0.86 mmol) in MeCN (2 mL) was stirred at 85° C. for 18 h. The mixture was filtered and concentrated, and the residue was purified by reverse phase HPLC (0.05% aqueous NH4HCO3 / MeCN, 5-95%) to give 104-5.

[0833] Step 5: To a solution of 104-5 (80 mg, 0.19 mmol) in 1,2-dichloroethane (1 mL) was added 1-chloroethyl chloroformate (274.5 mg, 1.92 mmol) and the reaction was stirred at 110°C for 96 hours. The mixture was concentrated in vacuo and the residue was diluted with THF and water. The mixture was then stirred at 70°C for 3 hours. The solvent was removed under reduced pressure to give 104-6, which was used directly in the next step without further purification.

[0834] Step 6: Compound 104 was prepared from compound 104-6 according to the synthetic procedure of compound 84-3 in Example 25. LCMS (ESI, m / z): [M+H] + =522.4. 1 H NMR(400MHz,DMSO-d6,ppm)δ9.49-9.46(m,1H),8.92-8.87(m,1H),8.56-8.51(m,1H),8.42-8.37(m,1H), 7.73-7.67(m,1H),7.30-7.23(m,1H),5.94-5.83(m,0.5H),5.45-5.23(m,0.5H),5.21-4.74(m,1H),3.64 -3.47(m,1H),3.46-3.40(m,0.5H),3.30-3.07(m,0.5H),2.92-2.80(m,1H),2.56-2.55(m,1H),2.30-2.2 3(m,1H),2.14-2.08(m,6H),2.00-1.82(m,3H),1.70-1.35(m,4H),1.03-0.94(m,3H),0.72-0.58(m,6H).

[0835] Example 32 Synthesis of Compounds 107 and 108

[0836]

[0837] Step 1: To a stirred solution of 107-1 (500 g, 3.27 mol) in dry DCM (5000 mL) were added benzaldehyde (352 g, 3.32 mol), KCO (494.9 g, 3.58 mol), and NaSO (462 g, 3.25 mol). The reaction mixture was stirred at room temperature for 6 hours. Sodium triacetoxyborohydride (1030 g, 4.86 mol) was then added portionwise to the mixture over 30 minutes in an ice bath. The mixture was stirred at room temperature for 16 hours. The solids were removed by filtration, and the solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate and HCl (1N). The mixture was extracted with ethyl acetate. The pH of the aqueous layer was adjusted to 8.0 with NaHCO (aq), and the milky white aqueous layer was immediately extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to afford 107-2.

[0838] Step 2: To a solution of 107-2 in DMF (3500 mL) was added DIPEA (885 mL, 5.08 mol) and HATU (966 g, 2.54 mol). The reaction mixture was stirred at 0°C for 10 minutes, and then (2R)-methyl 2-(benzylamino)butanoate (351 g, 1.69 mol) was added to the reaction mixture. The resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous Na2SO4, filtered, and evaporated under reduced pressure to afford 107-3.

[0839] Step 3: Compound 107-4 was prepared from compound 107-3 according to the synthesis procedure of compound 67-14 in Example 22.

[0840] Step 4: To a stirred solution of 107-4 (4.8 g, 11.31 mmol) in isopropanol (150 mL) was added Pd / C (10%, 0.96 g, 9.02 mmol) at room temperature, and the resulting mixture was stirred under a H2 balloon at 80°C for 15 hours. The reaction mixture was filtered through a pad of zeolite and the filtrate was concentrated to give 107-5.

[0841] Step 5: A mixture of 107-5 (1 g, 3.89 mmol), 34-2 (1.73 g, 7.78 mmol), NaI (1.2 g, 7.78 mmol), DIPEA (2.03 mL, 11.66 mmol) and KCO (6.1 g, 44.2 mmol) in CHCN (15 mL) was stirred at 85 ° C for 15 hours. Another portion of DIPEA (2.03 mL, 11.66 mmol), NaI (1.2 g, 7.78 mmol) and 34-2 (1.73 g, 7.78 mmol) were added to the reaction mixture at 20 ° C. The resulting mixture was stirred at 85 ° C and under N2 for 15 hours. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 2 / 3) to give 107-6.

[0842] Step 6: To a stirred solution of 107-6 (4.57 g, 10.09 mmol) in MeOH (20 mL) was added dropwise a solution of HCl in ethyl acetate (4 M, 9.1 mL) at room temperature, and the resulting mixture was stirred at 25° C. for 15 hours. The reaction mixture was concentrated under reduced pressure to afford 107-7.

[0843] Step 7: Compound 107-8 was prepared from compound 107-7 according to the synthesis procedure of compound 67-20 in Example 22.

[0844] Step 8: To a stirred solution of 107-8 (350 mg, 0.63 mmol) in DMF (10 mL) was added CsF (285.5 mg, 1.88 mmol) at 15 ° C., and the resulting mixture was stirred at 110 ° C for 15 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layers were combined, washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 0 / 1) to give 107 (60 mg) and 108 (crude, 110 mg). The crude 108 was again purified by reverse phase HPLC (MeCN / water (0.5% FA): 30 / 70) to give pure 108 (44 mg) as a 0.33 FA salt. 107: LCMS (ESI, m / z): [M+H] + =512.4. 1H NMR (400 MHz, methanol-d4, ppm) δ 8.04 (d, J = 8.7 Hz, 1H), 7.89 (d, J = 8.7 Hz, 1H), 7.69-7.62 (m, 2H), 7.61-7.54 (m, 2H), 4.36-4.25 (m, 1H), 4.09-4.03 (m, 1H), 4.02-3.92 (m, 1H), 3.87-3.78 (m, 1 H),3.79-3.70(m,4H),3.10-2.97(m,2H),2.96-2.85(m,1H),2.50-2.40(m,1H),2.20-2.05 (m,1H),1.98-1.85(m,1H),1.80-1.65(m,2H),1.22(t,J=7.4Hz,3H),0.72(t,J=7.3Hz,3H). 19 F NMR(376MHz,DMSO-d6,ppm):δ-63.83(3F).108:LCMS(ESI,m / z):[M+H] + =512.4. 1 H NMR (400 MHz, methanol-d4, ppm) δ 8.01 (s, 0.33H), 8.00-7.98 (m, 1H), 7.86-7.83 (m, 1H), 7.65-7.63 (m, 2H), 7.48-7.46 (m, 2H), 4.72-4.60 (m, 1H), 4.40-4.32 (m, 1H), 4.15-4.00 (m, 2H), 3.68 (s, 3H),3.45-3.38(m,1H),3.30-3.26(m,1H),3.23-3.16(m,1H),2.38-2.37(m,1H),2.26-2.20 (m,1H),2.10-1.92(m,2H),1.90-1.70(m,2H),1.03(t,J=7.4Hz,3H),0.87(t,J=7.3Hz,3H).; 19 FNMR (376MHz, DMSO-d6, ppm): δ-63.91 (3F).

[0845] Example 33 Synthesis of Compounds 109 and 110

[0846]

[0847] Step 1: A solution of 34-9 (845 mg, 1.63 mmol), tert-butyl carbamate (287.2 mg, 2.45 mmol), CsCO (1.06 g, 3.27 mmol), and XantPhosPdG (17.2 mg, 0.019 mmol) in dioxane (15 mL) was stirred at 100° C. under N₂ for 6 h. The mixture was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 3 / 1) to afford 109-1.

[0848] Step 2: To a solution of 109-1 (660 mg, 1.1 mmol) in DCM (8 mL) was added HCl / ethyl acetate (6 mL). The mixture was stirred at 30° C. for 12 hours. The mixture was concentrated to give 109-2.

[0849] Step 3: A solution of 109-2 (611 mg, 1.23 mmol), 2-chloroacetaldehyde (5 mL, 0.49 mmol) and AcOH (0.070 mL, 1.23 mmol) in EtOH (12 mL) was stirred at 80° C. for 16 hours. The mixture was concentrated. The residue was purified by reverse phase HPLC (MeCN / water (0.5% FA): 5%-80%) to give 109-3.

[0850] Step 4: Purification of 109-3 (80 mg) by preparative SFC (ChiralPak AD column, 250 × 30 mm ID, 5 μm, ethanol / CO₂ = 40 / 60) afforded 109 (42 mg) and 110 (17 mg). 109: SFC analysis: 100% ee; retention time: 1.393 min; column: Chiralpak AD-3 150 × 4.6 mm ID, 3 μm, 40% ethanol (0.05% DEA) in CO₂; pressure: 100 bar; flow rate: 2.5 mL / min; LCMS (ESI, m / z): [M+H] + =522.3; 1H NMR (400MHz, DMSO-d6, ppm) δ8.84-8.82 (d, J=8.8Hz, 1H), 8.47-8.45 (d, J=8.8Hz, 1H), 8.184-8.181 (d,J=1.2Hz,1H),7.75-7.73(d,J=8.0Hz,2H),7.59-7.57(d,J=8.0Hz,2H),7.328-7.325(d,J=1.2H z,1H),5.45-4.80(m,2H),3.73-3.54(m,1H),3.35-3.26(m,1H),3.01-2.91(m,1H),2.88-2.80(m,1 H),2.36-2.31(m,1H),2.12-1.88(m,3H),1.67-1.39(m,3H),1.03-0.86(m,3H),0.71-0.52(m,6H). 19 F NMR (377 MHz, DMSO-d6, ppm) δ -60.66 (3F). 110: SFC analysis: 100% ee; retention time: 3.046 min; column: Chiralpak AD-3 150×4.6 mm ID, 3 μm, 40% ethanol (0.05% DEA) in CO2; pressure: 100 bar; flow rate: 2.5 mL / min; LCMS (ESI, m / z): [M+H] + =522.4; 1 H NMR (400MHz, DMSO-d6, ppm) δ8.86-8.84 (d, J=8.8Hz, 1H), 8.49-8.47 (d, J=8.8Hz, 1H), 8. 26-8.14(m,1H),7.73-7.71(d,J=8.0Hz,2H),7.60-7.58(d,J=8.0Hz,2H),7.42-7.26(m, 1H),5.75-4.55(m,2H),3.61-3.41(m,2H),3.22-3.02(m,1H),2.66-2.53(m,1H),2.27-2 .12(m,1H),2.03-1.73(m,3H),1.69-1.36(m,3H),1.06-0.90(m,3H),0.71-0.49(m,6H). 19 F NMR(377MHz,DMSO-d6,ppm)δ-60.67(3...

Claims

1. The compound of III-2, or a pharmaceutically acceptable salt thereof: in: R 1 is hydrogen, halogen (such as F, Cl or Br), CN, OH, NH2, COOH, CONH2, R A , OR A NH(R A )、N(R A 2. COOR A CONH(R A )、CON(R A 2. SR A 、SOR A 、SO2R A or P(O)(R A )2, where R A Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7-membered heterocyclyl; R 2 is hydrogen, halogen (such as F, Cl or Br), CN, OH, NH2, R B , OR B NH(R B ) or N(R B )2, where R B Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 Cycloalkyl, or an optionally substituted 4-7 membered heterocyclic group; X is N or CR 5 , where R 5 For hydrogen, halogen, CN, CONH2, COOH, CONH(R C )、CON(R C )2.OR C , or COOR C , where R C Each occurrence is independently optionally substituted C 1-4 alkyl; U is N or CR 6 , where R 6 is hydrogen, halogen (e.g., F, Cl or Br), CN, OH, NH2, R D , OR D NH(R D )、N(R D )2, COOH, CONH2, COOR D CONH(R D )、CON(R D 2. SR D , SOR D 、SO2R D or P(O)(R D )2, where R D Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl; Y is N or CR 7 , where R 7 is hydrogen, F, Cl, CN, optionally substituted C 1-4 Alkyl, or optionally substituted C 1-4 heteroalkyl; L 1 is an optionally substituted 4-12 membered heterocycloalkylene group having one or more rings and 1-4 ring heteroatoms each independently selected from O, N or S, or -N(R E )-, where R E is an optionally substituted C 1-4 Alkyl or an optionally substituted 3-7 membered ring; L 2 is absent, O, NH, -N(R E2 )-, C(O), SO2, optionally substituted C 1-4 Alkylene, optionally substituted C 2-4 Alkenylene, optionally substituted C 1-4 Alkyne, optionally substituted C 1-4 heteroalkylene, or an optionally substituted 3-7 membered ring, wherein R E2 is an optionally substituted C 1-4 Alkyl or an optionally substituted 3-7 membered ring; R 30 is hydrogen, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, or an optionally substituted 8- to 12-membered ring having two or more rings.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Y is N.

3. The compound according to any one of claims 1 to 2, or a pharmaceutically acceptable salt thereof, wherein U is CR 6 .

4. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein R 6 For hydrogen.

5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R 1 For CN.

6. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein (i) R 1 is a halogen, such as F or Cl; (ii) R 1 for (iii) R 1 is an optionally substituted 5- or 6-membered heteroaryl group having 1-4 ring heteroatoms independently selected from O, S and N, such as an optionally substituted pyrimidinyl group or an optionally substituted thiazolyl group, for example, R 1 for or (iv) R 1 For SR A1 , where R A1 is independently optionally substituted C 1-4 Alkyl groups, such as R 1 For SCH3.

7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R 2 For hydrogen.

8. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein X is N.

9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein L 1 for (One of the two attachment points of piperidine, N or C, can be connected to L 2 ), in: n is 0, 1, 2, 3, or 4, and (1)R 9A Each occurrence is independently R N 、COOR N , COR N CONH(R N ) or CON(R N )2, where R N Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, optionally substituted phenyl, or optionally substituted 5- or 6-membered heteroaryl; or (2)R 9A Two instances of can be connected to form a double bond or a 3-5 membered ring and R 9A Any remaining instances of are defined as in (1).

10. The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein R 9A Each occurrence is independently CH3, CH2CH3, CH2CH2CH3, fluorinated C 1-3 Alkyl (e.g., CF2H), cyclopropyl, cyclobutyl, CH2OH, CH2OCH3, CH2OCH2CH3, CH2NH2, CH2N3 or CH2NHC(O)OCH3.

11. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein L 1 Select from the following (bottom connection point N or C connection L 2 ):

12. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein L 1 Select from the following (bottom connection point N or C connection L 2 ):

13. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein L 1 is an optionally substituted 7-12 membered heterocyclylene group having two or more rings and 1-4 ring heteroatoms each independently selected from O, N or S, and when substituted, the substituents may be attached to any one or more of the two or more rings.

14. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein L 1 Select from the following bicyclic heterocyclic groups (the bottom connection point is N or C connected to L 2 ): in, In each bicyclic heterocyclylene group, each of the two rings may be optionally substituted by 1 to 3 R 10 Substitution, where R 10 Each occurrence is independently halogen, OH, NH2, oxo (if applicable), R J , OR J 、CN、NH(R J ) or N(R J )2, where R J Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, or an optionally substituted 3-4 membered ring.

15. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein L 1 Select from the following bicyclic heterocyclic groups (the bottom connection point is N or C connected to L 2 ):

16. The compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein L 2 Does not exist.

17. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein L 2 is an optionally substituted C 1-4 Alkylene.

18. The compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, characterized in that: Having a structure according to Formula III-2-E-1, III-2-E-2 or III-2-E-3: in: R 13 is selected from hydrogen, halogen (e.g., F, Cl or Br), CN, OH, NH2, COOH, CONH2, SO2NH2, COR K 、COOR K CONH(R K )、CON(R K 2. SO2R K SO2NH(R K )、SO2N(R K 2. R K , OR K NH(R K )、N(R K 2. SR K , SOR K 、SO2R K or P(O)(R K )2, where R K Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 1-4 Heteroalkyl, optionally substituted C 3-6 cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7-membered heterocyclyl, wherein, when substituted, the optionally substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl, phenyl, 5- or 6-membered heteroaryl, or 4-7-membered heterocyclyl is substituted by 1-3 substituents independently selected from the group consisting of halogen (preferably F or Cl), OH, CN, C 1-4 alkyl, optionally substituted by 1-3 F 1-4 heteroalkyl, and 3-4 membered rings optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.).

19. The compound according to claim 18, or a pharmaceutically acceptable salt thereof, characterized in that Having a structure according to Formula III-2-F-1a, III-2-F-1b, III-2-F-2a, III-2-F-2b, III-2-F-3a or III-2-F-3b: in: R 9A Each occurrence is independently CH3, CH2CH3, CH2CH2CH3, fluorinated C 1-3 Alkyl (e.g., CF2H), cyclopropyl, cyclobutyl, CH2OH, CH2OCH3, CH2OCH2CH3, CH2NH2, CH2N3 or CH2NHC(O)OCH3, preferably R 9A Each occurrence is independently CH3, CH2CH3 or CH2CH2CH3, more preferably, R 9A In each occurrence it is CH2CH3.

20. The compound according to claim 18 or 19, or a pharmaceutically acceptable salt thereof, wherein R 13 For hydrogen.

21. The compound according to claim 18 or 19, or a pharmaceutically acceptable salt thereof, wherein R 13 It is C 1-4 Alkyl, such as methyl, isopropyl, etc.

22. The compound according to claim 18 or 19, or a pharmaceutically acceptable salt thereof, wherein R 13 is CN, OH, COOH, CONH2, methoxy, ethoxy, cyclopropyl, cyclobutyl, optionally substituted phenyl, or optionally substituted 5- or 6-membered heteroaryl having 1-3 ring heteroatoms independently selected from N, O and S, wherein When substituted, the optionally substituted phenyl or 5- or 6-membered heteroaryl is substituted with 1-3 substituents independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted with 1-3 F. 1-4 Alkyl, optionally substituted by 1-3 F 1-4 heteroalkyl, and a 3-4 membered ring optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), such as R 13 OH, methoxy, cyclopropyl, phenyl, 23. A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R 30 is an optionally substituted phenyl group, for example, having 1 to 3 (for example, 1 or 2) R 22 Substituted phenyl, wherein R 22 Each occurrence is independently halogen (e.g., F, Cl, or Br), CN, OH, NH2, R M , OR M 、COOH、CONH2、COOR M CONH(R M )、CON(R M )2、NHCO(R M )、N(R M )CO(R M )、SO2R M 、SO2NH2、S(O)(NH)R M 、S(O)(NR M )R M SO2N(R M 2. NHSO2R M 、N(R M )SO2R M 、P(O)(R M )2、P(O)(OR M )2、NH(R M )、N(R M 2. SR M or SF5, where R M Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl.

24. A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R 30 It is composed of 1-3 (e.g., 1 or 2) R 22 Substituted phenyl, wherein R 22 Each occurrence is independently halogen (e.g., F, Cl, or Br), CN, OH, R M1 , OR M1 、SO2R M1 、P(O)(R M1 2. SR M1 or SF5, where R M1 Each occurrence is independently optionally substituted C 1-4 alkyl or an optionally substituted 3-4 membered ring (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), wherein when substituted, the optionally substituted C 1-4 The alkyl or 3-4 membered ring is substituted by 1-3 substituents independently selected from the group consisting of halogen (preferably F or Cl), OH, CN, C optionally substituted by 1-3 F 1-4 alkyl, optionally substituted by 1-3 F 1-4 heteroalkyl, and a 3-4 membered ring optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), preferably, R 22 Each occurrence is independently F, Cl, Br, CF3, OCF3, SCF3, SF5, OMe, CN, methyl, CHF2, CF2CH3, cyclopropyl, CH3SO2 and OCH2-(cyclopropyl).

25. A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R 30 It is composed of 1-3 (e.g., 1 or 2) R 22 Substituted phenyl, wherein R 22 Each occurrence is independently F, Cl, CN, R M2 , OR M2 , SR M2 or SF5, where R M2 Each occurrence is independently C optionally substituted with 1-3 F 1-4 Alkyl, such as CF3.

26. A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R 30 is an optionally substituted 5-membered or 6-membered heteroaryl, such as pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Replace, where R 22 Each occurrence is independently halogen (e.g., F, Cl, or Br), CN, OH, NH2, R M , OR M 、COOH、CONH2、COOR M CONH(R M )、CON(R M )2、NHCO(R M )、N(R M )CO(R M ), SO2R M 、SO2NH2、S(O)(NH)R M 、S(O)(NR M )R M SO2N(R M 2. NHSO2R M 、N(R M )SO2R M 、P(O)(R M )2、P(O)(OR M )2、NH(R M )、N(R M 2. SR M or SF5, where R M Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl.

27. A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R 30 is a 5-membered heteroaryl group (e.g., ) or pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Substitution, where valence permits, where R 22 Each occurrence is independently halogen (e.g., F, Cl, or Br), CN, OH, R M1 , OR M1 、SO2R M1 、P(O)(R M1 2. SR M1 or SF5, where R M1 Each occurrence is independently optionally substituted C 1-4 alkyl or an optionally substituted 3-4 membered ring (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), wherein when substituted, the optionally substituted C 1-4 The alkyl or 3-4 membered ring is substituted by 1-3 substituents independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted by 1-3 F 1-4 alkyl, optionally substituted by 1-3 F 1-4 heteroalkyl, and a 3-4 membered ring optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), preferably, R 22 Each occurrence is independently F, Cl, Br, CF3, OCF3, SCF3, SF5, OMe, CN, methyl, CHF2, CF2CH3, cyclopropyl, CH3SO2 and OCH2-(cyclopropyl).

28. A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R 30 is a 5-membered heteroaryl group (e.g., ) or pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Substitution, where valence permits, where R 22 Each occurrence is independently F, Cl, CN, R M2 , OR M2 , SR M2 or SF5, where R M2 Each occurrence is independently C optionally substituted with 1-3 F 1-4 Alkyl, such as CF3.

29. A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R 30 Having a structure according to S-1-A, S-1-B, S-1-C or S-1-D: Where R 8 is C optionally substituted by 1-3 F 1-4 Alkyl (such as CH3, CF3, etc.), optionally substituted by 1-3 F 1-4 Alkoxy (such as OCH3, OCF3, etc.), SCF3, SF5, cyclopropyl, cyclobutyl, or 30. A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R 30 Select from the following options:

31. A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R 30 Select from the following options:

32. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein L 1 , L 2 and R 30 Together (ie L 1- L 2- R 30 ) is selected from:

33. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein L 1 , L 2 and R 30 Selected from: Or, L 1 , L 2 and R 30 Together (ie L 1- L 2- R 30 ) is selected from: Or, L 1 , L 2 and R 30 Together (ie L 1- L 2- R 30 ) is selected from:

34. A compound of formula III-4, or a pharmaceutically acceptable salt thereof, in R 1 is hydrogen, halogen (such as F, Cl or Br), CN, OH, NH2, COOH, CONH2, R A , OR A NH(R A )、N(R A 2. COOR A CONH(R A )、CON(R A 2. SR A , SOR A 、SO2R A or P(O)(R A )2, where R A Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7-membered heterocyclyl; R 2 is hydrogen, halogen (such as F, Cl or Br), CN, OH, NH2, R B , OR B NH(R B ) or N(R B )2, where R B Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 Cycloalkyl, or an optionally substituted 4-7 membered heterocyclic group; R 3 is hydrogen, optionally substituted C 1-4 Alkyl, or an optionally substituted 3-7 membered ring, such as an optionally substituted C 3-6 Cycloalkyl, or an optionally substituted 4-7 membered heterocyclic group (such as a saturated 4-7 membered heterocyclic group); U is N or CR 6 , where R 6 is hydrogen, halogen (e.g., F, Cl or Br), CN, OH, NH2, R D , OR D NH(R D )、N(R D )2, COOH, CONH2, COOR D CONH(R D )、CON(R D 2. SR D 、SOR D 、SO2R D , or P(O)(R D )2, where R D Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl; Y is N or CR 7 , where R 7 is hydrogen, F, Cl, CN, optionally substituted C 1-4 Alkyl, or optionally substituted C 1-4 heteroalkyl; Z is C(O), C(=N-OH), C(=NO-(C 1-4 alkyl)), C(=N-NH2), C(=N-NH-(C 1-4 alkyl)), C(=NN(C 1-4 Alkyl)(C 1-4 alkyl)), SO, SO2, S(O)(=NH) or S(O)(=N-(C 1-4 alkyl); L 2 is absent, O, NH, -N(R E2 )-, C(O), SO2, optionally substituted C 1-4 Alkylene, optionally substituted C 2-4 Alkenylene, optionally substituted C 1-4 Alkyne, optionally substituted C 1-4 heteroalkylene, or an optionally substituted 3-7 membered ring, wherein R E2 is an optionally substituted C 1-4 Alkyl or an optionally substituted 3-7 membered ring; R 30 is hydrogen, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, or an optionally substituted 8-12-membered ring having two or more rings; R 9 Each occurrence is independently R N 、COOR N , COR N CONH(R N ), or CON(R N )2, where R N Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 cycloalkyl, optionally substituted phenyl, or optionally substituted 5- or 6-membered heteroaryl; and n1 is 0, 1, 2 or 3.

35. The compound of claim 34, or a pharmaceutically acceptable salt thereof, wherein Y is N.

36. A compound according to any one of claims 34-35, or a pharmaceutically acceptable salt thereof, wherein U is CR 6 .

37. The compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein R 6 For hydrogen.

38. A compound according to any one of claims 34 to 37, or a pharmaceutically acceptable salt thereof, wherein R 1 For CN.

39. A compound according to any one of claims 34 to 37, or a pharmaceutically acceptable salt thereof, wherein (i) R 1 is a halogen, such as F or Cl; (ii) R 1 for (iii) R 1 is an optionally substituted 5- or 6-membered heteroaryl group having 1-4 ring heteroatoms independently selected from O, S and N, such as an optionally substituted pyrimidinyl group or an optionally substituted thiazolyl group, for example, R 1 for or (iv) R 1 For SR A1 , where R A1 is independently optionally substituted C 1-4 Alkyl groups, such as R 1 For SCH3.

40. A compound according to any one of claims 34 to 39, or a pharmaceutically acceptable salt thereof, wherein R 2 For hydrogen.

41. The compound according to any one of claims 34-40, or a pharmaceutically acceptable salt thereof, wherein Z is CO.

42. A compound according to any one of claims 34 to 41, or a pharmaceutically acceptable salt thereof, wherein R 3 is hydrogen, optionally substituted C 1-4 Alkyl, such as CH3, CD3, ethyl, isopropyl, CH2CHF2, etc., or an optionally substituted 3-4 membered ring, such as cyclopropyl or cyclobutyl, etc., preferably R 3 Methyl or CD3.

43. The compound according to any one of claims 34-42, or a pharmaceutically acceptable salt thereof, wherein n1 is 0 or 1.

44. The compound according to any one of claims 34 to 42, or a pharmaceutically acceptable salt thereof, characterized in that Having a structure according to Formula III-4-C:

45. A compound according to any one of claims 34 to 42, or a pharmaceutically acceptable salt thereof, wherein: Having a structure according to Formula III-4-C-4:

46. ​​A compound according to any one of claims 34 to 45, or a pharmaceutically acceptable salt thereof, wherein R 9 Each occurrence is independently CH3, CH2CH3, CH2CH2CH3, fluorinated C 1-3 alkyl (e.g., CF2H), cyclopropyl, cyclobutyl, CH2OH, CH2OCH3, CH2OCH2CH3, CH2NH2, CH2N3 or CH2NHC(O)OCH3, preferably, R 9 Each occurrence is independently CH3, CH2CH3 or CH2CH2CH3, more preferably, R 9 Each occurrence is independently CH2CH3.

47. A compound according to any one of claims 34 to 46, or a pharmaceutically acceptable salt thereof, wherein L 2 is an optionally substituted C 1-4 Alkylene.

48. The compound according to any one of claims 34 to 46, or a pharmaceutically acceptable salt thereof, characterized in that Having a structure according to Formula III-4-C-4a, III-4-C-4b, III-4-C-4c, III-4-C-4d, III-4-C-4e or III-4-C-4f: in R 13 is selected from hydrogen, halogen (e.g., F, Cl or Br), CN, OH, NH2, COOH, CONH2, SO2NH2, COR K 、COOR K CONH(R K )、CON(R K 2. SO2R K SO2NH(R K )、SO2N(R K 2. R K , OR K NH(R K )、N(R K 2. SR K 、SOR K 、SO2R K or P(O)(R K )2, where R K Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 1-4 Heteroalkyl, optionally substituted C 3-6 cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7-membered heterocyclyl, wherein, when substituted, the optionally substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl, phenyl, 5- or 6-membered heteroaryl, or 4-7-membered heterocyclyl is substituted by 1-3 substituents independently selected from the group consisting of halogen (preferably F or Cl), OH, CN, C 1-4 alkyl, optionally substituted by 1-3 F 1-4 heteroalkyl, and 3-4 membered rings optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.).

49. The compound according to claim 48, or a pharmaceutically acceptable salt thereof, wherein R 13 For hydrogen.

50. The compound according to claim 48, or a pharmaceutically acceptable salt thereof, wherein R 13 C 1-4 Alkyl, such as methyl, isopropyl, etc.

51. The compound according to claim 48, or a pharmaceutically acceptable salt thereof, wherein R 13 is CN, OH, COOH, CONH2, methoxy, ethoxy, cyclopropyl, cyclobutyl, optionally substituted phenyl, or optionally substituted 5- or 6-membered heteroaryl having 1-3 ring heteroatoms independently selected from N, O and S, wherein, When substituted, the optionally substituted phenyl or 5- or 6-membered heteroaryl is substituted by 1-3 substituents independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted by 1-3 F. 1-4 Alkyl, optionally substituted by 1-3 F 1-4 heteroalkyl, and a 3-4 membered ring optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), such as R 13 OH, methoxy, cyclopropyl, phenyl, 52. A compound according to any one of claims 34 to 51, or a pharmaceutically acceptable salt thereof, wherein R 30 is an optionally substituted phenyl group, for example, consisting of 1 to 3 (for example, 1 or 2) R 22 Substituted phenyl, wherein R 22 Each occurrence is independently halogen (e.g., F, Cl, or Br), CN, OH, NH2, R M , OR M 、COOH、CONH2、COOR M CONH(R M )、CON(R M )2、NHCO(R M )、N(R M )CO(R M )、SO2R M 、SO2NH2、S(O)(NH)R M 、S(O)(NR M )R M SO2N(R M 2. NHSO2R M 、N(R M )SO2R M 、P(O)(R M )2、P(O)(OR M )2、NH(R M )、N(R M 2. SR M or SF5, where R M Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl.

53. A compound according to any one of claims 34 to 51, or a pharmaceutically acceptable salt thereof, wherein R 30 It is composed of 1-3 (e.g., 1 or 2) R 22 Substituted phenyl, wherein R 22 Each occurrence is independently halogen (e.g., F, Cl, or Br), CN, OH, R M1 , OR M1 、SO2R M1 、P(O)(R M1 2. SR M1 or SF5, where R M1 Each occurrence is independently optionally substituted C 1-4 alkyl or an optionally substituted 3-4 membered ring (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), wherein when substituted, the optionally substituted C 1-4 The alkyl or 3-4 membered ring is substituted by 1-3 substituents independently selected from the following: halogen (preferably F or Cl), OH, CN, C optionally substituted by 1-3 F 1-4 alkyl, optionally substituted by 1-3 F 1-4 heteroalkyl, and a 3-4 membered ring optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), preferably, R 22 Each occurrence is independently F, Cl, Br, CF3, OCF3, SCF3, SF5, OMe, CN, methyl, CHF2, CF2CH3, cyclopropyl, CH3SO2 and OCH2-(cyclopropyl).

54. A compound according to any one of claims 34 to 51, or a pharmaceutically acceptable salt thereof, wherein R 30 It is composed of 1-3 (e.g., 1 or 2) R 22 Substituted phenyl, wherein R 22 Each occurrence is independently F, Cl, CN, R M2 , OR M2 , SR M2 or SF5, where R M2 Each occurrence is independently C optionally substituted with 1-3 F 1-4 Alkyl, such as CF3.

55. A compound according to any one of claims 34 to 51, or a pharmaceutically acceptable salt thereof, wherein R 30 is an optionally substituted 5-membered or 6-membered heteroaryl, such as pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Replace, where R 22 Each occurrence is independently halogen (e.g., F, Cl, or Br), CN, OH, NH2, R M , OR M 、COOH、CONH2、COOR M CONH(R M )、CON(R M )2、NHCO(R M )、N(R M )CO(R M ), SO2R M 、SO2NH2、S(O)(NH)R M 、S(O)(NR M )R M SO2N(R M 2. NHSO2R M 、N(R M )SO2R M 、P(O)(R M )2、P(O)(OR M )2、NH(R M )、N(R M 2. SR M or SF5, where R M Each occurrence is independently optionally substituted C 1-4 Alkyl, optionally substituted C 2-4 Alkenyl, optionally substituted C 2-4 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl having 1-4 ring heteroatoms independently selected from O, S and N, or optionally substituted 4-7 membered heterocyclyl.

56. A compound according to any one of claims 34 to 51, or a pharmaceutically acceptable salt thereof, wherein R 30 is a 5-membered heteroaryl group (e.g., ) or pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Substitution, where valence permits, where R 22 Each occurrence is independently halogen (e.g., F, Cl, or Br), CN, OH, R M1 , OR M1 、SO2R M1 、P(O)(R M1 2. SR M1 or SF5, where R M1 Each occurrence is independently optionally substituted C 1-4 alkyl or an optionally substituted 3-4 membered ring (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), wherein when substituted, the optionally substituted C 1-4 The alkyl or 3-4 membered ring is substituted by 1-3 substituents independently selected from halogen (preferably F or Cl), OH, CN, C optionally substituted by 1-3 F 1-4 alkyl, optionally substituted by 1-3 F 1-4 heteroalkyl, a 3-4 membered ring optionally substituted by F and / or methyl (including cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, etc.), preferably, R 22 Each occurrence is independently F, Cl, Br, CF3, OCF3, SCF3, SF5, OMe, CN, methyl, CHF2, CF2CH3, cyclopropyl, CH3SO2 and OCH2-(cyclopropyl).

57. A compound according to any one of claims 34 to 51, or a pharmaceutically acceptable salt thereof, wherein R 30 is a 5-membered heteroaryl group (e.g., ) or pyridyl (e.g., ) or pyrimidinyl (e.g., ), which consists of 1-3 (e.g., 1 or 2) R 22 Substitution, where valence permits, where R 22 Each occurrence is independently F, Cl, CN, R M2 , OR M2 , SR M2 or SF5, where R M2 Each occurrence is independently C optionally substituted with 1-3 F 1-4 Alkyl, such as CF3.

58. A compound according to any one of claims 34 to 51, or a pharmaceutically acceptable salt thereof, wherein R 30 Having a structure according to S-1-A, S-1-B, S-1-C or S-1-D: Where R 8 is C optionally substituted by 1-3 F 1-4 Alkyl (such as CH3, CF3, etc.), optionally substituted by 1-3 F 1-4 Alkoxy (such as OCH3, OCF3, etc.), SCF3, SF5, cyclopropyl, cyclobutyl, or 59. A compound according to any one of claims 34 to 51, or a pharmaceutically acceptable salt thereof, wherein R 30 Select from the following options:

60. A compound according to any one of claims 34 to 51, or a pharmaceutically acceptable salt thereof, wherein R 30 Select from the following options:

61. A compound according to any one of claims 34 to 51, or a pharmaceutically acceptable salt thereof, wherein R 30 Select from the following options:

62. A compound of formula III-1, III-2, III-3, III-4, III-5, III-6, III-7, III-8, III-9, III-10, III-11 or III-12 as defined herein, or a pharmaceutically acceptable salt thereof, for example as defined in Embodiments A1-A38 and B1-B45.

63. A compound selected from the group consisting of compounds Nos. 1-347 or any of the compounds disclosed in Table A, or a pharmaceutically acceptable salt thereof.

64. A pharmaceutical composition comprising a compound according to any one of claims 1 to 63 or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable excipient.

65. A method for treating a disease, comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound according to any one of claims 1-63 or a pharmaceutical composition according to claim 64, wherein the disease is cancer or a viral infection.

66. The method of claim 65, wherein the cancer is selected from the group consisting of colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, kidney cancer, head and neck cancer, lymphoma, leukemia, and melanoma.

67. The method of claim 65 or 66, further comprising administering to the subject an immuno-oncology agent (e.g., as described herein, such as a protein antagonist that inhibits T cell activation and / or a protein agonist that stimulates T cell activation), preferably, the immuno-oncology agent is one or more antibodies selected from anti-PD-1, anti-PD-L1, anti-CTLA-4, and a combination thereof.

68. A method for inhibiting the activity of at least one diacylglycerol kinase selected from diacylglycerol kinase alpha (DGKa) and diacylglycerol kinase zeta (DGKz), comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound according to any one of claims 1-63 or a pharmaceutical composition according to claim 64.

Citation Information

Cited By

  • Tri-ring diacylglycerol kinase inhibitor and application thereof

    CN116969943A